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Although often referred to as simply "cancer," uncontrolled cell growth and division in a 
human body is often the result of a variety of biochemical perturbations. Efforts to improve 
diagnosis and treatment of cancer patients are increasingly relying upon more detailed individual 
biochemical information—i.e. a "personalized medicine" approach. One method to ascertain 
individual biochemical conditions is by measuring the levels of certain proteins in the blood 
stream, commonly referred to as cancer biomarkers. Traditional quantitative methods for 
biomarker analysis have typically relied on a single biomarker to provide information. However, 
single biomarker analyses have proven to be woefully incomplete in the information content 
needed for a personalized medical diagnosis. Multiplexed biomarker panels have the potential to 
overcome the limitations of single biomarker analysis due to the greater information content 
present in a panel of biomarkers, but technologies to rapidly, accurately, and reproducibly make 
multiplexed measurements, especially in a quantitative manner, are as yet undeveloped.  
This doctoral dissertation presents the development of silicon photonic microring 
resonator technology in the Ryan Bailey research laboratory towards multiplexed cancer protein 
biomarker measurements. Microring resonator sensing technology relies upon changes in 
refractive index that induce a resonance shift in circular silicon waveguides. Taking advantage of 
standard semiconductor processing techniques and facilities, it has been possible to rapidly 
develop sensor chips with 32 active sensors with the potential to be scaled even higher. These 
chips have thus been developed for making multiplexed biomarker measurements. 
This dissertation represents the development of microring resonator technology from a 
novel technology to applied multiplex detection in cancer patient blood serum samples. Chapter 
1 introduces more fully the topic of microring resonators, followed by a discussion of the basic 
physical characteristics, properties, and abilities of the sensors in Chapter 2. Chapter 3 introduces 
singleplex protein biomarker detection with multiplex detection in buffer following in Chapter 4. 
Multiplexed capture agent screening, a necessity for multiplexed immunoassays, is covered in 
Chapter 5 followed by the singleplex detection of a protein biomarker in human serum in 
Chapter 6. The final work of this project concludes with Chapter 7 which describes the methods 
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1.1 Introduction to Waveguide-Based Biosensors  
 
 By enabling efficient solution transport, mixing, separation, and analysis of small sample 
volumes on a single integrated fluidic chip, recent advances in microfluidic technologies have 
made possible the miniaturization and integration of many standard bioanalytical assays.1 
Although many lab-on-a-chip devices feature elegant fluid handling capabilities, the actual 
process of sample quantitation is often achieved with far less grace, requiring bulky and 
cumbersome instrumentation which, at some level, diminishes the overall utility of these 
miniature analytical devices. Of particular relevance are optical detection schemes that, while 
providing high sensitivity and assay versatility, can require large and expensive microscopy 
instrumentation. 
 Over the past several decades, fiber optic probes have been demonstrated as promising 
tools for chemical and biological sensing within small sample volumes.2 However, these 
methods typically remain reliant upon external optical components and their sensitivity is often 
directly tied to the physical length of the fiber-sample interaction, meaning that ultrasensitive 
measurements require larger probes that may no longer be amenable to small volume analyses. 
 Recent advances in microfabrication have enabled high density, chip-scale integration of 
optical components, such as light sources and photodetectors.3-9 These devices offer substantial 
advantages for lab-on-a-chip applications by enabling integration of both fluidic handling and 
optical analysis onto a single chip. These types of integrated sensing devices have the potential to 
enable creation of high-density biosensors that can provide rapid, sensitive, and multiplexed 
measurements in point-of-care diagnostic applications.10 
 While significant advances have been made in the incorporation of light sources and 
detectors into chip-based analytical platforms, the research work of the Bailey lab and of my 
doctoral dissertation features another essential element of chip-integrated optical detection: 
waveguides. Propelled by advances in wafer-scale microfabrication over the past two decades, it 
is now relatively straightforward to incorporate many hundreds or even thousands of chip-
integrated waveguides into a single sensor substrate, and this intrinsic scalability allows 
researchers to envision high levels of measurement multiplexing within small sample volumes. 
 Many examples, including several commercial products, exist in which integrated 
waveguides are used as excitation and/or collection elements for fluorescence-based sensors.11, 12 
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However, our work has primarily focused on chip-integrated biosensors that transduce the 
presence of a target analyte on the basis of binding-induced changes in the refractive index 
proximal to the waveguide surface. These types of devices provide promising detection elements 
for a myriad of biosensing applications, largely due to the fact that they do not require the 
labeling of any biomolecule, a procedure that can perturb native interactions, as well as increase 
assay cost and complexity.13  
  The governing physics of waveguide operation and the concept of their utility as an 
analytical device are quite simple. Due to the contrast in refractive index between the core and 
cladding of an optical waveguide, light is guided through the device on account of total internal 
reflection, which generates an evanescent optical field that decays exponentially from the sensor 
surface. Biomolecular binding events modulate the refractive index contrast and thus attenuate 
the propagation of light through the waveguide. By monitoring the coupling and/or propagation 
properties of light through an appropriately modified waveguide, it is possible to construct 
sensors responsive to target biomolecular analytes of interest. The literature has several examples 
of refractive index-sensitive, waveguide-based sensors such as grating-coupled,14-16 
interferometric,17, 18 photonic crystal,19-22 and microresonator-based23 waveguide sensors.  
 
1.2 Introduction to Resonant Optical Microcavity Sensors 
 
 Our group has focused on microresonator-based waveguide sensors for the detection of 
biomolecules, and thus my dissertation will center around the detection capabilities of this 
technology. These sensors, which can be fabricated out of a variety of materials and with several 
similar, but distinct, cavity geometries, generally function by coupling light from an adjacent 
linear waveguide into a circular microcavity.23 Optical interference between photons in the linear 
waveguide and microcavity dictate that only specific wavelengths of light are resonantly 
supported, as defined by the equation:  
 
mλ = 2pirneff 
 
where m is an integer, λ is the wavelength of light, r is the radius of the ring, and neff is the 
effective refractive index of the waveguide mode. 
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When fabricated with very high precision and limited cavity surface roughness, the 
resonance peaks become incredibly spectrally narrow and the structures are referred to as high Q 
(quality) factor cavities. The narrow peaks facilitate resolution of small shifts in the spectral 
position of the resonance, making these devices very sensitive to the local refractive index near 
the resonator. By functionalizing the microcavities with appropriate biomolecular capture agents, 
binding-induced changes in refractive index are transduced via a shift in the optical wavelengths 
resonantly supported by the structure. This concept is schematically illustrated for the case of a 
microring resonator in Figure 1.1A wherein biomolecular (protein) binding to a capture agent 
modified cavity (shown functionalized with antibody) causes the resonance wavelength to shift 
(black trace to red trace). 
 Microsphere,24 microtoroid,25 and microcapillary26 cavities have been reported to have 
tremendous detection sensitivities.  However, these devices are not readily fabricated in a 
chip-based format and optical interrogation of such cavities is not trivial (often requiring 
positioning of extruded optical fibers with nanometer precision and alignment). For this reason, 
microring resonators with chip-integrated linear access waveguides have emerged as promising 
candidates for scalable and multiplexable biosensing. Although the Q factor is lower for planar 
microcavity formats, as opposed to sphere, microtoroid, or capillary designs, the robust nature of 
the device in terms of ease in sensor interrogation, fabrication scalability, and functionalization 
offers advantages for applications in multiplexed biomolecular detection.27  
 Microring resonators sensors can be fabricated from a variety of materials, including 
polymers,28 silicon oxide,29, 30 silicon nitride,31, 32 and SOI.33-35 Figure 1.1B shows a scanning 
electron micrograph of a single microring resonator with corresponding linear access waveguide 
fabricated in the top layer of SOI. Typical sensitivities enable discrimination of changes in 
refractive index of 10-6 or better.27, 32, 36, 37 In their most basic format, these sensors feature a 
single microring coupled horizontally to a linear waveguide, but methods have been devised for 
vertical coupling.37 Furthermore, coiled38 and slotted31, 39 microring waveguides have also been 
demonstrated as well as Mach-Zehnder-integrated microrings, which show promise for increased 
sensitivity but at present face a potential drawback of reduced thermal stability.40, 41 
 Because the microring resonator format is readily amenable to highly scalable and 
commercially validated microfabrication approaches, several groups have demonstrated the 




Figure 1.1 (A) Illustration of proteins binding to a microring resonator and the subsequent shift of the resonance 
frequency. (B) SEM image of a SOI microring resonator as revealed through an annular opening in a polymeric 





for quantitative analysis of biological samples as well as multiplexed sensing. For example, 
Ramanchandran et al. have demonstrated a chip with five microring sensors and have shown that 
they could derivatize the rings with antibodies against E. coli.30 These functionalized rings 
respond specifically to E. coli in comparison to unresponsive control rings. In the same paper the 
authors also showed specific binding of nucleic acids, as well as quantifying IgG binding. 
Subsequently, Wang and co-workers used an identical microring resonator array to monitor 
physical changes in cell behavior upon exposure to cytotoxic chemicals.42 
 Carlborg and co-workers have demonstrated the utility of slotted microring resonators by 
developing a chip that contains eight integrated microring resonators, six of which can be used as 
active sensing rings and two of which are employed as thermal controls.32 Furthermore, this 
sensor chip was incorporated into a microfluidic casing that enabled independent fluidic access 
to each microring, which was then used to monitor the attachment of anti-BSA antibodies to the 
microcavities with good sensitivity. 
 
1.3 Introduction to Protein Biomarker Detection and Dissertation Work 
 
 The overarching goal of my dissertation work has been to utilize microring resonator 
sensors for detecting protein biomarkers. In particular, my research has taken many progressive 
steps towards developing a multiplexed sensor chip that can detect multiple protein cancer 
biomarkers from human blood serum samples. The driving motivation behind the development 
of a multiplex biomarker chip is for personalized medicine applications. The fundamental tenet 
underlying personalized medicine is that multi-faceted diseases, such as cancer, are derived from 
a multitude of biochemical pathway perturbations, even though identical clinical symptoms are 
presented.43 Or as the Canadian physician Sir William Osler (1849–1919) said,44 “variability is 
the law of life, and as no two faces are the same, so no two bodies are alike, and no two 
individuals react alike and behave alike under the abnormal conditions we know as disease.”   
The ultimate goals of personalized medicine are embodied in the rising field of 
theragnostics, which seeks to utilize molecular diagnostics to confirm which specific treatments 
or drug would help or harm a particular patient. For example, the drug trastuzumab (Herceptin) 
is particularly effective for patients that overexpress the HER2 protein. Thus corresponding 
diagnostic tests for HER2 overexpression in tumors make it possible to limit trastuzumab 
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treatment to only those patients who will be most likely to benefit.45 Similarly, molecularly 
targeted therapies for glioblastoma multiforme have been under development for quite some time, 
but unlike HER2 protein, there exists no clinically available test to determine which patients 
would benefit from targeted treatments.46  
Protein cancer biomarkers in blood serum have been investigated as a means to 
effectively diagnose and treat cancer. Unfortunately, single biomarker analysis has been shown 
to be rather limited in the personalized treatment of cancer. For example, prostate specific 
antigen (PSA) has been used as a stand-alone biomarker to inform the diagnosis and treatment of 
prostate cancer, but recent studies have questioned the efficacy of such screening.47, 48 To 
improve upon this performance, it has been suggested that panels of protein biomarkers could 
provide a much more informative diagnostic and theragnostic picture.49 The recent FDA 
approval of the OVA1 biomarker panel test for evaluation of ovarian tumor malignancy 
illustrates progress in the development of biomarker panels.  
Microring resonators provide a convenient technology for the development of protein 
biomarker panels for several reasons. First, the ability to incorporate multiple sensors onto one 
microchip makes it possible to develop a single chip that can measure multiple cancer 
biomarkers from a single sample. Second, such chips can be manufactured in a scalable manner 
via standard semiconducting processing technologies that would enable sensor chips to be 
fabricated on a scale necessary for clinical use. Third, unlike other protein biomarker 
immunoassays which rely on fluorescent or enzymatic signal read-out strategies, microring 
resonator using refractive-index-based sensing can detect the binding of antigen, secondary 
antibodies, as well as any amplification step. By being to measure the binding at all steps of an 
assay, it is possible to rapidly evaluate capture agents, cross-reactivity, and appropriate 
immunoassay conditions. 
The chapters of this dissertation are indicative of the stepwise progression towards 
developing a multiplex cancer biomarker chip using the novel silicon photonic microring 
resonator platform. Chapter 2 contains initial experiments done to evaluate and characterize the 
performance and sensitivity of the microring resonator chips. Chapter 3 similarly demonstrates 
the proof-of-principle label-free detection of a single cancer biomarker. This chapter also 
illustrates some of the challenges facing label-free detection in complex matrices. Chapter 4 
builds on the work done in Chapter 3 by demonstrating the ability to create a multiplex cancer 
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biomarker chip. However, the work at this stage is still proof-of-principle in that the analytes are 
detected in a simple buffer environment rather than a complex matrix like blood serum. In 
continuing on to develop a larger multiplex array and to obtain sufficient sensitivity, the proper 
capture antibodies must be obtained. Chapter 5 discusses the means to evaluate antibody kinetics 
via a screening approach as well as how to utilize DNA-encoded antibodies for a more advanced 
surface chemistry development. Chapter 5 also shows how secondary antibodies can be screened 
for developing sandwich-type immunoassays. Chapter 6 finally demonstrates the ability to detect 
a single protein biomarker (cardiac) in human blood serum samples by using a sandwich 
immunoassay detection methodology followed by a bead-based signal amplification process. The 
ability to amplify signal without a large background is critical for detecting a multiplex panel of 
cancer biomarkers in human blood serum. Thus, Chapter 7 chronicles the use of all the previous 
advances in the development and creation of an eight-plex cancer biomarker chip. The detection 
of all eight cancer biomarkers from human serum samples from cancer patients illustrates the 
viability of microring resonators for personalized medicine applications. 
 
1.4 Other Microring Resonator Work 
 
In addition to my work with protein cancer biomarkers, the Bailey lab has also utilized 
microring resonators for other analytical applications, of which I will make brief mention here. 
For example, Luchansky et al. demonstrated the monitoring of interleukin-2 (IL-2) secretion 
from stimulated Jurkat T-cells in cell-free culture media using a sandwich assay approach.50 
Changes in secreted IL-2 levels were monitored over a period of 24-hours post stimulation and 
the results were found to be in excellent correlation with a commercial ELISA assay, with an 
added advantage of enhanced measurement precision. Byeon et al. demonstrated the monitoring 
of aniline-catalyzed antibody surface ligation, and determined the conditions under which 
optimal antibody attachment to the surface can be achieved.51 Byeon et al. also used the 
multiplexing capabilities of microring resonators to compare the performance of an aptamer and 
antibody against the same antigen target.52 
 In addition to protein detection, the Bailey group has also demonstrated the ability to 
detect nucleic acids via microring resonators. Using a direct hybridization assay with DNA 
capture probes, Qavi et al. were able to detect four different micro RNAs (miRNAs) on a single 
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sensor chip.53 Those four-plex chips were then used to detect those same four miRNAs isolated 
from a cell line model of glioblastoma. As follow-up work, Qavi et al. demonstrated that 
DNA:RNA duplexes can be specifically detected with an anti-DNA:RNA antibody.54 This not 
only adds greater specificity to a miRNA assay but also enables amplification of the RNA-
binding signal. In addition to miRNA detection, direct detection of DNA was demonstrated using 
multiplexed microring resonator sensors.55 In this work, it was possible to discriminate single-
nucleotide polymorphisms by comparing real-time dissociation rates of DNA duplexes.  
 Beyond detection of biomolecules, microring resonators can be utilized for monitoring 
surface chemistry such as surface-bound polymer growth. Limpoco et al. demonstrated that 
microring resonators can be used to measure the rates of growth of polymer brushes on silicon 
surfaces via an atom transfer radical polymerization process.56 This detection methodology opens 
the door to studying surface polymer growth in a combinatorial fashion. 
 Overall, microring resonators have proven to be a promising technology that can be used 
in a vast array of detection schemes. Although the remainder of this dissertation will focus on 
cancer biomarker detection, a multitude of other analytical applications are available using the 
multiplexable microring resonator technology. Future developments of microring resonator 
technology—including the development of 128-plex chips with integrated fluidic cartridges—
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Waveguides, including fiber optics, have become valuable tools for detecting chemical 
and biological species through a range of optical transduction mechanisms, including absorbance, 
fluorescence, and refractive index-induced phase or transmission intensity modulation.1-6 For all 
waveguide materials and geometries, light propagates through the waveguide on account of total 
internal reflection that occurs due to the contrast in refractive index between the core and 
cladding materials. At the core/cladding interface, an evanescent optical field extends from the 
surface and decays exponentially with distance.7 Regardless of the particular transduction 
mechanism utilized for sensing, the measured signal is elicited through light-matter interactions 
between this evanescent field and proximal target molecules. 
 Most relevant to this report are label-free transduction methods whereby the presence of a 
particular analyte causes a fundamental change in the optical transmission properties of the 
waveguide, thus eliminating requirements for chromophoric or fluorescent labels.8 In most 
examples, the waveguide is chemically modified to present a target-specific capture element, and 
localization of the analyte at the core-cladding interface leads to an attenuation in the power of 
the transmitted light. 
Recently there have been reports of chemical and biomolecular sensors based upon 
waveguides fabricated from a range of different materials, many of which leverage advances in 
semiconductor processing for micro- or nano-scale device fabrication.1 A particularly promising 
waveguide material is silicon-on-insulator (SOI), a feedstock of the microelectronics industry.9 
SOI waveguides are patterned into the top layer of silicon, and light is effectively guided due to 
the high refractive index contrast between Si and the cladding layers, which include the buried 
oxide and the top/side cladding layers. In addition to the obvious advantages of SOI in terms of 
scalability and potential for mass production, silicon photonic devices also feature good modal 
overlap between the guided optical mode and an analyte recognition layer.10  The high refractive 
index of the waveguide core layer leads to a high sensitivity towards surface-confined binding 
events. Several groups have demonstrated silicon photonic waveguide configurations for 
chemical or biological sensing applications, including Mach-Zehnder interferometers,10-12 
resonant gratings,13 and microcavity resonators.14-18 Using arrays of SOI microring resonators, 
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we previously reported  a bulk refractive index sensitivity of 7.6 x 10-7 refractive index units 
(RIU)19 and have demonstrated the sensitive, label-free detection of multiple proteins and nucleic 
acid sequences in both single and multiparameter analytical applications.20-23 
Another label-free optical method that is particularly well-suited to analyzing 
biomolecular binding, thus serving as a basis for comparison, is surface plasmon resonance 
(SPR). SPR measures the interaction of an evanescent field extending from a metallic film, 
usually gold, in contact with the analyte-containing solution. Binding events that change the 
refractive index at the gold-solution interface are measured either as a change in the angle or 
wavelength of light which is maximally coupled into the metal film. SPR has been actively 
investigated as a biosensing technique over the past several decades with a number of reported 
sensor geometries and modes of operation, several of which are available commercially.24-26 For 
SPR sensors, the evanescent field penetration depth, which is a function of wavelength and 
dielectric environment, is on the order of hundreds of nanometers27 with bulk refractive index 
sensitivities usually varying between 10-5 and 10-7  RIU.25, 28 For reference,25 a bulk index 
sensitivity of 10-6 RIU corresponds to a surface coverage resolution of 0.91 pg/mm2. 
Presented in this chapter is a simulation of the waveguide optical intensity profile as well 
as a direct, experimental interrogation of the evanescent intensity decay profile of a silicon 
photonic microring resonator. We empirically measured the distance dependence of the sensing 
platform utilizing layer-by-layer electrostatic polymer multilayer deposition.29, 30 We also 
directly determined the bound mass sensitivity and limit of detection (LOD) of our system by 
correlating the resonance wavelength shifts with the amount of bound 125I-lableled streptavidin, 
measured via radiometric methods. Importantly, this chapter presents key, experimentally 
determined sensitivity metrics for an emerging silicon photonic biomolecular sensing platform. 
In addition to providing a benchmark for comparison, the dependence of device sensitivity on 
distance from the sensor surface will be important when designing coatings for optimal analyte 








2.2 Materials and methods 
2.2.1 Materials 
 
N-hydroxysuccinimidobiotin (NHS-Biotin), streptavidin, Zeba spin filter columns, and 
pre-coated iodination tubes were obtained from Pierce (Rockford, IL). 3-
aminopropyltriethoxysilane (APTES) was purchased from Gelest (Morrisville, PA). 
Succinimidyl 4-formylbenzoate (S-4FB) and 3-N-((6-(N'-Isopropylidene-
hydrazino))nicotinamide)propyltriethoxysilane (HyNic silane), were purchased from SoluLink 
(San Diego, CA). Shipley 1813 photoresist, MF 319 developer, and 1165 photoresist stripper 
were purchased from MicroChem Corp. (Newton, MA). Poly(sodium 4-styrene-sulfonate) (PSS, 
MW~70,000 Da) , polyethyleneimine (PEI, 50% w/w in H2O, MW~750,000 Da), and 
poly(allylamine hydrochloride) (PAH, MW~56,000 Da) were obtained from Sigma Aldrich (St. 
Louis, MO). Biotinylated, monoclonal mouse anti-human IL-2 antibody (catalog# 555040, clone 
B33-2 was purchased from BD Biosciences (San Jose, CA). All other chemicals were used as 
received from Sigma Aldrich (St. Louis, MO). 
All buffers were made with purified water (ELGA PURELAB filtration system; Lane 
End, UK), and the pH was adjusted using 1 M HCl or 1 M NaOH. Tris buffer consisted of 0.5 
mM Tris and 100 mM NaCl adjusted to pH 7.1.  Tris/ EDTA buffer was made by dissolving 1.21 
g Tris base, 0.558 g disodium EDTA, and 0.2 g sodium azide in 1 L water and adjusting to pH 
7.4.  PBS was made by dissolving 9.6 g Dulbecco’s phosphate buffered saline mixture into 1 L 
water and adjusting to pH 7.4. Antibody immobilization buffer consisted of 100 mM PBS with 
150 mM NaCl adjusted to pH 6.0. BSA-PBS buffer  consisted of 0.1 mg/mL BSA in PBS. For 
blocking, StartingBlock blocking buffer (Pierce) was used. 
 
2.2.2 Microring Resonator Array Chips and Instrumentation 
 
The design and fabrication of microring resonator array chips, the accompanying 
instrumentation, and the fluidics have been described in other papers.19, 22 Briefly, chips having 
32 individually addressable microrings were used for the experiments. The entire substrate was 
coated with a fluoropolymer cladding layer that was removed from annular openings over 24 of 
the sensors. The remaining eight microrings were left occluded by the cladding and were utilized 
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as thermal controls, since they were not exposed to the solution. Microring resonance 
frequencies were measured as described previously. Briefly, the beam of a 1560-nm center 
wavelength tunable, external cavity diode laser is focused onto an input grating coupler on the 
chip surface to couple light into the linear waveguide adjacent to a given microring. The laser 
output is then rapidly swept through a 12-nm spectral window, and the intensity of light 
projected from the output grating coupler  is monitored as a function of laser wavelength. 
Resonance wavelengths are determined as minima in output coupler intensity. This process is 
repeated for each interrogated microring sensor by rastering the laser across all 32 input grating 
couplers , allowing resonance determination with ~250-ms time resolution. Thermal control ring 
responses are used to control for  ambient thermal drift. 
 
2.2.3 Layer-by-layer Deposition 
 
For the layer-by-layer electrostatic deposition of polymers, PEI, PSS, and PAH were 
dissolved in Tris buffer to  5 mg/mL. After cleaning the microring surface with piranha solution 
(3:1 H2SO4:H2O2) and loading the chip into a previously described microfluidic flow cell,22 chips 
are exposed to PEI for 5 min at  30 µL/min. Maintaining constant flow conditions with a P625 
peristaltic pump from Instech Laboratories (Plymouth Meeting, PA), the surface is then rinsed 
with Tris buffer and exposed to PSS for 10 min followed by a buffer rinse. The surface is then 
exposed to PAH for 4 minutes with a 5 minute buffer rinse. The PSS and PAH deposition cycles 
(with the PSS time reduced to 6 minutes) and buffer rinses were repeated until a total of 72 
bilayers had been grown.  
To facilitate automated solution switching, we constructed a robot using the LEGO 
(Billund, Denmark) MINDSTORMS NXT 2.0 system that automatically moved the inlet tubing 
between solutions (see Figure 2.1). To automate fluid delivery, 0.38-mm inner diameter Teflon 
inlet tubing was connected from the ring resonator microfluidic system to the sipper arm motor 
of the robot which rotated up and down ~55° to raise and lower the tubing into the six different 
solutions used for the multilayer experiments. Typically, solutions 1–3 contained running buffer 
and the two components of the multilayer experiment while solutions 4–6 contained buffer rinses 
so that solution on the tip of the tubing would not contaminate the other vials. To switch 






Figure 2.1 Picture of LEGO MINDSTORMS NXT 2.0 robot for automation of multilayer formation with labels on 
each component. The LEGO control console loaded with customized software for the solution switching process and 




was lowered into the next vial. The control console was programmed using LEGO 
MINDSTORMS NXT 2.0 software and powered with a 9.0 V DC power supply. Constant fluid 
flow was maintained via the peristaltic pump fitted with 0.79-mm inner diameter silicone tubing 
which was connected to the 0.5-mm inner diameter Tygon outlet tubing of the microring 
resonator system. 
To verify PAH/PSS bilayer thickness, we performed a large-area layer-by-layer 
experiment on four different silicon substrates. In order to confirm both the layer thickness and 
the growth linearity, the layer growth process was halted at a different point for each wafer 
section prior to performing ellipsometry. Because ellipsometry requires a wider area than what 
our microfluidic channels provide, we created the multilayers on the silicon wafer pieces using a 
dipping approach rather than a microfluidic flow-based approach. We utilized the same 
concentrations and exposure times for the microfluidics setup, and we reconfigured the LEGO 
robot to dip the pieces of silicon wafer into the solution vials. At the end of the layer growth, 
each substrate was washed briefly with water and then dried under a gentle stream of nitrogen. 
Ellipsometry was performed using a J.A. Woollam variable angle spectroscopic ellipsometer 
(Lincoln, NE). For each spot, three different angles of incidence were measured (65°, 75°, 85°) 
and the thicknesses were calculated assuming a SiO2 thickness of 2.4 nm, and a Cauchy layer 
model for the dried polyelectrolyte bilayers with an assumed refractive index of 1.68.31  
Prior to performing layer-by-layer deposition of proteins, hydrazine moieties were 
installed on the silicon oxide chip surface by flowing a solution of HyNic-silane (1 mg/mL in 
95% ethanol and 5% dimethyl formamide) over the surface for 30 min at 5 µL/min followed by 
rinsing with ethanol. Separately aldehyde groups were introduced to biotinylated IgG antibodies 
by reaction with a 5-fold molar excess of 0.2 mg/mL S-4FB for 2 h at room temperature. After 
buffer exchanging with a Zeba spin column into 100 mM PBS pH 6.0 to remove excess S-4FB, 
the antibody solution was diluted to 0.1 mg/mL and flowed over the entire sensor array for 
covalent attachment via a hydrazone linkage. Aniline (100 mM) was added to catalyze the 
formation of the hydrazone bond between the antibody aldehyde and the hydrazine-
functionalized surface.32 After rinsing the chip in buffer, the surface was blocked in 
StartingBlock overnight at 4 ˚C. 
 For layer-by-layer protein deposition, biotinylated anti-IL-2 and streptavidin were diluted 
in BSA-PBS to 2 µg/mL. After loading the antibody-functionalized chip into the flow cell, BSA-
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PBS buffer was flowed at 23 µL/min . Maintaining the same flow conditions, the surface was 
exposed to streptavidin for 20 min, followed by a 2-min buffer rinse, and then to biotinylated 
antibody for 20 min, followed by a 2-min buffer rinse.  This cycle was repeated for a total of 75 
layers (37 bilayers on top of an antibody-functionalized surface). The LEGO robot was again 
used to facilitate automated solution switching over the ~30-hr multilayering process. 
 
2.2.4 125I-Streptavidin Experiments 
 
 Streptavidin was labeled with 125I, a γ-emitter, according to the manufacturer’s 
instructions using pre-coated iodination tubes (Pierce). Labeled streptavidin was purified from 
free 125I using a G-25 Sephadex-packed glass column. The concentration of radiolabeled 
streptavidin  (> 90% purity) was determined to be 1-2 µg/mL for each of three trials. 
 The Storm 840 PhosphorImager (GE Healthcare) utilized to image the amount of 125I-
streptavidin deposited on the substrate did not have adequate spatial resolution to allow 
visualization of individual sensing elements. Therefore, the fluoropolymer cladding layer was 
removed in its entirety from half of each chipusing photolithography and reactive ion etching 
(RIE). 
To remove the fluoropolymer layer, the chip was spin-coated with Shipley 1813 (2000 
RPM, 30 sec) photoresist, followed by a 1-min post-bake at 115 ˚C. Half of the chip was then 
exposed for 1 min to a 30 mW/cm2 dose of 350-nm light through a mask covering half of the 
chip. The photoresist was then developed for 5 min in MF-319, and the fluoropolymer was 
removed on the exposed half of the chip by performing oxygen RIE (4 min, 9.8 sccm O2, 50 
sccm Ar, 16 mTorr, 100 W, 310 V DC bias) on a PlasmaLab RIE System. The protective 
photoresist layer was subsequently removed by a 15-min soak in 1165 stripper followed by a 10-
min sonication in acetone, an isopropanol rinse, and drying in a nitrogen stream. 
Before flowing 125I-streptavidin over the sensor surface, the chip was piranha cleaned as 
and loaded in the microfluidic flow cell with a gasket that allowed exposure of the entire array to 
a single solution volume. The surface was first modified with an amine-terminated silane by 
flowing a 2% solution of APTES in ethanol over the surface at 30 µL/min for 10 minutes, 
followed by rinsing with ethanol. A 0.4-mM NHS-Biotin solution (in 100mM PBS, pH 7.4 with 
4% DMF) was flowed over the surface at 30 µL/min for 30 min, followed by rinsing with PBS.  
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Finally, the sensor surface was exposed to the 125I-streptavidin solution for 10-30 min and 
washed with buffer. After the microring resonance shift determination, the chip was imaged on 
the phosphorimager along with a set of spotted protein standard solutions that were allowed to 
evaporate onto a glass slide. The bound streptavidin surface density was determined by 
comparison to protein standards and correlated with the wavelength shifts from rings on the side 





 For waveguide sensors, the sensing modality is based on the interaction of the 
propagating evanescent field with the molecules of interest at or near the waveguide surface. In 
our silicon-on-insulator platform, light is coupled into linear Si waveguides that access the 
microring waveguides. As shown in Figure 2.2, each 30-µm ring is separated from the linear 
waveguide by 200 nm to allow for efficient light coupling between the waveguides only at 
wavelengths (λ) that match the resonance condition defined by:  
 
mλ = 2pirneff      
 
where m is an integer, r is the microring radius, and neff is the effective refractive index of the 
optical mode. Since organic and biological molecules have higher refractive indices (n = 1.4-1.6) 
than water (n = 1.33), their binding to the sensor surface increases the effective refractive index 
sampled by the optical mode.33 The monitoring of resonant wavelength shift as a function of 
target binding provides the label-free sensing modality. 
The equations describing the evanescent field propagation are derived from the boundary 
conditions of the electromagnetic wave equations that require a non-zero electric field at the 
reflective dielectric interface. As a result, the evanescent wave decays exponentially from the 
surface and, ignoring light scattering, the rate at which the field intensity decays can be described 
by: 
 




Figure 2.2 Scanning electron micrograph of a Si microring resonator waveguide adjacent to a linear waveguide. An 
annular opening in the fluoropolymer cladding layer exposes the surrounding SiOx surface only in the immediate 




where I(z) is the intensity of the evanescent as a function of perpendicular distance z from the 
surface, I0 is the initial intensity, and γ is the exponential decay constant. As described previously, 
the shift in resonance wavelength is proportional to the intensity of the evanescent field  
extending into the surrounding environment.34 
Simulations of the waveguide optical intensity profile were performed using the classic 
eigenfunction approach as described previously.35 Briefly, Maxwell’s equations are solved 
satisfying the boundary conditions at the dielectric interfaces of the waveguides, resulting in a set 
of transcendental equations that were solved for the wavenumber of the transverse optical mode. 
The mode is oscillatory in the core of the waveguide, but in the evanescent region external to the 
core, it decays exponentially as shown in Figure 2.3. The physical constants used in the 
calculation were matched to those in the experimental system, characterized by a 200-nm thick 
by 500-nm wide waveguide having ncore = 3.43, nsubstrate = 1.46, nsurroundings = 1.33, and λ = 1.56 
µm. The exponential decay coefficient, γ, in Eq. 2 was found to be 9.56 µm-1 for the optical field 
at the surface of the waveguide extending into the analyte sensing region. At a distance of z = 
1/2γ = 52.3 nm from the waveguide, the intensity of the evanescent field, I(z), has decreased to 
(1/e) × I0 or 36.7% of its initial value.   
 
2.4 Results and discussion 
2.4.1 Polyelectrolyte Layer-by-layer Results 
 
 To experimentally profile the evanescent decay from our microrings, we utilized layer-
by-layer assembly of alternating anionic and cationic polymers onto the surface to map the 
intensity of the sensor response as a function of z. Specifically, PSS and PAH were selected due 
to the extensive literature describing  PSS/PAH multilayers with linear growth over a wide range 
of thicknesses.36-38 Following these previous reports, we prepared our silicon oxide-passivated 
surface with a layer of the highly branched polymer PEI to ensure sufficient coverage of the 
initial polyelectrolyte, followed by the addition of subsequent layers of PSS and PAH. Figure 
2.4A illustrates the growth process, starting with the negatively charged silicon oxide surface. 
After addition of a PEI layer, PSS and then PAH are added in sequence. This process is repeated 
to form 72 PSS/PAH bilayers. Figure 2.4B shows the real-time shift in resonance wavelength 





Figure 2.3 Cross-sectional plot of the evanescent field intensity for the 0.2 x 0.5- micron optical waveguide.  The 
dashed lines represent the top and bottom extents of the waveguide core.  The top surface of the waveguide exposed 
to the chemical reactions is at x = 0. Refractive indices of each region utilized in the simulation of the evanescent 




Figure 2.4 (A) Schematic showing the layer-by-layer addition of polyelectrolytes to a negatively charged silicon 
oxide surface. Layer 1 involves addition of positively charged, highly branched PEI, and Layer 2 involves addition 
of negatively charged PSS on top of the PEI. Layer 3 consists of positively charged PAH adhering to the PSS layer. 
Multilayers are added by alternating deposition of PSS and PAH layers. (B) Real time data showing the relative shift 
in resonance frequency (∆ pm) upon addition of PAH and PSS layers. Inset shows six layer-by-layer depositions at 
higher resolution. (C) Plot showing the relative resonance wavelength shift for each successive PAH/PSS bilayer as 
a function of bilayer number. The exponential fit shown in the plot models the decay rate as the polyelectrolyte 
multilayers grow further from the surface and experience the decreasing evanescent field intensity, as evidenced by 




With each additional layer, the differential sensor response decreases as multilayer assembly 
occurs at a greater distance from the surface. The decreasing sensitivity to refractive index 
changes corresponds to the evanescent intensity decay profile extending off of the microring 
waveguide. Figure 2.4C shows the average net sensor response (n = 23 rings) for each successive 
polymer bilayer as a function of the number of PSS/PAH bilayers added.  
By fitting the points in Figure 2.4C to an exponential function, it becomes apparent that 
the response for each subsequent layer decays exponentially. From the exponential fitting 
function, the 1/e decay length for sensor response is 20.9 bilayers, which can be converted to a 
decay distance of 63 ± 4 nm using a 3.0 ± 0.2 nm thickness for each hydrated bilayer.37, 38 
 The literature value for PSS/PAH bilayer thickness was also experimentally confirmed 
through ellipsometry performed at several points during a layer-by-layer deposition process on a 
large area substrate. Based on the ellipsometry data shown in Figure 2.5, the thickness at each 
point in the growth process shows a highly linear correlation to the number of bilayers.  The 
slope of a linear regression fit to these points was found to be 2.44 ± 0.04 nm/bilayer (R2 = 
0.999). This corresponds well with the dry thickness of PAH/PSS bilayers given in previous 
reports.36, 38, 39 By incorporating a ~30% increase38, 40 in size due to swelling in water, the 
hydrated thickness can be calculated to be 3.17 nm. This confirms the 3.0-nm value we use to 
calculate our layer thickness. 
 This experimentally determined decay distance of 63 nm is in reasonable agreement with 
the evanescent intensity simulation, which yielded a value of 52 nm. Possible sources of 
discrepancy include: uncertainty in hydrated bilayer thickness and film uniformity; the difference 
in surrounding index of buffer solution (experimental) versus water (simulation); dynamic 
changes in the mode profile during the course of multilayer growth; and other experimental 
deviations from idealized conditions. However, both simulation and empirical measurement 
provide sufficient information regarding the evanescent decay to interpret the results from the 
following protein multilayer study. 
 
2.4.2 Antibody/Streptavidin Layer-by-layer Results 
 
After verifying the exponential decay length experimentally using the electrostatic 




Figure 2.5 Thickness of PSS/PAH polyelectrolyte multilayers as a function of bilayer # based on ellipsometric 




characteristics. As a test case, we constructed multilayers of an antibody (biotinylated mouse 
anti-human IL-2 IgG) functionalized with ~10 biotin molecules, and streptavidin, which binds 
with high-affinity (Kd ~ 10-15 M) to up to four biotin molecules. The multivalent nature of both 
biomolecules ensures that extended assemblies can be grown. As shown in Figure 2.6A, the 
surface is first functionalized with SFB-modified biotinylated antibody (Ab) as has been 
described previously,20 followed by addition of a streptavidin (SA) layer. Additional biotinylated 
Ab was attached to the bound SA. This process was repeated, resulting in multilayer growth (75 
total layers). The resonance wavelength shift associated with the growth of each layer was 
monitored in real time under conditions empirically optimized to insure complete layer formation. 
As shown in Figure 2.6B, the resonant wavelength shift for each layer initially follows a non-
linear growth trend, as will be further discussed below, before the effect of the decaying 
evanescent intensity dominates as the distance from the ring increases. This leads to a pseudo-
inflection point in Figure 2.6B at ~300 min. Following this inflection point, the average 
cumulative shift arising from protein layers 16 through 75 can be fit to an exponential function, 
as shown in Figure 2.6C. This fit is in the same form as the exponential function used to model 
the response to polymer multilayers. The shifts corresponding to layers 1-15 were not included 
since layer growth during this stage not only involves propagation through a decaying 
evanescent field, but also likely variations in the physical characteristics of each protein layer 
(packing density, surface coverage, protein orientation, etc.). 
From the protein multilayer exponential fitting equation, we can determine that the 1/e 
decay length is 9.6 layers.  In other words, after 9.6 protein layers, the evanescent intensity has 
decreased to 1/e (or ~37%) of its initial value at the ring surface.  Using the 1/e distance of 63 
nm determined experimentally with electrostatic polymer layers, these 9.6 monolayers each 
represent a 6.6-nm thickness on average (or ~13 nm per Ab/SA bilayer). IgG antibodies have a 
molecular weight (MW) of ~150 kDa with approximate molecular dimensions of 15 x 7 x 3.5 nm, 
and their four-polypeptide-chain structure is highly flexible.41, 42 Streptavidin (MW ~ 53 kDa ) is 
roughly one-third the size of an antibody with dimensions of 5.8 x 5.4 x 4.8 nm 43, 44, and a 
densely packed streptavidin monolayer has a thickness of 4.5-5 nm from studies using 
ellipsometry and electron microscopy.45, 46 By simple addition of thicknesses, an Ab/SA bilayer 
is expected to be between 8 and 21 nm thick. Considering that the Abs are randomly oriented on  
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Figure 2.6 (A) Schematic showing the layer-by-layer addition of biotinylated antibody (Ab) and streptavidin (SA) 
to the ring resonator surface. Layer 1 shows covalent attachment of 4FB-modified, biotinylated antibody to the 
HyNic-silane functionalized silicon surface. We hypothesize that initial antibody functionalization yields incomplete 
surface coverage, which is followed by an annealing process that initially results in non-linear layer growth as 
vacancies are filled. Layers 2 and 3 show subsequent addition of streptavidin and biotinylated antibody, respectively. 
Extended multilayers are formed by alternating deposition of streptavidin and biotinylated antibody. Though each 
antibody is functionalized with ~10 biotins, fewer are shown for clarity. (B) Real time data showing the relative shift 
in resonance frequency (∆ pm) upon addition of SA and Ab layers. Inset shows six layer-by-layer depositions at 
higher resolution. (C) Plot showing the cumulative relative shift per antibody or streptavidin layer (each individual 
addition of streptavidin or antibody is counted as a single layer). The exponential fit shown in the plot indicates the 




the surface and that this disorder propagates with the addition of SA, the average thickness of 13 
nm per bilayer seems quite reasonable. 
Comparing the cumulative sensor response of the electrostatic polymer and the protein 
multilayers provides additional insights into the nature of the assemblies.  In Figure 2.4C, the 
signal arising from 72 polymer bilayers effectively levels off at a maximum cumulative 
wavelength shift of ~10,000 pm. These 72 bilayers extend ~210 nm from the ring surface before 
the additional signal arising from subsequent layers becomes increasingly negligible due to the 
evanescent intensity decay. However, in the case of the protein multilayers, as depicted in Figure 
2.6C, the cumulative wavelength shift arising from 37 protein bilayers levels off at ~2,700 pm, 
approximately four times less than the maximum signal from polymer multilayers.  This implies 
that, given the similar refractive indices of the proteins and polymers (n ≈ 1.5), the polymers 
form a higher density assembly that yields a larger total response within the bounds of the same 
evanescent field profile. 
In contrast to the linear trend of the initial electrostatic polymer multilayers, the first 15 
protein layers display a non-linear growth profile in which each layer yields a larger resonance 
wavelength shift than the previous layer. This effect can be observed in Figure 2.7, where the 
differential resonance shift between each layer is plotted as a function of layer number. Prior to 
bilayer 8 (the first 15 protein layers), each successive layer corresponds to an increasing 
differential shift despite the decreasing evanescent field intensity, with a maximum shift of 250 
pm/protein bilayer at bilayer 8.  Following this maximum shift, the observed resonance shift 
behavior is dominated by the decay of the evanescent intensity.  We attribute this interesting 
multilayer assembly behavior to an increasing protein binding density throughout the early phase 
of growth (layers 1-15) where later layers are more complete than those initially deposited. We 
imagine initial antibody surface loading yields an incomplete monolayer, and subsequent 
biomolecular layers effectively anneal the initial holes in the film. After the addition of 15 
protein layers (8 bilayers), we suspect that most holes have been filled as further layer growth 
appears linear. This means that subsequent resonance wavelength shifts for the remaining layers 
are completely dictated by the decay in the evanescent intensity. This model of linear layer 
growth following complete annealing by layer 15 is consistent with the measured shift in 
resonance wavelength for layers 16-75. A simple exponential decay function effectively fits the 





Figure 2.7 Plot displaying the relative differential shift per antibody/streptavidin bilayer. Notably, the signal 
increases initially to a maximum shift of ~250 pm at bilayer 8. Beyond this point the signal from subsequent layers 
decreases in an exponential fashion as they are deposited further away from the surface where there is a lower 




multilayers and calculate an average protein layer thickness of 6.6 nm. This analysis reveals that 
our understanding of the evanescent intensity decay at increasing distances from the sensor 
surface allows for the isolation of contributions from non-linear layer growth and estimation of 
the protein layer thickness. Most importantly, however, we can directly observe the diminishing 
signal measured as capture agents are localized farther away from the sensor surface.  
 
2.4.3 Absolute Mass Sensitivity via 125I-labeled Streptavidin 
 
 Another metric that is valuable for comparing the relative performance of different 
sensing methodologies is the number of target molecules required to elicit a measureable sensor 
response. Clearly, the mode of signal transduction, the sensor configuration and geometry, and 
the size or mass of the target molecule play a critical role in determining how best to define this 
metric. Therefore, we decided to determine the absolute LOD of the microring resonator 
biosensing platform in terms of the minimum mass that can be detected. Since most biological 
molecules have similar refractive indices, we assert that this metric can be converted to the LOD 
in terms of the number of molecules for any bound analyte of known molecular weight. 
 In order to probe the mass sensitivity of the microring resonator platform, the amount of 
material bound at the surface must be carefully measured and correlated with the resonance 
wavelength shift upon binding. Our approach involves (1) measuring the wavelength shift of 
radioactive streptavidin binding to a biotinylated microring surface and then (2) determining the 
mass of bound streptavidin using standard radiometric techniques. Specifically, we used 125I-
labeled streptavidin and phosphorimaging to determine the amount of mass bound to the surface. 
The relationship between 125I-streptavidin surface density and net resonance wavelength shift 
response was measured for three different sensor chips and used to determine the mass 
sensitivity and LOD for the biosensing platform. 
 The phosphorimager utilized for streptavidin mass quantitation has a spatial resolution of 
50 µm, which is not sufficient to resolve individual microring sensing elements, especially 
considering that the fluoropolymer cladding material is only removed from an 8-µm wide 
annular opening over each microring (see Figure 1). Furthermore, we observed a non-zero 
radioactive response from the cladding material, meaning not all signal in a single 
phosphorimager pixel can be attributed to a microring. Therefore, we utilized RIE to remove the 
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cladding layer from one half of the chip before the surface was functionalized. Etching only half 
of the chip allowed half of the rings to remain unaltered to ensure that no binding artifacts or 
inconsistencies resulted from the etching process and to preserve unexposed thermal control 
rings for drift correction.  
Given that the silicon microrings possess a native layer of silicon oxide, we feel it is a 
reasonable assumption that the binding density of 125I-streptavidin on a microring will be 
comparable to that of the freshly-exposed bulk silicon oxide surface. To ensure that replicate 
measurements were independent of chip-to-chip variations, we tested the refractive index 
sensitivity of each chip by measuring the relative wavelength shift elicited by switching the 
surrounding solution from water to 1 M NaCl. All rings on all chips responded to 1 M NaCl with 
a 475 ± 25 pm shift. This variation falls well within the precision tolerance required to assess the 
absolute mass bound to the microring surface. 
Each chip was functionalized with APTES and NHS-biotin, and then exposed to 125I-
streptavidin, creating a protein layer as shown in Figure 2.8A. To obtain a range of surface 
densities for calculating mass sensitivity, variable streptavidin loadings were produced by 
monitoring the real-time binding of streptavidin and initiating a buffer rinse after different 
exposure times (from 10 to 30 minutes). Figure 2.8B shows a representative binding curve where 
1.2 µg/mL 125I-streptavidin is introduced at t = 12. With varied streptavidin exposure times, we 
were able to obtain net sensor responses of 46 pm (low coverage), 165 pm (medium coverage), 
and 216 pm (high/saturated coverage). Following the buffer rinse and net binding shift 
determination, the chips were imaged, and the amount of bound mass was determined by 
comparison with spotted standards. 
As shown in Figure 2.8C, 125I-streptavidin bound to all areas over which flow was 
directed, including the half of the chip where the cladding layer was intact (although to a lesser 
extent). A rectangular region directly over the rings on the etched half of the substrate was 
selected on each chip, and the integrated total image intensity from the selected area was 
converted to a mass of bound streptavidin based on calibration with the 125I-streptavidin 
standards (see Figure 2.9). Based on the pixel count of the sampled channel area and the pixel 
size of the phosphorimager, the bound mass was converted to a surface density.  By dividing the 




Figure 2.8 (A) Schematic showing the APTES-modified silicon surface coated with a layer of NHS-biotin followed 
by a layer of 125I-labeled streptavidin. (B) Real time data showing binding of 125I-labeled streptavidin to a biotin-
functionalized surface. After rinsing the surface with buffer, the average net shift (relative shift after streptavidin 
minus relative shift before streptavidin) is measured for multiple rings. (C) Phosphorimage showing the relative 
intensity of 125I-streptavidin standards compared with that bound on the U-shaped area of the chip to which flow was 
directed by microfluidics. The red rectangle highlights the region of interest directly over the rings on the chip where 
the radioactivity intensity was measured. In this selected area, the cladding layer was etched off exposing silicon 
oxide over the entire surface. (D) Calibration curve relating the mass of spotted protein standards (black dots) from 
(C) to the phosphorimager intensity obtained. The blue square represents the signal arising from the selected area 





Figure 2.9 (A) Phosphorimager calibration curve for Chip 1, medium coverage 125I-streptavidin (B) Calibration 
curve for Chip 2, high/saturated coverage 125I-streptavidin (C) Calibration curve for Chip 3, low coverage 125I-
streptavidin (same as Figure 6D). The blue squares represent the phosphorimager intensity of the selected area on 


























1 60844 2.25 0.65 3465 165 21.0 0.1 2.1 
2 105948 2.18 0.65 3361 216 15.6 0.1 1.6 






average mass sensitivity of the three chips was determined to be 14.7 ± 6.7 [pg/mm2]/∆pm (see 
Table 2.1). Thus, a resonance wavelength shift of 1 pm represents 15 ± 7 pg/mm2 of bound 
protein, or inversely, each 1 pg/mm2 of protein density generates a 0.07 ± 0.03 pm shift in 
resonant wavelength.  
To determine a LOD for the platform, we determined the noise floor to be 0.1 pm based 
on the minimal resolvable peak shift. To obtain the minimal resolvable peak shift, we utilize a 
calculation based on the ability to differentiate two different sets of data at the 95% confidence 
interval. Because measurements are made in real time, we can measure the average microring 
resonance wavelength shift value for 5 minutes (initial baseline) before a certain amount of 
substance is added to a ring surface, and then measure the average shift over a 5-min  period 
after the addition of the substance to the surface. Given a baseline noise level with a standard 
deviation of 0.2 pm,19 we can calculate the t-statistic for the two sets of data using the formula47 
as shown below: 
 
  ∆ /2 
 
where ∆ is the average difference between the two mean values, s is the pooled standard 
deviation (in this case, we assume that both the standard deviations and sample sizes are exactly 
the same, so the pooled standard deviation equals the standard deviation of the single sample), 
and n is the number of points in the sample. To be significantly different at the 95% confidence 
interval, tcalculated must be greater than 2.02. Solving for ∆ using n = 40 (number of data points 
for each ring collected in a 5-min span) and s = 0.2 pm, we get ∆ = 0.09 pm. Thus, assuming a 
minimum resolvable peak difference of 0.1 pm for calculating the absolute mass sensitivity is a 
reasonable assumption. 
Based on a 0.1 pm peak shift resolution, the platform’s LOD was calculated at 1.5 ± 0.7 
pg/mm2.Using the surface area of 66 µm2/ring and the surface density LOD described above, we 
determine the absolute mass LOD to be 97 ag of bound protein.  This mass sensitivity signifies 
the ability to detect just 0.6 zmol (~400 molecules) of an antibody bound to the microring in a 
direct and label-free assay. The use of secondary antibodies in sandwich assay formats can 
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further augment the sensitivity of the platform to a protein target, especially for lower molecular 




 Through a combination of two multilayer studies on a silicon photonic microring 
resonator biosensing platform, the experimentally determined evanescent intensity decay profile 
was found to be in reasonable agreement with simulation results. The 1/e decay distance of 
binding sensitivity was measured to be 63 nm, highlighting the outstanding overlap of the 
waveguide mode with the biomolecular sensing region. Since most biological binding 
interactions with a capture probe (i.e. antibody, nucleic acid strand) and target analyte have 
dimensions on the order of tens of nanometers, this platform is well-suited for  sensing specific 
binding events near the ring without large contributions from the surrounding environment.48 
Furthermore, with an empirical measure of the decay length characteristics of the microrings, it 
may be possible to design and optimize capture strategies to maximally utilize this property. For 
example, it is clear that assay designs involving non-fouling surface modifications (i.e. PEG 
chains, polymer brushes, etc) and secondary/tertiary signal amplification steps should take under 
consideration the strong evanescent decay distance dependence of sensor response. These 
considerations become especially clear in the protein multilayer data where the signal is reduced 
by 63% after only 5 SA/Ab bilayers. Understanding the decay length also enables elucidation of 
non-linear growth processes such as those observed in the protein multilayer system.  
 Beyond characterizing the sensing modality and the extent to which the evanescent 
intensity propagates through the sample, the inherent mass sensitivity of the platform was also 
empirically determined. Through the use of radio-labeled protein binding to the sensor surface, it 
was possible to directly relate a given resonance wavelength shift to an empirically determined 
protein surface density.  This allowed for determination of the platform’s inherent sensitivity, 
which is 15 [pg/mm2]/∆pm.  The high sensitivity of ring resonators to biological binding events 
at this early stage of technology development, with a ~1.5 pg/mm2 LOD, is comparable to that of 
SPR 25 and other label-free techniques.3, 8, 15 By improving peak resolution and reducing system 
noise, this sensitivity may be improved further. In both the multilayering and surface density 
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studies, the ability to monitor each ring’s response in real time was vital to the characterization 
of platform performance metrics. 
This paper presents important empirical determinations of key sensitivity metrics for a 
promising silicon photonic microring resonator chemical and biomolecular sensing platform. 
This information will be useful not only in comparing this platform to others, both optical and 
non-optical, but also provides key insights into the current limitations of sensor response which 
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Fluorescent,1 nanoparticle,2 or enzymatic labels3 are utilized in many common 
biomolecular assays and can provide exceptional sensitivity down to the single molecule level. 
However, they may also introduce challenges in terms of cost, complexity, labeling 
heterogeneity,4 and perturbations to the native biomolecular interaction of interest.5 For these 
reasons, the development of label-free approaches for bioanalysis, especially those that can 
measure multiple analytes simultaneously, has been an active area of research over the past 20 
years.6 Particularly relevant to this report are optical methods of label-free analysis,7 including 
surface plasmon resonance,8 photonic crystals,9 and interferometric devices,10 which have all 
been utilized to sensitively detect biomolecules as well as determine binding kinetics.  
High quality factor (Q factor) microcavity resonators represent a promising class of 
optical devices that have only recently been utilized for biomolecular analysis.11, 12 In 
microcavity resonator sensors, which include microspheres,13-15 microtoroids,16 capillaries,17-21 
microdisks,22, 23 and microrings,24-30 light is coupled into the cavity via an adjacent linear 
waveguide positioned within the evanescent field. Optical modes are supported along the 
circumference of the cavity according to the resonance condition: 
mλ = 2pirneff 
where m is an integer, λ is wavelength of light, r is the radius of the resonator, and neff is the 
effective refractive index. Precise fabrication leads to high Q factor cavities which, from a 
practical analytical standpoint, lead to a dramatic increase in the effective optical pathlength as 
well as a sharpening of the resonance to an extraordinarily narrow spectral dispersion. Chemical 
and biomolecular binding events at the surface of the microcavity lead to an increase in the 
effective refractive index, neff, and thus a shift in the resonance frequency, as shown in Figure 
3.1A. The narrow resonance allows resolution of small shifts, and thus tiny binding-induced 
changes in neff, can be clearly discerned, directly facilitating highly sensitive detection. 
Silicon-on-insulator (SOI) optical microring resonators are an attractive technology for 
applications in label-free biomolecular analysis holding significant promise for multiplexed 
biomolecular detection. Since both the ring and waveguide are physically anchored to the same 






Figure 3.1 (A) Schematic diagram illustrating the principle of microring optical resonator biosensing, including a 
representative transmission spectrum. (B) Top-view scanning electron micrograph image of a microring resonator 




using well-characterized semiconductor processing techniques and easily interrogated via chip-
integrated optics.  
Prior reports of optical microring resonators for protein sensing have generally focused 
on proof-of-principle demonstrations, such as measurements in buffer of avidin-biotin 
interactions24, 26-28 or detection of polyclonal IgG.30 Besides demonstrating the ability to monitor 
in real time the steps involved in the chemical and biomolecular functionalization of the sensor 
surface, we also utilize multiple types of integrated on-chip control sensors for nonspecific 
response normalization and implement a time-based quantitation method that enables rapid 
calibration and precise concentration determination. As a demonstration of the impact of these 
features, we focus on the direct and label-free quantitation of carcinoembryonic antigen (CEA), a 
185 kDa glycoprotein that is secreted into the blood and has been established as a biomarker for 
many human cancers, including colorectal,31 cervical,32 lung,33 and breast34 cancers. We show 
that the detection limit of our platform is comparable to that of a commercial enzyme-linked 
immunosorbent assay (ELISA) kit and is satisfactory for the quantitation of CEA over the 
clinically-relevant range of 5-100 ng/mL. We also report for the first time operation of microring 
optical resonators in undiluted fetal bovine serum and show that CEA can be detected in this 
complex medium at concentrations found in patients with advanced cancers, from 20 to well 
over 70 ng/mL.35 This report establishes microring resonator arrays as a promising tool for a 
variety of real-world protein detection applications. 
 
3.2 Materials and Methods Sections 
3.2.1 Materials 
 
The silane 3-aminopropyltriethoxysilane (APTES), was purchased from Gelest 
(Morrisville, PA). Succinimidyl 6-hydrazinonicotinamide acetone hydrazone (S-HyNic) and 
succinimidyl 4-formylbenzoate (S-4FB) were purchased from SoluLink (San Diego, CA). 
Monoclonal mouse antibody to human CEA (Cat# M37401M) and human CEA (Cat# A32030H) 
were purchased from Meridian Life Science (Saco, ME). CEA ELISA kits were purchased from 
GenWay Biotech (San Diego, CA) and Signosis (Sunnyvale, CA). Fetal bovine serum (FBS) was 
purchased from Gemini Bio-Products (West Sacramento, CA). Zeba spin filter columns were 
purchased from Pierce (Rockford, IL). PBS was reconstituted from Dulbecco’s Phosphate 
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Buffered Saline packets purchased from Sigma-Aldrich (St. Louis, MO). All other chemicals 
were obtained from Sigma-Aldrich and used as received.  
All buffers were made with purified water (ELGA PURELAB filtration system; Lane 
End, UK), and the pH was adjusted using 1 M HCl or 1 M NaOH. PBS pH 7.4. Acetate buffer 
consisted of 50 mM sodium acetate and 150 mM sodium chloride adjusted to pH 4.75. Glycine 
buffer was 10 mM glycine and 160 mM NaCl adjusted to pH 2.2. BSA-PBS buffer was made by 
dissolving solid bovine serum albumin (BSA) in PBS (pH 7.4) to a final concentration of 0.1 
mg/mL.  
 
3.2.2 Substrate Design, Fabrication, and Sensor Chip Layout 
 
Microring resonator array substrates were designed as previously described36 and 
fabricated on 8" silicon-on-insulator (SOI, 200 nm thick top-layer Si) wafers by the silicon 
foundry at LETI (Grenoble, France). The entire 8" wafer was spin-coated with a fluoropolymer 
cladding material, and windows were opened over selected individual sensor elements via 
photolithography and reactive ion etching. Individual sensor chips having sixty-four 30 µm 
diameter microrings on a 6 x 6 mm footprint were diced from the 8" wafers by Grinding and 
Dicing Services, Inc. (San Jose, CA). Next to each microring was a linear waveguide that had 
input and output diffractive grating couplers at either end, allowing the optical cavity spectrum 




The instrumentation used to measure shifts in microring resonance frequency is described 
in detail in a separate manuscript.36 Briefly, the beam of a tunable, external cavity diode laser 
operating with a center frequency of 1560 nm is rapidly rastered across the surface and the back 
reflection is monitored as a function of position to image the substrate. This image is used to 
register the location of the input and output grating couplers associated with each individual 
microring. To determine the resonance frequency of an individual microring, the beam is focused 
onto a single input grating coupler. The intensity of light projected off of the chip by the 
corresponding output grating coupler is measured as the frequency of the laser is rapidly swept 
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through a suitable spectral bandwidth. In this mode of operation, a resonance appears as a 
decrease in the intensity of light projected out of the output coupler at a given laser frequency, 
since under resonance conditions light is nearly completely coupled into the microring and no 
longer propagates down the adjacent linear waveguide. Resonance frequencies and shifts in 
frequency are determined and displayed on-screen in near real time with up to ~250 ms 
resolution using the provided instrument control software. Multiple resonator sensors in an array 
are probed by serially positioning the laser beam on different input grating couplers that address 
unique microrings and then the resonance frequency is recorded as described above. Up to 32 
microring sensors can be monitored during an experiment. Eight of the sensors monitored are not 
exposed to the solution and serve as controls for thermal drift. 
Sensor chips are loaded into a custom cell with microfluidic flow channels defined by a 
0.010" thick laser-cut Mylar gasket (fabricated by RMS Laser; El Cajon, CA) that is aligned over 
top of the microring arrays and sandwiched between an aluminum chip holder and a Teflon lid 
(see Figure 3.2 for a diagram of the microring layout, including an overlay of the Mylar gasket). 
Solutions are introduced to the chip at controlled flow rates using an 11 Plus syringe pump (from 
Harvard Apparatus; Holliston, MA) operated in withdraw mode. 
 
3.2.4 Surface Functionalization and Biomolecule Attachment 
 
To remove any residual organic contaminants remaining from fabrication, silicon 
microring surfaces are first cleaned by a one-minute immersion in piranha solution37 (3:1 
H2SO4:30% H2O2) and are then rinsed with copious amounts of water and dried under a stream 
of nitrogen. Following cleaning, the silicon microrings are then organically modified using 
standard silanization chemistry. The entire chip is exposed to a 2% solution of APTES in 95% 
ethanol for 10-20 min, followed by a removal of residual siloxane by rinsing in 95% ethanol. 
Covalent attachment of biomolecules to the sensor surface is achieved in two steps using 
hydrazone-bond-formation chemistry. The freshly silanized surfaces are exposed to a 17 mM 
solution of S-HyNic in PBS (with 4% dimethylformamide (DMF) to dissolve S-HyNic) for 3–4 
h. In parallel, a reactive aldehyde moiety is conjugated to the antibody (1 mg/mL) by reaction 
with a 5-fold molar excess of S-4FB (dissolved first in DMF and diluted in PBS to less than 5% 




Figure 3.2 Schematic (not to scale) showing a layout of 32 microrings on a 6 × 6 mm silicon chip. The yellow 
overlay indicates the portion of the Mylar gasket used to define flow channels. The entire gasket is not shown as it 
extends beyond the boundaries of the chip. A duplicate set of 32 microrings (offset by 0.5 mm) are also not shown 




per antibody, according to the manufacturer, and was empirically determined to be optimal. After 
reacting for 2 h at room temperature, unreacted S-4FB is removed by buffer-exchanging the 
antibody into acetate buffer using Zeba spin filter columns. HyNic-functionalized surfaces are 
exposed to solutions of 4FB-functionalized antibodies (generally 0.1 mg/mL or higher) for at 
least 1 h to maximize the amount of covalently immobilized antibody. A glycine buffer rinse is 
then used to remove noncovalently bound antibody. A final blocking step is accomplished by 
exposing the sensor surface to a 2% solution (w/w) of BSA in PBS. In a typical assay, half of the 
sensor rings are functionalized with antibody while the other half are not exposed to antibody. 
These nonfunctionalized sensors are used as internal references to correct for temperature and 
instrument drift, as well as for bulk refractive index shifts associated with switching solutions. 
All silanization and HyNic conjugation reactions, as well as detection experiments, are 
performed in linear microfluidic channels defined by the Mylar gasket. For experiments in which 
antibodies are immobilized only onto certain regions of the substrate, a different Mylar gasket is 
used that directs fluid to only selected portions of the sensor chip. While microfluidics alone 
provide adequate spatial resolution for the measurements in this paper, preliminary work in our 
group has indicated that higher order multiplexing can be achieved by interfacing with 
conventional microarray spotting technologies.  
 
3.2.5 CEA Detection  
 
For CEA detection experiments in buffer, BSA-PBS (0.1 mg/mL BSA in PBS) was used 
as a running buffer to help prevent nonspecific adsorption of protein in the tubing and flow cell. 
CEA solutions were made by serial dilution in BSA-PBS starting from an original 2.5 mg/mL 
stock solution. Those solutions were then flowed through the sample chamber and over the 
sensor chip surface at a rate of 30 µL/min. For CEA detection in serum, 100% FBS was used as a 
running buffer. To detect CEA in serum, CEA-spiked FBS samples were made by adding CEA 
stock solution to 100% FBS. Additional solutions were made by directly diluting the CEA-
spiked FBS stock solution with 100% FBS to dilute the CEA to the appropriate concentration. 
Because of the viscosity of 100% FBS, the flow rate was reduced to 10 µL/min for sensing 
experiments in serum. For all of the sensing assays, the original surfaces were regenerated after 
CEA exposure using a 1–2 minute rinse of glycine buffer that disrupted protein-antibody 
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complexes, followed by a return to the running buffer to reestablish the sensor baseline. Single-
blind solutions having unknown CEA concentrations were generated—by a laboratory worker 
otherwise not involved in this study—by adding an aliquot of an original stock solution into 
either BSA-PBS buffer or 100% FBS. 
For the CEA ELISA, absorbance was measured at 450 nm using a SpectraMax Plus384 
spectrophotometer from (Molecular Devices; Sunnyvale, CA). 
 
3.2.6 Data Processing 
 
All microring detection data was corrected for drift related to thermal and instrumental 
fluctuations, as well as minimal amounts of non-specific binding by referencing to “unmodified” 
rings that were exposed to solution in the same sample flow chamber but were masked during the 
antibody immobilization step. Graphs of sensor responses have been processed post-acquisition 
by subtracting the unmodified reference ring responses from the antibody-conjugated sensor 
rings. All data fitting was performed using the OriginPro 8 software package (OriginLab 
Corporation; Northampton, MA).  
 
3.3 Results and Discussion 
3.3.1 Surface Derivatization of Microring Resonator Surface 
 
For sensitive detection of biomolecules, a robust capture agent immobilization strategy is 
needed. Figure 3.3 schematically outlines the multiple steps used to covalently attach antibodies 
to the silicon surface of a microring sensor. As shown in Figures 3.3A and 3.3B, the oxide-
passivated silicon surface is first modified with 3-aminopropyltriethoxysilane (APTES). Because 
addition of organic molecules and biomolecules to the sensor surface changes the local refractive 
index, each surface reaction can be monitored in real time. Figure 3.4A shows the real-time 
response of twelve individual microrings simultaneously exposed to a 2% solution of APTES.  
Following addition of the silane, an immediate shift in resonance frequency is observed that 





Figure 3.3 Schematic showing surface functionalization. (A) Silicon surface of microring sensors prior to 
modification. (B) APTES reacts with the surface siloxane groups to generate an amino-terminated surface. (C) S-
HyNic reacts with primary amines to create a HyNic-displaying surface. (D) Addition of 4FB-modified antibodies 





well as from rapid surface silanization. As the sensors are rinsed with 95% EtOH and returned to 
the original bulk refractive index environment, the sensors decrease in signal but a residual shift 
in the resonance wavelength of approximately 75 pm indicates the covalent attachment of 
APTES to the surface. 
 As indicated by the schematic in Figure 3.3C, the amine-reactive succinimidyl 6-
hydrazinonicotinamide acetone hydrazone (S-HyNic) is added to the APTES-functionalized 
surface. This hydrazide group is then used to covalently immobilize the antibody capture agent 
using hydrazone-bond-formation chemistry. Figure 3.4B shows in real time the addition of S-
HyNic to the same twelve microrings shown in Figure 3.4A. Similar to the silanization reaction, 
a large bulk refractive index shift is observed, but this time it is even larger due to the transition 
from PBS to PBS containing 4% DMF and S-HyNic. The bulk shift is followed by a much 
slower increase over approximately two hours due to the reaction of the succinimidyl esters of 
the S-HyNic reacting with surface amines. Returning to PBS reveals a residual shift of 50–100 
pm which is the result of covalently immobilized HyNic. The reasons behind the differential 
response at each ring are still under investigation, but it likely is the result of heterogeneous 
chemical reactivity of individual sensors. 
Following the generation of a hydrazine-presenting surface, antibodies tagged with 
succinimidyl 4-formylbenzoate (S-4FB) are covalently coupled to the surface via hydrazone 
bond formation between the aryl aldehydes on the antibodies and the hydrazine moieties on the 
surface, as illustrated in Figure 3.3D. Figure 3.4C shows the real-time data for the addition of 
4FB-tagged anti-CEA antibodies to five identical HyNic-modified microrings resulting in a 300–
350 pm shift in the resonance frequencies of each ring. A rinse with glycine buffer helps remove 
any noncovalently bound antibody, and after returning to the original acetate buffer, the 
remaining 260–280 pm shift for each ring corresponds to antibody attached to the microring 
surface via a hydrazone bond linkage. 
By monitoring each surface derivatization step, it is possible to verify that each individual 
chemical modification of the surface has occurred. In addition, it is possible to determine the 
sensor-to-sensor consistency of antibody loading. Since inconsistency in antibody loading is a 
common source of assay variability, this is a very significant feature of our detection system that 




Figure 3.4 (A) Real-time monitoring of the shift in resonance frequency for twelve microrings within the same 
sample flow chamber during organic modification via reaction with APTES. The microrings were initially 
submerged in 95% ethanol solution and a 2% solution of APTES injected at t = 6.5 min. The silane was flushed 
from the chamber and microrings returned to 95% ethanol after 10 min. (B) Real-time observation of the reaction 
between S-HyNic (introduced at t = 10 min) and the surface amine groups as followed by monitoring the shift in 
resonance frequency. (C) Real-time shift in resonance frequency from five individual microrings during covalent 
immobilization of antibody onto the sensor surfaces. The 4FB-tagged anti-CEA antibody was added at t = 10 min 




Following the immobilization of anti-CEA antibodies, microring sensors were tested to 
verify that the immobilized antibody was still functional and that the sensors were responsive to  
antigen binding. Figure 3.5 shows the uncorrected (no control ring subtraction) response of anti-
CEA functionalized microrings to a 1 µg/mL solution of CEA in BSA-PBS at t = 5 min, 
followed by regeneration with glycine buffer at t = 12 min with a return to BSA-PBS at t = 14 
min. The exposure to CEA induces a specific response from five individual antibody-
functionalized microrings, each displaying a net frequency shift of ~100 pm after 7 min of 
binding. Notably, the relative response of each of the rings is extremely similar, consistent with 
the observed antibody loading shown in Figure 3.4C.  Also shown in Figure 3.5 are the responses 
of five individual control rings that are in the same channel as the five rings that showed a 
specific response. These microrings are identical except that they were not exposed to the 4FB-
tagged antibody solution, and they showed no response during the same exposure to antigen. 
Thus, for all following biomolecular binding/detection experiments in this chapter, these 
unmodified rings are used as references. An important advantage of using an array of microring 
sensors is that unmodified rings can be used as reference rings in order to subtract out any 
systematic instrumental or thermal drift, as well as to remove sensor response caused by a 
change in the bulk refractive index or from small amounts of nonspecific binding. 
 
3.3.2 Quantitative Detection of a Cancer Biomarker 
 
To make quantitative measurements of CEA, microring resonators were covalently 
functionalized with anti-CEA antibodies as described. To demonstrate the dynamic range for this 
sensing technique, aliquots of CEA were sequentially flowed over the sensor array at 
concentrations of 45, 114, 228, 575, and 1183 ng/mL in BSA-PBS, and the shift in resonance 
frequencies of several microrings were monitored in real-time. At each concentration, the CEA 
solution was flowed for 25 minutes of binding followed by a quick (1–2 minute) rinse with 
glycine to regenerate the original antibody-presenting sensor surface and a 5-10 minute rinse 
with BSA-PBS to reestablish the baseline. Figure 3.6 shows a representative response from a 
single microring during the entire concentration exposure series. This dose and regeneration 
protocol was repeated three times in order to obtain all association curves in triplicate for post-




Figure 3.5 Time-resolved detection of CEA using five anti-CEA-functionalized microrings alongside five control 
microrings that were not functionalized with antibody. Following exposure to CEA, the antibody surface was 





Figure 3.6 Real-time monitoring of resonance frequency shifts of an anti-CEA antibody-functionalized microring 
upon exposure to increasing concentrations of CEA in BSA-PBS. After exposure to antigen, the antigen-antibody 
interaction was disrupted with glycine buffer, regenerating the original sensor surface, and the sample chamber was 





To demonstrate the consistency of the observed CEA detection response, the data from a 
single microring during each of the three concentration series runs was overlaid, as shown in  
Figure 3.7A. The good agreement in both the magnitude and shape of the association curves 
allows CEA concentration determination with high precision. From the data in Figure 3.7A, a 
calibration curve was generated based upon the initial slopes of the association curves. As 
described by Fick’s first law, under the mass-transport limiting conditions usually present in 
trace biomolecular analysis, the initial slope is linearly proportional to the concentration of the 
analyte in solution.38 The resulting concentration-response calibration curve is generally linear 
over a wide dynamic range, and thus the method is advantageous for real-time detection 
assays.30, 39-41 In addition, we have found that using an initial slope-based method provides 
increased precision as compared to fixed-time-point measurements for the 10-minute assays 
described in this paper. This increased precision is largely because the initial slope is determined 
from multiple data points over a given time range, whereas equilibrium-based measurements 
typically measure the response at a single time point, or over a discrete time range, during which 
the response is growing. For our system, multiple measurements based on initial slope typically 
have standard deviations about 3–6 times smaller than the standard deviations based on multiple 
measurements using a fixed time point. 
In order to accomplish this analysis, the initial portion of the association curve is fit to an 
exponential functional form and then the exponential function is differentiated and the derivative 
function is evaluated at t = t0, where t is time, and t0 is the time at which solution is introduced to 
the microring. The equation utilized is a modified form of the integrated rate equation for a 1:1 
Langmuir binding system and is given by: 
( )( )0( ) 1 B t tS t A e− −= −
 
where S(t) is the relative shift as a function of time, and A and B are fitting parameters. The 
variables A, B, and t0 were fit to each binding curve independently and all parameters were 
allowed to vary. Curve fitting was done using the nonlinear curve fit routine in OriginPro 8. To  
determine initial slopes, the exponential equation can be differentiated to give the expression: 







Figure 3.7 Real-time, label-free detection of CEA using microring resonators. (A) Overlay of three time-resolved 
association curves for the same ring at each concentration of CEA. The colored traces are tangent lines to the 
association curve at t = 0 and are used to determine the initial slope of sensor response. (B) Concentration-response 
calibration plot of the initial slope of sensor response versus CEA concentration upon introduction of antigen 
standard solutions. The dashed box in the corner of the graph represents the range shown in Figure 3.9C for 








Figure 3.8A shows the regions of each curve from Figure 3.7 used for fitting, and Figure 
3.8B shows the best fits overlaid on each curve. The colored lines in Figure 3.7A represent fitted 
tangent lines that give the initial slope for each association curve at each concentration. The 
initial slope values determined from the data in Figure 3.7A are plotted as a function of 
concentration in Figure 3.7B (error bars 95% confidence interval (C.I.), number of measurements 
(n) = 3). Table 3.1 gives the fitting parameters (A, B, t0, AB, and χ2 ,the chi-squared distribution) 
for each curve fitting in Figure 3.8B. 
Notably, the resulting slope-based calibration plot is linear (coefficient of determination 
(R2) for the linear fit is 0.997), which enables simple sensor calibration and extended linear 
dynamic range, particularly at higher antigen concentrations. While data from only a single 
microring is shown for clarity, the response of multiple sensors were simultaneously recorded 
and found to also yield linear calibration plots with extended dynamic ranges. While each 
microring behaved in a similar fashion, it is apparent that small differences in antibody loading 
require each microring sensor to be independently calibrated. Methods of a priori sensor 
normalization have the potential to enable independent calibration and fully automated 
applications in the future. 
To demonstrate the ability of microring sensors to quantify samples containing lower 
concentrations of CEA, a second calibration curve was constructed based on the initial slope 
approach using standard concentrations from 0 to 121 ng/mL—encompassing the clinically-
relevant range of 5–100 ng/mL. Figure 3.9A shows the overlaid time-response curves used to 
generate the initial slopes for the standard concentrations. Each concentration was run in 
triplicate with best-fit lines shown in color. Given that the rate of association is very slow at 
these concentrations, we directly fit the data from to a linear function, bypassing the exponential 
fit and derivative determination required at higher concentrations. 
The initial slope-based concentration response curve is shown in Figure 3.9C (error bars 
95% C.I., n = 3). Again a linear calibration plot is observed (R2 = 0.997). The real-time 




Figure 3.8 (A) Selected initial regions for each binding curve from Figure 6A (B) Best fits of exponential function 

















45 600.5 0.00176 -0.0692 1.057 0.0669 
45 41.5 0.02858 -0.1982 1.187 0.0683 
45 19.3 0.06947 -0.0745 1.343 0.0494 
114 87.2 0.03224 0.0340 2.813 0.0607 
114 86.7 0.03405 0.0336 2.951 0.0623 
114 67.3 0.04482 0.0191 3.018 0.0643 
228 76.0 0.07345 0.0188 5.580 0.1373 
228 78.9 0.07224 -0.0042 5.699 0.0758 
228 73.0 0.08461 0.0333 6.180 0.0654 
575 77.4 0.17261 0.1328 13.355 0.2019 
575 80.0 0.16998 0.0739 13.605 0.3361 
575 81.9 0.17305 0.1175 14.179 0.1465 
1183 92.7 0.25708 -0.0189 23.831 0.4325 
1183 82.6 0.32173 0.0604 26.591 0.2257 






Figure 3.9 Real-time, label-free detection of low concentrations of CEA using microring resonator sensors. (A) 
Overlay of three time-resolved association curves at each concentration of CEA, as listed on the plot. The colored 
lines are linear fits to association data used to determine the initial slope of sensor response. (B) Overlay of three 
time-resolved association curves for unknown A and unknown B with linear fits shown in red. (C) Concentration-
response calibration plot for CEA as determined by the initial slope method based on the initial slopes determined 
















0 -0.03562 0.01713 0.372 0.0697 0.03654 
0 -0.01616 0.01617 0.085 0.06581 0.00869 
0 0.02516 0.01646 -0.044 0.067 0.02009 
6.0 0.07964 0.02004 0.177 0.08169 0.12163 
6.0 0.12607 0.01924 0.018 0.07875 0.27352 
6.0 0.12799 0.01998 -0.122 0.08128 0.26475 
10.9 0.17368 0.01679 0.192 0.06819 0.48414 
10.9 0.20138 0.01470 0.094 0.06076 0.61812 
10.9 0.20924 0.01817 0.291 0.07412 0.53777 
21.9 0.48175 0.01490 -0.197 0.06094 0.90169 
21.9 0.50773 0.01791 -0.178 0.07283 0.87575 
21.9 0.52727 0.01267 -0.118 0.05159 0.93827 
48.4 0.94338 0.01830 0.096 0.07452 0.95888 
48.4 0.95315 0.01542 0.314 0.06305 0.97104 
48.4 0.96077 0.01392 0.336 0.05685 0.97662 
121 2.23048 0.01504 0.046 0.06142 0.99484 
121 2.30533 0.01525 -0.044 0.06223 0.99503 
121 2.33983 0.02154 -0.240 0.0879 0.99043 
Unknown A 1.70922 0.01657 0.334 0.07494 0.9882 
Unknown A 1.72481 0.01438 0.358 0.06667 0.99104 
Unknown A 1.7344 0.01372 0.468 0.06291 0.99206 
Unknown B 0.34016 0.01730 0.160 0.07278 0.76611 
Unknown B 0.35153 0.01313 0.264 0.05705 0.85552 




different days. While the slopes of the calibration traces are similar, they are not identical, and 
there is a noticeable difference in the y-intercept—largely due to the variation in the dynamic 
range of each calibration plot. This observation reinforces the notion that at this stage each 
sensor must be independently calibrated on the same day and, ideally, calibrated directly in series 
with unknown samples. As with any calibration curve, the greatest accuracy for evaluating an 
unknown will be obtained by using calibration concentrations within a relevant range for the 
unknowns. 
 
3.3.3 Measurement of unknown CEA concentrations 
 
While the generation of calibration curves from standards is important, the obvious 
objective is the quantitation of unknown samples of CEA. Two blinded unknown samples A and 
B were measured to determine the concentrations of CEA using both a microring sensor and a 
commercial CEA ELISA kit. Both unknown solutions were flowed over the microring in 
triplicate, interspersed between the three concentration series shown in Figure 3.9A. The data for 
the unknown binding curves and subsequent linear fits are shown in Figure 3.9B. The initial 
slopes were determined for the lower concentration CEA standards and for the unknowns and the 
fitting parameters for each of these measurements is shown in Table 3.2. The unknown samples 
had slopes of 1.7 pm/min and 0.36 pm/min for unknowns A and B, respectively. Figure 3.9C 
shows the mapping of these initial slope values onto the calibration curve and quantitation of the 
unknowns as 90 ± 2 and 18 ± 1 ng/mL, respectively (uncertainties are based on the 95% C.I. for 
a calibration curve with n = 18, with three replicate unknown evaluations). The concentration 
values were then compared with those obtained using a commercial ELISA kit. The same 
unknown solutions (A and B) were assayed in a 96-well plate along with the provided standards 
according to manufacturer instructions. Concentration determination via ELISA gave 
concentrations of 112 ± 11 and 17 ± 9 ng/mL for unknowns A and B, respectively (uncertainties 
are based on the 95% C.I. for the ELISA calibration curve with n = 18, with three replicate 
unknown evaluations). The calibration curve for the ELISA is shown in Figure 3.10. 
Following quantitation of CEA via both microring sensors and the commercial ELISA 
kit, the concentrations of the prepared blinded unknowns A and B were revealed to be 91 and 17 




Figure 3.10 Overlay of the unknown solutions on the concentration-response calibration plot for CEA in BSA-PBS 
using a commercial ELISA kit; the concentration of the unknown solutions were determined to be 112 ± 11 and 17 ± 




concentration with a high degree of accuracy. Unknown A, which is higher in concentration, was 
also correctly determined via the microring resonators. However, the “correct” value falls outside 
the 95% confidence interval for the ELISA assay. Notably, the 95% confidence intervals are 
considerably larger for the ELISA assay. At higher concentrations this is likely due to the larger 
absorbance values that test the linearity of the spectrometer. The error in high concentration 
determination might be reduced by shortening the time of the development step, but this would 
compromise the ability to accurately quantitate at lower concentrations. This trade-off in the 
quantitative ability of ELISA across a one order of magnitude dynamic range is clearly less of a 
concern using the label-free microring resonator sensor. 
To determine a detection limit for the microring resonator sensor, a minimum resolvable 
change in initial slope must be established in comparison to the normal baseline “slope noise.” 
To achieve this, the standard deviation of the linear slope (slope noise, σ) of representative 7 min 
baseline sections (the same period of time over which the initial slope was fit for determination 
of low antigen concentrations) was measured to be 0.02 pm/min. Extrapolating to the 3σ 
threshold, the limit of detection for CEA in BSA-PBS was determined to be ~2 ng/mL. Notably, 
this value is below the basal levels (3-5 ng/mL) of CEA present in the serum of “healthy” adults. 
The microring detection limit is also comparable to the stated manufacturer value for the 
commercial ELISA kit of 1 ng/mL. Notably, the initial slope-based concentration determination 
can be accomplished in less than 30 minutes using microring resonators—a total of four 7 min 
runs (three standards and one unknown sample)—which is significantly faster than the 3+ hour 
ELISA procedure. Given the favorable precision, similar limit of detection, and assay speed in 
comparison to an ELISA assay, the potential of microring resonators for rigorous quantitation of 
unknown protein concentrations is high. 
By way of comparison, multiple microring sensors on a given chip are observed to vary 
in the slope of the calibration curve slope by about 10-20%. However, the precision of each 
calibration curve remains fairly consistent, allowing unknowns to be evaluated among multiple 
sensors with a standard deviation of around 1-2 ng/mL, on the same magnitude as the observed 






3.3.4 Cancer Biomarker Detection in Serum 
 
We have also evaluated the ability of microring sensors to detect CEA in 100% fetal 
bovine serum. By adding human CEA to FBS, the detection platform was challenged with a 
complex sample matrix similar to that encountered when analyzing human serum or other 
biological fluids. CEA standards were created in FBS at concentrations of 0, 19, 49, 98, and 199 
ng/mL, and the analysis was performed on a sensor chip functionalized with an anti-CEA 
antibody. As with CEA detection in buffer, the concentration of CEA in FBS was directly related 
to the initial slope following addition of the samples. However, because FBS contains a high 
concentration of proteins that nonspecifically adsorb to the sensor surface, addition of FBS 
resulted in a drifting baseline signal that could only be partially corrected using the on-chip 
control rings, as can be seen from an example trace in Figure 3.11A. Therefore, to accurately 
determine the sensor response to CEA, the slope of the baseline was measured 5 min before 
injection of the CEA sample and the slope of the drifting baseline was subtracted from the 
measured slope after the injection time. Table 3.3 gives the fitting parameters for the linear fits 
used in the serum analysis to create the calibration plot shown in Figure 3.11B. To test the 
validity of the calibration curve, a blinded unknown was evaluated and determined to have a 
concentration of 61 ± 23 ng/mL by comparison with the standard calibration curve shown in 
Figure 3.11B (uncertainties for unknowns are based on the 95% C.I. for a calibration curve with 
n = 15, unknown run one time). The microring resonator results were again correlated with those 
of a commercially-available ELISA, which gave a value of 67 ± 9 ng/mL. The calibration plot 
for this ELISA is shown in Figure 3.12. Both values were in good agreement with the prepared 
unknown concentration of 70 ng/mL, as revealed by analyses using microring and ELISA 
methods. 
By comparing the slopes of the calibration curves for microring resonator detection of 
CEA in both buffer and serum, it is apparent that sensitivity is greatly reduced in serum. Whereas 
detection in buffer gives a slope of 0.019 (pm/min)/(ng/mL), see Figure 3.9C, detection in serum 
shows a ~6 fold decrease to 0.0036 (pm/min)/(ng/mL), as shown in Figure 3.11. This is not 
unexpected, however, since the specific binding of CEA is in competition for available antibody 
recognition sites with nonspecific interactions from serum proteins, some of which are present at 




Figure 3.11 (A) Example sensor response following addition of CEA in 100% FBS. Initial slope is determined by 
using a linear fit of the baseline to subtract the drifting baseline from the change in signal caused by addition of CEA 
in FBS. (B) Overlay of the unknown solution on the concentration-response calibration plot for CEA in 100% FBS. 





Table 3.3 Fitting parameters used to create the trace shown in Figure 6B in the manuscript. 
Concentration 











0 baseline 0.121 0.029 0.311 0.085 0.310 
 response 0.072 0.013 0.430 0.076 0.302 
0 baseline 0.142 0.030 0.357 0.088 0.359 
 response 0.122 0.012 0.390 0.076 0.566 
0 baseline 0.158 0.026 0.403 0.077 0.476 
 response 0.070 0.012 0.459 0.072 0.328 
19 baseline 0.263 0.027 0.672 0.079 0.707 
 response 0.249 0.012 0.733 0.073 0.853 
19 baseline 0.187 0.024 -1.668 0.069 0.611 
 response 0.201 0.010 -1.827 0.058 0.857 
19 baseline 0.146 0.026 0.374 0.075 0.451 
 response 0.196 0.011 0.351 0.065 0.819 
49 baseline 0.158 0.028 0.505 0.081 0.444 
 response 0.335 0.013 0.433 0.076 0.907 
49 baseline 0.133 0.019 0.342 0.057 0.538 
 response 0.308 0.010 0.532 0.060 0.928 
49 baseline 0.106 0.026 0.271 0.079 0.280 
 response 0.242 0.012 0.403 0.071 0.855 
98 baseline 0.298 0.035 0.627 0.106 0.638 
 response 0.601 0.014 0.913 0.086 0.962 
98 baseline 0.093 0.023 0.233 0.066 0.293 
 response 0.469 0.011 0.099 0.070 0.958 
98 baseline 0.105 0.025 0.268 0.074 0.302 
 response 0.361 0.010 0.254 0.057 0.951 
199 baseline 0.249 0.039 0.716 0.117 0.505 
 response 0.940 0.013 0.409 0.079 0.986 
199 baseline 0.156 0.030 0.398 0.089 0.398 
 response 0.868 0.011 0.640 0.068 0.988 
199 baseline 0.105 0.025 0.268 0.074 0.302 
 response 0.361 0.010 0.254 0.057 0.951 
Unknown baseline 0.180 0.025 0.463 0.075 0.555 






Figure 3.12 Overlay of the unknown solutions on the concentration-response calibration plot for CEA in 100% FBS 




the same manner as for detection in buffer) was found to be 0.03 pm/min, which is slightly larger 
than the 0.02 pm/min for detection in buffer. This increased slope noise is largely the result of 
nonspecific serum adsorption that causes the drifting baseline, which, although largely linear, 
does have a slowly decreasing slope over time. While this nonlinear behavior limits the precision 
of slope determination it does not preclude quantitation of CEA levels in an unknown sample. 
Taken together, the decreased sensitivity to CEA in serum (as compared to buffer) and the 
slightly increased baseline noise result in a limit of detection of 25 ng/mL. Although still within 
the range monitored clinically (5–100 ng/mL), future work to lower the detection limit and 
improve measurement precision in serum will be necessary. One area of particular focus is 




The work of this chapter establishes that arrays of silicon photonic optical microring 
resonators are a robust emerging tool for bioanalysis of clinically relevant samples. We show the 
ability to directly visualize the chemical and biochemical functionalization of the sensor surface 
to ensure consistent loading of antibody capture agents. We then demonstrate the applicability of 
the microring resonator platform for the sensitive and robust detection of a relevant marker of 
disease at clinically relevant levels in both buffer and fetal bovine serum. By utilizing a 
quantitation scheme based upon measuring the time-resolved initial slope of the sensor response, 
the concentration of unknown CEA solutions in buffer are determined in a label-free format with 
comparable sensitivity and improved precision over commercial ELISA assays. The established 
limits of detection are among the lowest ever reported for microring resonators applied to protein 
detection at the time of publication of this data. We also demonstrate the first-ever operation of 
such a device in undiluted serum. While still at an early stage of development, the inherent 
multiplexing capability of this optical semiconductor-based analysis technology, coupled with 
the detection limits and precision demonstrated herein, establishes silicon-on-insulator microring 
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Label-free bioanalytical technologies have recently garnered increased interest for their 
ability to generate highly sensitive and quantitative measurements without the cost, complexity, 
or labeling heterogeneity introduced by techniques requiring fluorescent or enzymatic tags.1, 2 In 
particular, optical biosensors based on refractive index (RI) changes associated with analyte 
binding hold particular promise for conducting multiparameter biological analyses without 
labels.3-5 Within the realm of label-free RI-based optical biosensors, microcavity resonators have 
demonstrated the ability to sensitively detect a diverse array of biological analytes including 
proteins,6-9 nucleic acids,10, 11 cells,12 and viruses.13, 14 Arrays of silicon photonic microring 
resonators, which can be routinely fabricated using well-established semiconductor processing 
techniques, have been previously demonstrated for biomolecular detection.8, 15-18 However, 
despite their promise for highly multiplexed detection, previous reports have yet to demonstrate 
the ability to simultaneously detect and rigorously quantitate multiple clinically relevant analytes 
from a single sample volume using a single sensor array. 
Chapter 3 demonstrated the use of silicon photonic microring resonators for quantitation 
of the cancer biomarker carcinoembryonic antigen (CEA) with a clinically relevant limit of 
detection comparable to a CEA enzyme-linked immunosorbent assay (ELISA). Extending 
beyond single parameter quantitation, this chapter demonstrates multiplexed detection using 
arrays of silicon-on-insulator microring resonators. Multiparameter bioanalytical technologies 
that provide multiple clinically relevant measurements from a single sample are of great value to 
applications ranging from individualized diagnosis to fundamental studies in systems biology.19, 
20
 Though a previous report has indicated the ability to perform multiplex measurements on 
nucleic acids using a microsphere-based sensing strategy,11 we significantly extend the 
multiplexing capabilities of microcavity resonators by demonstrating the ability to 
simultaneously perform 20 unique label-free immunoassays in parallel. Using these twenty 
independent sensors, we report an assay, run in quadruplicate, for five clinically relevant protein 
biomarkers [CEA, prostate specific antigen (PSA), alpha-fetoprotein (AFP), interleukin-8 (IL-8), 
and tumor necrosis factor-alpha (TNF-α)] on a single silicon photonic microring resonator array. 
Cross-reactivity profiles and individual calibration curves are generated for each antigen, and the 
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platform is validated by accurate quantitation of three separate unknown protein cocktails in a 
blind analysis. 
 
4.2 Materials and Methods 
4.2.1 Materials 
 
Succinimidyl 4-formylbenzoate (S-4FB), and the silane 3-N-((6-(N'-Isopropylidene-
hydrazino))nicotinamide)propyltriethyoxysilane (HyNic Silane), were purchased from SoluLink 
(San Diego, CA). Aniline was obtained from Acros Organics (Geel, Belgium). Monoclonal 
mouse anti-human CEA (Cat# M37401M), human CEA (Cat# A32030H), monoclonal mouse 
anti-human PSA (Cat #M86506M), human PSA (Cat# H6M07-323), monoclonal mouse anti-
human AFP (Cat #H45610M), and human AFP (Cat# A81510H) were purchased from Meridian 
Life Science, Inc. (Saco, ME). Recombinant human IL-8 (Cat# 208-IL/CF) and monoclonal 
mouse anti-human IL-8 (Cat# MAB208) were obtained from R&D Systems (Minneapolis, MN). 
Monoclonal anti-human TNF-α (Cat# 16-7348), recombinant human TNF-α (Cat # 34-8329), 
and mouse IgG isotype control (Cat # 16-4714-85) were obtained from eBioscience (San Diego, 
CA).  Zeba spin filter columns were purchased from Pierce (Rockford, IL). Silicone elastomer 
kit (RTV 615 2-Part Addition Cure Clear Silicone) was obtained from Momentive Performance 
Materials (Albany, NY). PBS was reconstituted from Dulbecco’s phosphate buffered saline 
packets purchased from Sigma-Aldrich (St. Louis, MO). All other chemicals were obtained from 
Sigma-Aldrich and used as received.  
All buffers were made with purified water (ELGA PURELAB filtration system; Lane 
End, UK), and the pH was adjusted as necessary with 1 M HCl or 1 M NaOH. Acetate buffer 
consisted of 50 mM sodium acetate and 150 mM sodium chloride adjusted to pH 6.0. Glycine 
buffer was 10 mM glycine and 160 mM NaCl adjusted to pH 2.2. BSA-PBS buffer was made by 
dissolving solid bovine serum albumin (BSA) in PBS (pH 7.4) to a final concentration of 0.1 
mg/mL. For blocking, 2% BSA (w/v) in PBS was used. All solutions were degassed under 






4.2.2 Microrings and Instrumentation 
 
Microring resonator array substrates and the instrumentation for analyzing the microring 
resonance frequencies were acquired from Genalyte, Inc. (San Diego, CA) and have been 
previously described.6, 21 Briefly, 6 × 6 mm substrates hold sixty-four 30-µm diameter 
microrings with adjacent linear access waveguides that have input and output diffractive grating 
couplers at each end to independently measure the optical cavity spectrum of each microring. 
The entire wafer was spin-coated with a commercially-available perfluoro (alkenyl vinyl ether) 
copolymer (Asahi Glass Company) and annular openings were created over the active sensing 
rings via photolithography and reactive ion etching. Up to thirty-two microring sensors can be 
monitored simultaneously, with eight of the sensors not exposed to solution (covered by the 
fluoropolymer cladding) and used exclusively to compensate for thermal drift. The 
instrumentation uses a tunable, external cavity diode laser (center frequency 1560 nm) to rapidly 
scan the chip surface and couple light into the waveguides via grating couplers. Resonance 
wavelengths are determined as the wavelength at which the out-coupled light that has passed by 
the microring is at a minimum.  
 
4.2.3 Microfludic Setup 
 
For all steps except antibody functionalization, sensor chips were loaded into a custom 
cell with microfluidic flow channels defined by a Mylar gasket described in Chapter 3. Flow 
rates were maintained at 30 µL/min throughout the sensing experiments. For antibody 
functionalization, a 6-channel PDMS device was molded over a SU-8 template fabricated on a 
silicon wafer using standard photolithographic techniques. The PDMS device was created by 
mixing the base and curing agent in a 10:1 ratio and allowing the mixture to completely cure at 
80 °C. Figure 4.1 contains an illustration of how both the microfluidic device and the one-








Figure 4.1 Schematic showing the layout of microrings and grating couplers on the microchip surface. Projections 
of the 6 PDMS microchannels used to differentially functionalize microrings with antibodies are shown in red. The 
PDMS microfluidic device was used exclusively for the directed antibody functionalization step. The placement of 




4.2.4 Microring Surface Functionalization 
 
Before functionalizing the microring surfaces, sensor chips are first cleaned by a 30-
second immersion in piranha solution22 (3:1 H2SO4:30% H2O2) followed by copious rinsing with  
water and drying with nitrogen gas. To add a HyNic moiety to the surface, the sensor chip is 
exposed to a solution of 0.5 mg/mL HyNic Silane in 98% EtOH and 2% DMF for 10 minutes 
and then rinsed with 100% EtOH. Covalent attachment of antibodies is achieved by reacting the 
antibody (1 mg/mL) with a 5-fold molar excess of S-4FB (dissolved first in DMF and diluted in 
PBS to less than 5% DMF) for 2 h at room temperature. Excess S-4FB was removed by spin 
filtration with Zeba spin filter columns, which also allowed buffer exchange into acetate buffer. 
The antibodies are then covalently attached in a spatially-controlled fashion via microfluidic 
channels. Each 4FB-modified antibody was flowed through a different channel to functionalize 
five sets of four rings, each with a different antibody: anti-PSA, anti-AFP, anti-CEA, anti-IL-8, 
anti-TNF-α. The sixth channel was functionalized with a mouse IgG isotype control antibody to 
serve as an on-chip control for non-specific adsorption and bulk refractive index changes.  
Aniline (100 mM) is added to each antibody solution to catalyze hydrazone bond 
formation23 and enable the reaction to proceed in 20 minutes. A glycine buffer rinse is then used 
to remove any noncovalently bound antibody. A final blocking step is accomplished by 
overnight soaking in a 2% solution (w/v) of BSA in PBS. 
 
4.2.5 Microring Calibration and Unknown Analysis 
 
Antigen calibration standards were prepared by diluting stock solutions of the antigens 
(0.1 mg/mL or greater) in BSA-PBS to concentrations below 1 ug/mL. Unknowns for the blind 
analysis were prepared in a similar manner. The concentrations of antigens in each of the 
mixtures are given in Table 4.1. Air bubbles present while solution #8 was being analyzed 
resulted in several outliers, so the data from that run was discarded; however, because each of the 
concentrations was assayed in triplicate, quantitative analysis was still achieved. To generate an 
array of variable, but non-repeating concentrations, we consulted a website containing 5 × 5 
Sudoku puzzles (http://www.sudoku-download.net) and assigned a different antigen 
concentration to each numerical value.  
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Table 4.1 Concentration of antigen in ng/mL according to calibration solution number 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
PSA 150 20 10 50 100 50 150 20 10 100 100 20 10 50 150 
IL-8 10 150 100 20 50 10 100 50 150 20 20 150 50 10 100 
AFP 100 10 50 150 20 20 50 150 100 10 150 10 100 20 50 
CEA 20 50 150 100 10 100 20 10 50 150 50 100 20 150 10 
TNF-α 50 100 20 10 150 150 10 100 20 50 10 50 150 100 20 
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4.3 Results and Discussion 
4.3.1 Cross Reactivity Testing 
 
Following microring sensor functionalization, the specificity of the sensors for each 
antigen was tested to ensure that antibody cross-reactivity was minimal. The six-channel PDMS 
microfluidic was replaced by a single channel Mylar gasket (see Figure 4.1) to probe all of the 
sensors simultaneously. Five different solutions, each containing 1 µg/mL of a different purified 
protein cancer biomarker diluted in 0.1 mg/mL bovine serum albumin in PBS (BSA-PBS), were 
sequentially flowed for 10 minutes. As expected, the rings functionalized with the mouse IgG 
isotype control did not interact with any of the biomarkers; thus, these rings were utilized as 
controls to correct off baseline drift due to thermal fluctuations or bulk refractive index changes.  
Figure 4.2 displays the control-subtracted response of the microrings (four microrings per 
antibody) plotted with the relative shift in the resonance wavelength (given as the change of 
wavelength in picometers, or ∆ pm) as a function of time. Each set of microrings functionalized 
with a particular biomarker-specific antibody responded only to the appropriate antigen solution. 
The lack of response in the off-diagonal plots demonstrates that there was minimal sensor cross-
reactivity for these antibody-antigen combinations and that the control rings effectively removed 
any sensor drift. The only minor exception occurs with the anti-CEA- and anti-AFP-
functionalized sensors in response to IL-8. This response results from a bulk refractive index 
shift from a constituent in the IL-8 stock solution; upon dilution of IL-8 for experiments at more 
physiologically relevant concentrations, this bulk refractive shift becomes essentially negligible. 
Differences in the antigen responses in Figure 4.2 (both within a set of sensors 
functionalized with the same antibody and between sets of sensors functionalized with different 
antibodies) are the result of several factors. First, variations in protein size result in different 
responses.24 Binding of a large protein such as CEA (185 kDa) gives a proportionally larger 
change in refractive index near the surface than a smaller protein such as IL-8 (8 kDa).  Second, 
any variation in antibody surface coverage will lead to differences in the number of available 
active binding sites on a given sensor. Finally, the fractional occupation of available binding sites 
on the sensor is strongly influenced by antibody-antigen binding affinity, which differs for each 
antibody used in this study. As seen in Figure 4.2, each set of rings functionalized within a 




Figure 4.2 Cross-reactivity diagram. Each row represents the response of four rings functionalized with a particular 
antibody, as designated on the left hand axes (shift given as change in resonance peak wavelength in picometers); 
each column shows the sensor response upon addition of a 1µg/mL solution of a single antigen designated at the top 




notable exception is for IL-8, where two of the rings have a noticeably smaller response than the 
other two rings. 
 
4.3.2 Quantitative Multiplexed Sensing 
 
To demonstrate quantitative multiplexed sensing, standard solutions were created that 
contain a mixture of each of the five antigens at different concentrations. We utilized the 
responses from these standards to independently calibrate each microring sensor using the 
previously described initial slope analysis method described in Chapter 3. Real-time response 
curves for CEA and TNF-α were fit to linear functions since these sensors were far from 
saturation at the particular concentrations and time intervals we used. Responses from PSA, IL-8, 
and AFP more closely approach binding equilibrium and therefore were more accurately fit to 
exponential functions as discussed in Chapter 3. As previously, initial slopes were determined by 
solving for the first derivative of the fitted exponential function at t = 0. From the initial slope 
data, calibration curves for each sensor ring were constructed. 
Figure 4.3 displays overlays of the real-time response curves for all 20 sensor rings. Each 
column in Figure 4.3 represents a set of four microrings functionalized with a different antibody. 
Each color on the graph represents a different concentration of antigen between 0 and 150 
ng/mL. Figure 4.4 shows the calibration curves generated from the real-time data in Figure 4.3 
using the initial slopes of the response curves.  
Since all antigens are mixed together and introduced simultaneously, it is possible to 
calibrate all of the sensors at once rather than individually with each antigen. The concentration 
of each of the antigens was varied within every calibration mixture so that any interferences 
between antigens could be minimized. In addition, simultaneous calibration with variable 
concentrations of each antigen helps avoid systematic errors that might be caused by long-term 
instrument drift or operator error while performing serial dilutions. To ensure reproducibility of 
the calibrations, each standard solution was analyzed in triplicate. Following analysis of a single 
solution, the sensor surface was regenerated with glycine buffer (pH 2.2) in preparation for 
subsequent standard and unknown solution analyses that were all performed sequentially on the 
same chip. Single-blind analyses of unknown samples containing variable concentrations of all 




Figure 4.3 Real-time response curves for all sensors used in the experiment. The graphs within each column 
represent data taken from separate microrings functionalized with the same antibody. For the response curves, the 
colored lines represent the following concentrations of antigen: red, 150 ng/mL; green, 100 ng/mL; blue, 50 ng/mL; 





Figure 4.4 Calibration curves generated from the real-time response curves in Figure 4.3. The relative position of a 
calibration curve in the figure corresponds to the graph in the identical position in Figure 4.3. For these graphs, 




Using the calibration curves for each ring, antigen concentrations for the three unknown 
mixture were determined. Figure 4.5 displays the concentrations of the unknowns as determined 
using the microring resonator sensors. Table 4.2 shows the actual values for the evaluation of 
unknowns as given in Figure 4.5. The first column gives the concentration as prepared by the 
researcher who created the unknowns. The second column lists the concentrations as determined 
from the calibration curves in Figure 4.4. The uncertainty is then given as the 95% confidence 
interval based on four independent measurements, and the percent error is the ratio of the 
prepared concentration and the difference between the prepared and measured concentrations. 
 Comparing the determined concentrations  with the as-prepared values in Figure 4.5, it is 
apparent that all of the as-prepared concentrations fall within the error bounds of the 
measurement techniques (95% confidence interval, 4 independent measurements). The average 
measurement error was approximately 8 ng/mL. Measurements for IL-8 display relatively higher 
uncertainty compared to the other sensors. However, as shown in Figure 4.5, averaging the 
results from each of the four microring sensors still enables a reasonably accurate measurement 
of the concentrations (within  10% of exact concentration), even though the IL-8 precision could 
be improved. Overall, Figure 4.5 demonstrates that the system can simultaneously quantitate 
multiple protein biomarkers in solution via a method that would only require a 5-minute analysis, 




This chapter describes a critically important development for resonant optical 
microcavity-based biosensors in that it details the first platform capable of high-level 
multiplexing and demonstrates that there is no significant sacrifice of absolute sensitivity and 
measurement precision, compared to an analogous single-parameter analysis. The system 
described herein—consisting of five antigens in albumin-containing buffer—is admittedly less 
complex than that encountered in a clinical setting, and future work will focus on analyses in 
samples such as human serum or whole-cell lysate. Chapter 3 describes complications that can 
arise due to non-specific adsorption from complex solutions, and therefore efforts to improve the 




Figure 4.5 Evaluation of unknown protein cocktails A, B, and C comparing the measured values (unfilled bars) with 
the actual, as-prepared values (bars hatched with diagonal lines) for each of the five antigens. Error bars represent 




Table 4.2 Values for unknown determinations: as-prepared concentration values, measured values, the associated 










 (95% C.I.) % error 
Unknown A 
PSA 32.4 31.5 8.3 2.7 
IL-8 146.4 138.9 53.7 5.1 
AFP 21.6 24.6 8.6 13.7 
CEA 10.8 8.0 3.0 25.8 
TNF- 52.1 44.8 7.1 13.9 
 
     
Unknown B 
PSA 130.7 129.2 19.3 1.2 
IL-8 31.5 29.3 18.0 7.1 
AFP 57.5 48.1 8.5 16.3 
CEA 69.5 64.2 2.9 7.7 
TNF- α 15.8 12.5 7.2 20.9 
 
     
Unknown C 
PSA 86.6 86.4 17.3 0.2 
IL-8 47.1 43.0 22.1 8.6 
AFP 32.0 27.9 8.5 12.9 
CEA 24.5 21.6 3.0 11.6 




approach allowed introduction of six different capture agents to the sensor chip surface, higher 
level multiplexing will require interfacing the microring resonator array with conventional 
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 A major challenge in developing sensitive and robust protein immunoassays is 
identifying appropriate antibody capture agents for the intended target antigen. Although assay 
performance is profoundly affected by the ultimate sensitivity of the analytical methods, an oft-
encountered limitation is imposed by poor antibody performance. Furthermore, many 
ultrasensitive detection techniques acquire their sensitivity from the use of extremely high 
affinity capture agents rather than fundamentally more sensitive measurement technologies—a 
complication when performing head-to-head evaluation of different methodologies in the 
absence of more general comparables. Nonetheless, high affinity protein capture agents are 
absolutely essential for robust immunoassays, and many hurdles are often encountered in their 
pursuit. For example, among a selection of commercially available antibodies against a certain 
target, the equilibrium and kinetic binding constants can vary significantly from vendor to 
vendor, clone to clone, and even lot to lot. Furthermore, these metrics are rarely available from 
vendors, making the direct evaluation of the performance of antibodies an important component 
of biosensor development.  
 Label-free, refractive index-sensitive sensor platforms,1-8 have been widely used for 
evaluating protein-protein binding kinetics. Typically, these methods utilize microspotting or 
microfluidic technologies to directly create arrays of protein capture agents on the sensor surface 
in a process that is completely separate from the subsequent interaction screening. Although 
these screening formats work well for many applications, in this paper we demonstrate an 
expansion upon these capabilities by utilizing DNA-encoded antibodies for the screening of 
antibody kinetics using arrays of microring optical resonators. Microring resonators are 
refractive index-responsive optical devices that our group has recently demonstrated as a 
versatile tool for the sensitive detection of biomolecules.9-11 Beyond these detection applications, 
the modular multiplexing capability of the semiconductor-based platform make it an attractive 
technology for multiplexed and label-free interaction monitoring.8 
As described previously,12-18 DNA microarrays can be converted into antibody arrays via 
a self-assembly process that involves conjugating antibodies with DNA strands which are 






Figure 5.1 Covalent DNA-antibody conjugates (blue, red, and green) are created in parallel with a microring 
resonator chip (not to scale) that has been functionalized with unique complementary DNA strands via 
microspotting. After flowing the conjugates over the surface, the conjugates self-assemble onto the chip surface as 
dictated by the complementary DNA-DNA base pairing interactions. Non-functionalized rings serve as controls 




this concept whereby ssDNA-tagged antibodies are directed to specific cDNA-modified 
microrings via the Watson-Crick base pairing of the respective DNA sequences.  
Advantages of this approach—both for biomolecule detection as well as capture agent 
screening—come from several factors. First,  DNA microarrays, are generally more robust than 
protein microarrays on account of the high sensitivity of proteins to denaturation on hydrophobic 
surfaces,19, 20 at air/water interfaces,21 and under dehydrated storage  conditions.22 To avoid these 
deleterious effects on protein microarrays, microfluidic deposition techniques can be used to 
create patterned arrays of antibodies in situ, immediately before analysis. For example, Nahsol et 
al. used the ProteOn XPR36 with a 6 x 6 array of fluidics for screening applications.4 However, 
microspotting has an advantage over microfluidic approaches in that it can allow larger and 
higher density arrays to be created. A second advantage of the DNA-encoded strategy comes 
from the nature of the surface immobilization interaction. Although the DNA-DNA interaction is 
sufficient to provide a robust linkage under assay conditions, the base-pairing interaction can be 
disrupted using chaotropic agents. This allows for the regeneration of sensor surfaces even when 
the desired antibody-antigen interactions are irreversible under standard antibody regeneration 
conditions (e.g. low pH, high pH, chaotropic, highly chelating, and high ionic strength 
conditions).23 This capability can also be advantageously used to dynamically reprogram the 
specificity of sensor arrays by replacing one set of antibodies with others that have a different set 
of specificities but are encoded with the same DNA sequences. 
In this paper we explored the combined utility of DNA-encoded antibodies and arrays of 
silicon photonic microring resonators as a versatile, multiplexed bioanalysis platform. We first 
confirmed the ability of the DNA-encoding strategy to direct antibodies to the appropriately 
cDNA-modified microring resonators and then validated the antigen-recognition capability of the 
immobilized capture agents. We next utilized DNA-encoded antibodies to evaluate the kinetics 
and secondary antibody recognition properties of 12 different commercial capture agents: six that 
recognized prostate specific antigen (PSA) and six specific for α-fetoprotein (AFP). For kinetic 
measurements we used the kinetic titration method described by Karlsson et al.,24 which 
streamlines the evaluation process by avoiding the need to regenerate the surface between each 
addition of antigen. We first evaluated the six PSA antibodies in parallel; then after only a 15-
minute rinse with 8 M urea, we reprogrammed the same microring resonator array substrate with 
the six AFP antibodies, which were subsequently interrogated in parallel. In addition to 
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screening binding kinetics, we also evaluated antibody pairs for secondary antibody recognition 
of antigen bound to each of the different primary antibodies immobilized on the chip. In this 
manner we were able to quickly determine which combinations of antibodies could function as a 
set for sandwich immunoassays. This also provided information about common binding epitopes 
among antibodies, since it is assumed that antibodies that form sandwich pairs are binding 
separate epitopes, whereas antibody pairs that bind in a mutually exclusive fashion are assumed 
to bind to proximal epitopes.  Overall, the combination of DNA-encoded antibodies and 
microring resonator arrays is shown to be a promising combination for not only the evaluation of 
capture agent binding kinetics, but also other key characteristics that are important in the 
development of robust protein immunoassays. 
 
5.2 Materials and Methods 
5.2.1 Materials 
 
Succinimidyl 4-formylbenzoate (S-4FB), succinimidyl 6-hydrazinonicotinamide acetone 
hydrazone (S-HyNic), 3-N-((6-(N'-Isopropylidene-hydrazino))nicotinamide)propyltriethyoxy-
silane (HyNic Silane), and antibody-oligonucleotide conjugation kits were purchased from 
SoluLink (San Diego, CA). Custom DNA oligonucleotides were synthesized by Integrated DNA 
Technologies (Coralville, IA). Monoclonal mouse anti-human PSA antibodies clones B732M, 
B731M, 5A6, 5G6, 8A6, monoclonal mouse anti-human AFP antibodies clones B491M, 131-
12210, 057-11301, 1301, 1305, and purified human AFP and PSA were purchased from 
Meridian Life Science, Inc. (Saco, ME). Monoclonal mouse anti-human PSA antibody clone 
6915780 and monoclonal mouse anti-human AFP antibody clone 2127435 were obtained from 
Fitzgerald Industries International (Concord, MA). For convenience, all of the antibodies will be 
referred to by their specificity and clone number for future reference (e.g. anti-AFP-B491M). 
However, modifications to this convention include: anti-AFP-210 for clone 131-12210, anti-
AFP-301 for clone 057-11301, anti-PSA-780 for clone 6915780, and anti-AFP-435 for clone 
2127435. 
Zeba spin filter columns and Starting Block were purchased from Pierce (Rockford, IL). 
Vivaspin molecular weight cutoff filters (50,000 and 5,000 Da MWCO), were obtained from GE 
Healthcare (Waukesha, WI). Phosphate buffered saline (PBS), with a standard 10 mM phosphate 
100 
 
ion concentration, was reconstituted from Dulbecco’s phosphate buffered saline packets 
purchased from Sigma-Aldrich (St. Louis, MO). Aniline was obtained from Acros Organics 
(Geel, Belgium). All other chemicals were obtained from Sigma-Aldrich and used as received.  
All buffers were made with purified water (ELGA PURELAB filtration system; Lane 
End, UK), and the pH was adjusted as necessary with 1 M HCl or 1 M NaOH. A different PBS 
buffer with 100 mM phosphate (100 mM PBS) was made with 150 mM NaCl, 22.5 mM 
monobasic sodium phosphate, and 77.7 mM dibasic sodium phosphate and then pH-adjusted to 
either pH 7.4 or pH 6.0. PBS with 0.05% Tween-20 (PBST) was made by adding Tween-20 to 
standard PBS buffer (Dulbecco’s formulation). All solutions were degassed under vacuum 
sonication before being flowed across the sensor surface. 
 
5.2.2 Instrumental Setup and Chip Fabrication 
 
The sensor chips and microring resonator interrogation instrumentation was acquired 
from Genalyte, Inc. (San Diego, CA), and have been previously described.25 Each 6 x 6 mm 
microchip contains thirty-two 30-µm diameter microrings that have adjacent linear waveguides 
with input and output diffractive grating couplers at each end to enable independent 
determination of the optical cavity spectrum of each microring using a tunable, external cavity 
diode laser (center frequency 1560 nm). Resonance wavelengths are measured as the wavelength 
at which the out-coupled light that propagates past the microring is negatively attenuated. A 
fluoropolymer cladding layer over the chip with etched annular openings enables exposure of 
active sensing rings while keeping thermal control rings buried under the cladding layer. In each 
experiment, twenty-four rings are responsive to surface chemistry and biological modification 
while eight are left under the cladding as thermal controls. All measurements for these 
experiments were made with the sensor chips loaded into a custom cell with microfluidic flow 
channels defined by a 0.007-inch thick Mylar gasket (both single and dual channel) with a 
previously described design.9  Solutions were flowed through the chips using an integrated 
autosampler that draws from Parafilm-coated (Pechiney Plastic Packaging Company; Chicago, 





5.2.3 Silane Functionalization 
 
Microring array substrates were first cleaned with piranha solution26 (3:1 H2SO4:30% 
H2O2) for 30 seconds followed by rinsing with water and N2 drying. To introduce reactive 
functional groups, the substrates are immersed in a 1 mg/mL solution of HyNic Silane (20 
mg/mL HyNic Silane in DMF stock solution diluted to 1 mg/mL with ethanol) for 30 minutes, 
followed by rinsing with ethanol and then water.  
 
5.2.4 Oligonucleotide Functionalization 
 
Oligonucleotide sequences, which were designed to minimize cross-reactivity between 
DNA probes, were previously reported for their utility in spatially localizing DNA-antibody 
conjugates.16 The exact sequences, named A, A′, B, B′, F, F′, K, K′, L, L′, and M, M′, (where a 
prime symbol indicates a complementary sequence), are listed in Table 5.1. All oligonucleotides 
were synthesized with a 5′ amino terminal group to facilitate attachment to either the substrate or 
antibody. Oligonucleotides were functionalized with S-4FB according to manufacturer 
(SoluLink) instructions. Briefly, oligonucleotides were buffer exchanged to 100 mM PBS pH 7.4 
and then a 20-fold molar excess of S-4FB in DMF was added. Solutions were allowed to react 
overnight at room temperature and then were buffer exchanged into 100 mM PBS pH 6.0 using 5 
kDa MWCO filters.  
 
5.2.5 DNA Spotting 
 
 Multiplexed functionality was installed on the microring arrays by alternately spotting 
4FB-functionalized DNA strands A, B, F, K, L, M onto a microchip that had been previously 
functionalized with HyNic Silane. For initial tests with F′-anti-PSA-5A6 and/or B′-anti-AFP-
B491M, only strands B and F were added to the chips. In all cases, several rings on each chip 
were not functionalized with DNA and used as controls. Six-plex chip spotting was achieved 
using a Nano eNabler spotting system from BioForce Nanosciences (Ames, IA) using a 




Table 5.1 List of DNA oligonucleotide sequences used. All sequences have a 5′ terminal amino group attached via a 
6-carbon chain (5AmMC6 from IDT) 
 
Name Sequence (5′ to 3′) 
A AAA AAA AAA AAT CCT GGA GCT AAG TCC GTA 
A′ AAA AAA AAA ATA CGG ACT TAG CTC CAG GAT 
B AAA AAA AAA AGC CTC ATT GAA TCA TGC CTA 
B′ AAA AAA AAA ATA GGC ATG ATT CAA TGA GGC 
F AAA AAA AAA AAT CAG GTA AGG TTC ACG GTA 
F′ AAA AAA AAA ATA CCG TGA ACC TTA CCT GAT 
K AAA AAA AAA ATA ATC TAA TTC TGG TCG CGG 
K′ AAA AAA AAA ACC GCG ACC AGA ATT AGA TTA 
L AAA AAA AAA AGT GAT TAA GTC TGC TTC GGC 
L′ AAA AAA AAA AGC CGA AGC AGA CTT AAT CAC 
M AAA AAA AAA AGT CGA GGA TTC TGA ACC TGT 




DMSO, to slow solvent evaporation. For chips with only one or two different DNA strands 
added, the DNA was spotted manually using a stereoscope to direct fluid placement. After 
spotting, the drops of solution were dried on a hot plate (~70 °C) and incubated in 80% relative 
humidity (or higher) for 1-2 hours to allow rehydration of the DNA on the surface. Chips were 
then immersed into S-4FB-modified Starting Block. The Starting Block was modified following 
the same procedure as oligonucleotide functionalization but 100 µL of 5 mg/mL S-4FB was 
added to 1.5 mL Starting Block. The blocking solution was removed by rinsing with water, and 
then additional S-4FB modified blocking solution was added to the chip before incubating 
overnight in a humidity chamber at 4°C. Sensor chips were then rinsed with water, immersed in 
8M urea for 20 minutes to remove excess blocking protein, and then finally rinsed with water 
and dried under nitrogen. 
 
5.2.6 DNA-Antibody Conjugate Synthesis 
 
 To create DNA-antibody conjugates, antibodies were first functionalized with S-HyNic 
following the manufacturer’s guidelines.27 Briefly, S-HyNic in DMF was added in 5-fold molar 
excess to ~1 mg/mL antibody that had previously been buffer exchanged into 100 mM PBS pH 
7.4 with a Zeba spin filter and reacted for at least two hours at room temperature. The antibody 
was then exchanged into 100 mM PBS pH 6.0 and concentrated using a 50 kDa MWCO filter, 
which also served to remove residual S-HyNic. The 4FB-modified DNA was then added in 20-
fold molar excess to the HyNic-modified antibody solution and allowed to react overnight at 4 
°C. DNA-antibody conjugates were then purified away from the excess DNA using a Superdex 
200 10/300 GL column on an AKTA FPLC, both from GE Healthcare (Waukesha, WI). The 
separation was performed at 4 °C with a PBS isocratic elution. The collected fractions were 
concentrated with 50 kDa MWCO filters to yield purified solutions of DNA-antibody 
conjugates. The final conjugate concentration measured between 100-400 µg/mL, as determined 
by measuring the differential absorption at 260 versus 280 nm, corresponding to the DNA and 
IgG, respectively, using a NanoDrop UV-Vis absorbance system (ThermoFisher Scientific, 
Wilmington, DE). Alternatively, an oligonucleotide-antibody conjugation kit from SoluLink was 
used to synthesize and purify the conjugates using a magnetic-bead-based separation, according 
to manufacturer’s instructions. Although both purification methods provided conjugates of 
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identical analytical behavior, the conjugation kit is advantageous for the parallel preparation of 
multiple conjugates, as opposed to serial FPLC purification. The following conjugates were 
synthesized: A′-anti-PSA-8A6, B′-anti-PSA-B732M, F′-anti-PSA-5A6, K′-anti-PSA-780, L′-
anti-PSA-B731M, M′-anti-PSA-5G6, A′-anti-AFP-1301, B′-anti-AFP-B491M, F′-anti-AFP-435, 
K′-anti-AFP-1305, L′-anti-AFP-210, M′-anti-AFP-301. 
 
5.2.7 Validation of DNA-Encoded Antibody Binding to cDNA-Modified Microring 
Resonators and Subsequent Antigen Recognition Capability 
 
To validate the ability to localize DNA-antibody conjugates onto microrings presenting 
specific cDNAs (strands F and B), we tested F′-anti-PSA-5A6 and B′-anti-AFP-B491M.  A 
solution of 20 µg/mL of the B′-anti-AFP-B491M conjugate was first flowed across the surface 
followed by 5 µg/mL of the F′-anti-PSA-5A6 conjugate. Because the relative binding rates of the 
DNA-antibody conjugates varied, the concentrations were adjusted so that the so that binding 
would occur at a similar rate. Following addition of conjugates, 1 µg/mL of AFP and then 1 
µg/mL of PSA were flowed across the chip surface. 
To test the loading-response behavior of the anti-PSA-5A6 antibody, two methods were 
used. First, several chips functionalized with strand F had different surface densities of F′-anti-
PSA-5A6 added to the surface by varying the concentration of the conjugate added to the chip as 
well as the incubation time of the conjugate. Following addition of the conjugate, 1 µg/mL of 
PSA was flowed across the surface and the equilibrium, saturation response was measured after 
5 minutes of exposure. Following this test, each chip was regenerated by flowing 8M urea over 
the chip surface for 15 minutes with water rinses before and after the urea. This enabled antibody 
conjugates loading to be repeated multiple times. 
To compare the capture performance of DNA-encoded antibodies with those directly 
immobilized on the sensor surface via a covalent linkage with HyNic silane (as we have 
described previously28), we flowed 4FB-modified anti-PSA-5A6 (using the same procedure as 
the S-HyNic modification, but substituting S-4FB for S-HyNic) over HyNic-silane-
functionalized sensor chips. We utilized a previously-described 4-channel flow cartridge8 to react 
rings with different concentrations of anti-PSA-5A6 from 0.7 µg/mL to 7 µg/mL. The variations 
in concentration enabled different amounts of capture antibody to be loaded on different rings on 
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the same chip, as directly measured by monitoring the real-time shifts in microring resonance 
wavelength during antibody immobilization. Since these surfaces could not be regenerated to 
reload antibody, two separate chips (8 channels total) were used to collect the covalent 
immobilization data. After functionalizing the chip with anti-PSA-5A6, the chip was blocked 
overnight with 4FB-modified Starting Block and then loaded into a flow cartridge with a single 
channel to direct the antigen solution over all the sensor rings. Then a solution containing1 
µg/mL of PSA was flowed over the chip and the saturation response was measured after 5 
minutes of exposure. 
 
5.2.8 DNA-antibody Conjugate Kinetic Screening Experiments 
 
 To load a DNA-antibody conjugate onto a chip, ~5 µg/mL (or higher concentration if 
DNA-DNA binding kinetics for a particular pair of complementary strands were slow) of 
conjugate was flowed over the chip surface and terminated with a buffer rinse of PBST after 
loading enough antibody to create a 30-50 pm shift. Saturation experiments with PSA were made 
by flowing 1 µg/mL PSA in PBST over the chip for 5 minutes. A chip surface could be 
regenerated by flowing 8M urea over the chip surface for 15 minutes with water rinses before 
and after the urea. Before performing the multiplexed kinetic evaluation experiments, the DNA-
antibody conjugates were tested individually to ensure that no cross-reactivity occurred and to 
determine the relative binding rate of each conjugate. Thereafter, conjugates could be added 
simultaneously by adjusting the concentrations so that the rate of addition to the surface was 
similar for all of the DNA-antibody conjugates, and thus, equivalent loadings were achieved for 
a single functionalization time period. Kinetic titration experiments were made by adding 
increasing concentrations of PSA or AFP for a 1.5-minute antigen association period followed by 
a 4.5-minute rinse with PBST during which desorption of the antigen was observed.  
Screening for secondary antibodies was accomplished by loading all six of the DNA-
antibody conjugates for a particular antigen over the chip surface and then adding 1 µg/mL of the 
appropriate antigen (PSA or AFP) for 5 minutes. Following this step, each antibody (not 
conjugated to DNA) was flowed sequentially over the chip at a concentration of 1 µg/mL.  Each 
chip was loaded into a flow cartridge with two separate microfluidic channels so that each 
channel could have a different sequence of antibodies flowed over the chip. Following sequential 
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addition of all 6 antibodies for a particular antigen on both channels, the chip was then 
regenerated with 8M urea, and the experiment was repeated with different sequences of 
antibodies added to each channel.  
 
5.2.9 Data Analysis 
 
 Raw microring resonance wavelength data, recorded as a function of time, was corrected 
for any thermal drift of bulk refractive index shifts using on-chip control rings (exposed to 
solution, but not functionalized with DNA). The signal from all of the control rings was averaged 
and then subtracted from each of the individual active sensor rings. Kinetic titration data was 
divided into association and dissociation traces and fit (OriginPro 8.1; OriginLab Corporation; 
Northampton, MA) using the integrated rate equation for one-to-one Langmuir binding, as 
described by Karlsson et al.24  
 
5.3 Results and Discussion 
5.3.1 Validation of DNA-Antibody Conjugate Functionality 
 
 Before measuring the kinetics of binding to DNA-antibody conjugates, we first wanted to 
validate the functionality of the conjugates both in terms of loading onto ssDNA-presenting 
microrings as well as their subsequent ability to recognize the targeted antigen. Initially, both F′-
anti-PSA-5A6 and B′-anti-AFP-B491M were sequentially loaded onto a chip functionalized with 
DNA strands F and B. Next, a saturating concentration (1 µg/mL) of AFP and then PSA were 
flowed across the chip. As can be seen in Figure 5.2A, introduction of the antibody conjugates 
results in large, positive shifts in the resonance wavelength (∆ pm), consistent with biomolecular 
deposition. The subsequent addition allows us to confirm that there is no non-complementary 
binding on rings to which a conjugate has not been specifically encoded in accordance with 
Watson-Crick base pairing. In addition, introduction of a high (1 µg/mL) concentration of AFP 
and then PSA to all the rings only results in a response on the rings functionalized with the 
specific DNA-antibody conjugates. From these results we can conclude that the DNA-antibody 
conjugates self-assemble to the appropriate sensor location and retain their specificity towards a 




Figure 5.2 (A) Initial validation of DNA-antibody conjugates showing orthogonal antibody loading and orthogonal 
antigen response. First B′-anti-AFP-B491M was added followed by F′-anti-PSA-5A6. Then 1 µg/mL of AFP was 
added followed by 1 µg/mL PSA. The red trace shows the response of a microring functionalized with DNA strand 
B and the blue trace shows the response of a microring functionalized with DNA strand F. For reference, an arrow is 
positioned at the time points of injection and asterisks (*) indicate the switch to running buffer. (B) Shift in 
resonance wavelength for F3′-anti-PSA-5A6-presenting microring resonators to 1 µg/mL PSA versus the amount (in 
units of ∆pm) of F3′-anti-PSA-5A6 originally loaded onto the sensors before antigen interaction. The slope of the 
DNA-encoded antibody loading versus antigen response is ~2.5-fold greater than that for covalently bound antibody, 




We also sought to investigate batch-to-batch and chip-to-chip robustness of DNA-
antibody conjugates, particularly in regards to the correlation between antigen binding response 
and the amount of antibody bound to the sensor. Using F′-anti-PSA-5A6, we performed multiple 
tests measuring the binding capacity of the antibody on the surface as a function of the amount of 
conjugate added to the DNA-functionalized surface. This was done by first adding F′-anti-PSA-
5A6 to a chip functionalized with the complementary DNA strand F, a process that was 
measured in real-time to establish the relative amount of antibody bound to each microring. 
Following the addition of the conjugate, 1 µg/mL PSA was flowed over the surface and the 
saturating antigen response signal generated was recorded. Using 8M urea to disrupt the DNA 
duplex formed between conjugate and ring surface, a single sensor chip could easily be reloaded 
multiple times with different amounts of conjugate via regeneration after measurement of antigen 
binding responses. In this way, it was very easy to rapidly accumulate a large amount of data 
establishing a correlation between antibody loading and antigen binding response. We also 
measured the response from multiple sensor chips and several batches of F′-anti-PSA-5A6 
conjugates, and the entirety of these data sets are compiled together as the black squares in 
Figure 5.2B. Impressively, the amount of antigen binding response is very well-correlated to 
antibody loading, a linear trend that holds across multiple sensor chips and independently 
synthesized batches of DNA-antibody conjugate. 
For the sake of comparison, we performed a similar study using antibodies that were 
covalently tethered to the sensor surface, using a previously reported hydrazone linkage-based 
bioconjugate strategy.28 The same anti-PSA-5A6 antibody used to make the DNA-antibody 
conjugates was directly attached to the sensor chips while recording the accompanying shift in 
resonance wavelength. The sensor chip was then exposed to 1 µg/mL PSA and the response was 
measured. This process was repeated for a second sensor chip, and all of the results are plotted as 
the circular red data points in Figure 5.2B. A linear relationship between antibody loading and 
antigen binding response is again observed, but the slope is 2.5 times greater in the case of the 
DNA-conjugate. Although the mechanism of this increase in antigen recognition capacity is still 
under investigation, we preliminarily attribute it to the fact that the underlying DNA 
functionalized microring surface is sufficiently hydrophilic to minimize the denaturation of 
attached antibodies through non-specific interactions. Furthermore, the flexibility afforded by the 
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DNA linker might allow the antibody to sample more optimal orientations for antigen capture, as 
opposed to the shorter and more rigid covalent linkage. 
 
5.3.2 Validation of Multiplex DNA-Antibody Conjugate Chip 
 
Having validated the performance and established the utility of DNA-antibody conjugates 
for antigen binding, we then created multiplexed substrates that presented different DNA strands 
(named A, B, F, K, L, M) on each sensor chip. Figure 5.3A demonstrates that complementary 
DNA strands bind specifically to the rings functionalized with the complementary surface-bound 
probes. As 1  µM complementary DNA strands A′, B′, F′, K′, L′, M′  are added sequentially, each set of 
rings with appropriate complementary strands shows a specific signal to the appropriate DNA strand with 
minimal cross reactivity. Similarly, Figures 5.3B and 5.3C show the specific binding of the anti-
PSA and anti-AFP DNA-encoded antibody conjugates, respectively. Again, only the appropriate 
rings respond as each DNA-encoded antibody is added sequentially. 
 
5.3.3 Kinetic Analysis of Six Anti-PSA and Six Anti-AFP Antibodies 
 
Following the determination that all six conjugates could be loaded without any non-
specific antibody localization, these 6-plex chips were then used to simultaneously evaluate the 
kinetic binding characteristics of multiple, commercially-available protein capture agents 
recognizing either PSA or AFP. 
 In order to expedite the data collection process for screening the binding characteristics 
of multiple antibodies,  we followed the strategy of Karlsson and coworkers,24 who previously 
reported a kinetic titration method. This method enables subsequent additions of antigen 
solutions without having to regenerate in between.  
Starting with a sensor chip spotted with 6 different ssDNAs at unique spatial locations, 
six different DNA-antibody conjugates were simultaneously loaded onto the sensor chip by 
flowing a mixture of all the conjugates simultaneously over the entire chip surface. In an effort to 
avoid the deleterious effects of steric crowding on kinetic measurements,29, 30 the amount of each 
bound antibody was maintained in the range of 450-750 pg/mm2, (30-50 pm resonance 




Figure 5.3 Real time data plots showing resonance wavelength shifts for arrays of microrings functionalized with 6 
different DNA strand sequences (strands A, B, F, K, L, and M, each shown in a different color, as seen in the 
legend). (A) Sequential addition of 1 µM complementary DNA strands A′, B′, F′, K′, L′, M′ with no apparent cross-
reactivity since only the appropriate rings respond at the time point at which the complementary strand is added. (B) 
Sequential addition of 6 different DNA-anti-PSA conjugates with appropriate complementary DNA. Again, only the 
appropriate rings respond at the time point during which the conjugate with the complementary DNA is added, so 
there is no apparent cross reactivity. The jump at ~27 minutes comes from an air bubble. (C) A similar experiment 




initially, before the surface was regenerated with 8M urea and the six anti-AFP antibodies were 
added to the chip. Each titration consisted of 1.5-minute association phases of solutions 
containing 10, 20, 50, 100, 300, 1000, 5000 ng/mL concentrations of antigen (either PSA or 
AFP) with 4.5-minute dissociation rinses with buffer.  
 Figures 5.4A and 5.4B show the real-time shifts in resonance wavelength during the 
aforementioned kinetic titrations for both anti-PSA and anti-AFP antibodies, respectively. Each 
set of traces was normalized according to the amount of each antibody loaded onto the sensor 
array. Measurements were made in triplicate for each antibody, with six control rings comprising 
the rest of the 24-element sensor array. However, for clarity, data from only a single 
representative microring per antibody is shown. 
As shown in Figure 5.4A, A′-anti-PSA-8A6 and K′-anti-PSA-780 conjugates show very 
low binding activity. To verify that the poor antigen recognition was not due to the covalently-
attached DNA, we tested all of the antibodies without pendant DNA by flowing them over a 
surface with immobilized rabbit-anti mouse IgG-Fc (RAM-Fc) (data not shown). Because the 
RAM-Fc binds mouse IgG in the Fc region, away from the antigen recognition sites, this method 
does not require antibody modification and has been used to orient  antibodies on biosensor 
surfaces.32 Comparing the RAM-Fc immobilization approach to the DNA-assembled approach, 
the antigen binding behavior remained consistent between methods, with anti-PSA-8A6 and anti-
PSA-780 displaying poor antigen binding performance in either case.  
Figure 5.4B shows the real-time shifts in resonance wavelength for the six anti-AFP 
antibodies in a manner identical to the anti-PSA antibodies (Figure 5.4A). In this case, all the 
antibodies responded well and most of the antibodies had similar association and dissociation 
rates. Only K′-anti-AFP-1305 displayed markedly different behavior, in contrast to the collection 
of anti-PSA antibodies, which showed greater variation in binding kinetics.    
 In order to quantitatively evaluate the binding kinetics of the arrayed antibodies, the real-
time shifts in resonance wavelength from the kinetic titration were fit using the integrated rate 
equation for the one-to-one Langmuir binding model. Figures 5.5 and 5.6 show the results of this 
fitting to the anti-PSA and anti-AFP antibodies, respectively. As noted above, the A′-anti-PSA-
8A6 and K′-anti-PSA -780 antibodies showed poor binding activity, which presented 





Figure 5.4 Real-time shifts in resonance wavelength from representative microring resonators functionalized with 
unique antibodies upon exposure to A) PSA, and B) AFP in a kinetic titration assay format. In both panels, solutions 
containing the targeted antigen at the listed concentrations (in units of ng/mL) are introduced for 1.5 minutes at time 
points indicated by black arrow. After this association phase, the solution was switched to buffer (as indicated with 






Figure 5.5 Real time data plots showing the kinetic titrations for 15 microring sensors (three sensors per antibody 
conjugate) for the anti-PSA conjugates. The black traces indicate the real time data, and the red traces indicate the 
global fit via a one-to-one Langmuir binding model. In each graph, the calculated ka, kd, and KD from the fit are 
listed, except for L′-anti-PSA (B731M), which had too slow of a dissociation rate to accurately measure, thus “n/a” 
is given for those values. Also, anti-PSA-780 performed too poorly to generate a reliable fit, so the data for K′-anti-




Figure 5.6 Real time data plots showing the kinetic titrations for 18 microring sensors (three sensors per antibody 
conjugate) for the anti-AFP conjugates. The black traces indicate the real time data, and the red traces indicate the 
global fit via a one-to-one Langmuir binding model. In each graph, the calculated ka, kd, and KD from the fit are 
listed, except for a few of the plots, which had too slow of a dissociation rate to accurately measure, thus “n/a” is 
given for those values.   
115 
 
poor fit, whereas we were unable to fit binding parameters for K′-anti-PSA -780, thus its 
omission from the figure.  
Table 5.2 summarizes the average values for the kinetic association (kon) and dissociation 
rates (koff) and equilibrium dissociation constant (   ) determined from the fitting the 
resonance wavelength shifts for the microring array during the kinetic titration assays. As 
described above, the poor performance of the K′-anti-PSA -780 antibody prohibited accurate 
fitting to the model, and thus did not allow for determination of kinetic or equilibrium binding 
constants. Furthermore, L′-anti-PSA-B731M possessed an incredibly slow dissociation rate that 
was difficult to measure (even over longer dissociation times than described herein), and thus an 
accurate kd (and KD) could not be attained, although the affinity appears to be very high. 
Due to subtle variations in experimental conditions and measurement methodology, as 
well as uncertainties in fitting, experimentally derived kinetic and equilibrium binding values 
often have variances from group-to-group or technology-to-technology, making absolute, cross-
platform comparisons of protein-protein interactions difficult. However, by comparing six 
antibodies side by side in identical assay conditions within same microfluidic volume, we 
demonstrate a direct, head-to-head comparison of antibodies which can enable accurate selection 
of an antibody for a particular assay. For example, a fast association rate may desirable for 
certain applications where kinetics are of utmost importance. However, a slow dissociation rate 
may be preferred when the tightest possible binding (smallest KD)  is needed, or if antigen needs 
to stay bound for additional rinse or recognition steps, such as with a sandwich-type assay. The 
parallel screening method presented herein provides a straightforward approach to rationally 
selecting antibodies with optimal characteristics for the desired assay.  
 
5.3.4 Antibody Sandwich Pair Screening 
 
In addition to characterizing the binding kinetics of each individual antibody, the easily 
programmable and readily regenerable DNA-encoded microring sensor array also provides a 
mechanism to rapidly screen for antibody sandwich pairs. The six DNA-antibody conjugates 
recognizing either PSA or AFP were loaded onto the chip surface, and then a high concentration 
of antigen was flowed over the sensor array, giving a saturated binding response. Each individual 
antibody (non-DNA conjugated) was sequentially flowed over the chip and sandwich pairs were  
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Table 5.2 List of kinetic and equilibrium binding parameters for DNA-antibody conjugates interacting with their 
target antigen. 
  ka 
(s-1M-1 × 10-5) 
kd 






A′-anti-PSA-8A6 8.7 9.2 1.1 
B′-anti-PSA-B732M 41 38 0.91 
F′-anti-PSA-5A6 94 63 0.67 
L′-anti-PSA-B731M 54 - - 
K′-anti-PSA-780 - - - 




A′-anti-AFP-1301 8.3 0.75 0.0091 
B′-anti-AFP-B491M 4.8 0.22 0.0046 
F′-anti-AFP-435 11 1.7 0.015 
K′-anti-AFP-1305 18 26 1.4 
L′-anti-AFP-210 6.7 3.9 0.58 




identified when shifts in resonance wavelength indicated the binding of the second antibody to 
the pre-bound antigen. After flowing all six antibodies in sequence, a urea regeneration step was 
used to strip the surface, which could then be reloaded with primary antibody conjugates and the 
process repeated with a different secondary introduction sequence. This reordering ensured that 
if the binding of one sandwich pair interfered with the binding of a second antibody, there would 
be an opportunity for the second antibody to be tested without the first antibody having been 
flowed over the surface already. By using a fluidic system that featured two identically-encoded 
channels, all sandwich pairs were unambiguously assessed using only a single regeneration (4 
tests overall). The results of these screening efforts are summarized in Table 5.3 (PSA) and 
Table 5.4 (AFP). As expected for monoclonal antibodies, capture agents did not show secondary 
recognition of antigens already bound to themselves, as the epitope was blocked during primary 
binding. Furthermore, in all cases successful sandwich pairs work in both configurations where 
either antibody is surface-immobilized and the other acting as the solution-phase secondary 
recognition agent. Interestingly, both the anti-PSA and anti-AFP libraries show a large number 
of valid sandwich pairs. Anti-AFP antibodies exhibit a somewhat larger selection of sandwich 
pairs than the anti-PSA antibodies; this is not totally unexpected given that AFP is a larger 
protein than PSA, and would therefore possess more potential epitopes. Similarly, non-
compatible sandwich pairs suggest that the antibodies bind to identical or proximal recognition 
domains and these types of analysis represent a form of epitope mapping. For example, anti-
AFP-1301, anti-AFP-780, and anti-AFP-210 all seem to bind to a similar location on the antigen 
since their binding is mutually exclusive.  Overall, the results show how readily secondary 
binding agent compatibility can be determined using a multiplexed sensor array of DNA-
encoded antibodies, and suggest a straight-forward and efficient method for identifying pairs of 




In this study we demonstrated the robust nature and utility of DNA-encoded antibodies 
for the multiplexed screening of capture agent binding properties, in terms of screening both 
their kinetic and equilibrium binding metrics, as well as their compatibility for forming 
sandwich pairs around a single antigen. Furthermore, this antibody attachment scheme appears  
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Table 5.3 Anti-PSA sandwich pair screening results showing sandwich-pair interactions (“X”) between surface-













A′-anti-PSA-8A6 - - X - X X 
B′-anti-PSA-B732M - - - X - - 
F′-anti-PSA-5A6 X - - X X X 
K′-anti-PSA-780 - X X - X X 
L′-anti-PSA-B731M X - X X - - 





Table 5.4 Anti-AFP sandwich pair screening results showing sandwich-pair interactions (“X”) between surface-














A′-anti-AFP-1301 - X - X - X 
B′-anti-AFP-B491M X - X X X X 
F′-anti-AFP-435 - X - X - X 
K′-anti-AFP-1305 X X X - X X 
L′-anti-AFP-210 - X - X - X 




to offer multiple advantages over covalent immobilization in terms of antibody binding capacity, 
and array regeneration and reprogramming capabilities, thus reducing the need for complex 
microfluidic designs. Coupled with the inherent long term solution-phase storage stability of the 
DNA-antibody conjugates and ssDNA-functionalized sensor array, we envision that DNA-
encoded antibodies will continue to be a valuable tool for both protein detection and the 
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 Many biosensor development efforts focus almost exclusively on improving detection 
sensitivity for a particular target analyte. While this is clearly a vital metric, assay dynamic range 
is also an important attribute that critically influences clinical utility. The dynamic range 
challenge is even more pronounced for multiplexed analyses, where both intra- and inter-analyte 
concentrations can vary widely. For example, the cardiovascular risk biomarker C-reactive 
protein (CRP) can increase by a factor of 10,000 in serum during an acute phase response.1 
Moreover, protein concentrations in human plasma are known to vary over 11 orders of 
magnitude.2 Whereas single-analyte assays can incorporate repeated dilutions, multiplexed 
analyses of antigens that natively vary in magnitude represent a significant analytical challenge. 
 Recently, chip-integrated, silicon photonic microcavities have been developed for a 
number of biosensing applications.3 Importantly, the scalability and multiplexing capability 
inherent to these semiconductor-based devices make them attractive for many high volume 
applications, including in vitro clinical diagnostics. Because they are responsive to binding-
induced changes to the refractive index (RI) environment near the resonator surface, these 
sensors are intrinsically label-free. As illustrated in Chapters 3 and 4, microring resonators have 
been used for protein analysis and detection of analytes in both single4 and multiplexed5 formats 
using an initial slope-based quantitation technique. This approach features a superior linear 
dynamic range of ~3 orders of magnitude, while maintaining a limit of detection (LOD) 
comparable to that of a commercial enzyme-linked immunosorbent assay (ELISA). Other work 
in our group has shown that the incorporation of a secondary antibody recognition event can 
further lower the limit of detection while also increasing assay specificity in complex sample 
matrices.6 However, because of surface-saturation effects, quantitation at higher concentrations 
is restricted, resulting in a more limited dynamic range similar to that of other sandwich 
immunoassays.7 
 In this paper, we report the analytical utility of a three-step assay format in which primary, 
secondary, and bead-enhanced tertiary binding events are observed in series in order to 
sensitively quantitate the presence of an antigen over a broad (~106) dynamic range. As shown in 
Figure 6.1, the primary and secondary measurements are conducted as described previously.4, 6 




Figure 6.1 Schematic and real-time data plot showing sequential addition of CRP, biotinylated secondary antibody, 
and SA-functionalized beads. The red trace is 10-1 µg/mL CRP. The blue trace is 10-3 µg/mL CRP. * indicates buffer 




micron (~100 nm diameter) beads to biotinylated secondary antibodies. Similar to previous 
reports using nanoparticles,8-10 carbon nanotubes,11 and enzymatic amplification12 to enhance the 
signal of RI-based sensing devices, our tertiary binding assay lowers the LOD by enhancing the 
optical signal arising from a single bound antigen. However, more useful here is the integration 
of a consecutively run assay that includes the real-time observation of all three discrete binding 
regimes. This methodology broadens the dynamic range to over six orders of magnitude.  As a 
representative analyte that is known to vary over a wide dynamic range in clinical samples,1 CRP 
is quantitated via a three-step assay protocol in buffer, human serum, and human plasma. 
 




silane), succinimidyl 6-hydrazinonicotinate acetone hydrazone (S-HyNic), and succinimidyl 4-
formyl benzoate (S-4FB) were purchased from Solulink (San Diego, CA).  Capture and 
secondary antibodies to CRP (clones M701289 and clones M701288, respectively) were 
purchased from Fitzgerald Industries (Concord, MA).  Capture (MAB206, clone 6708) and 
biotinylated secondary (BAF206) antibodies for interleukin-6 were purchased from R&D 
Systems, Inc (Minneapolis, MN). Recombinant human interleukin-6 and a human CRP ELISA 
kit (88-7502-28) were purchased from eBioscience (San Diego, CA). NHS-PEG4-Biotin was 
purchased from Thermo Scientific and dissolved in DMF to make a 20 mM stock solution.  
Streptavidin-coated polystyrene/iron oxide beads with a mean diameter of 114 nm were 
purchased from Ademtech (Pessac, France).  Human CRP (95% pure from human blood) was 
purchased from Meridian Life Science.  CRP-depleted processed serum and CRP High Plasma 
(with a reported CRP content of 69.1 µg/mL based on a Roche Modular immunoassay) were 
purchased from SunnyLab (Sittingbourne, UK).  Pooled normal human serum and single-donor 
human serum samples #1 and #2 (catalog number IPLA-SER-S, lot numbers K9207 BF 19 and 
55-25114 WM 19, respectively) were purchased from Innovative Research (Novi, MI).  Fresh 
single-donor human plasma was collected from a healthy donor under a plan approved by the 
University of Illinois Institutional Review Board. Zeba spin filter columns and StartingBlock 
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(PBS) were purchased from Pierce (Rockford, IL).  Vivaspin molecular weight cutoff filters 
(5000 and 50000 kDa) were purchased from GE Healthcare (Waukesha, WI). 
The capture anti-CRP antibody was immobilized onto the microring sensors using a 
DNA-encoding approach.13, 14 30-mer DNA strands for the DNA-encoded CRP capture antibody 
immobilization were synthesized with a C6 spacer and 5′ amination by Integrated DNA 
Technologies (Coralville, IA).  The surface 30-mer sequence was: 
 
 5'-AAAAAAAAAAGCCTCATTGAATCATGCCTA-3',  
 
and the complement sequence conjugated to anti-CRP capture antibodies was: 
 
 5'-AAAAAAAAAATAGGCATGATTCAATGAGGC-3'.  
 
 The 3′- biotinylated 30-mer for the simulated human papillomavirus (HPV) DNA target, 
simulated HPV DNA 46-mer target, and HPV surface capture strand were also synthesized by 






PBS buffer was prepared from Dulbecco’s phosphate buffered saline from Sigma Aldrich 
(St. Louis, MO).  PBST buffer consisted of PBS buffer and 0.05% Tween-20.  The pH of buffers 
was adjusted using 1M HCl or 1M NaOH.  All other chemicals were obtained from Sigma-
Aldrich and used as purchased. 
 
6.2.2 Antibody and DNA Modification  
 
An aldehyde moiety is added to the surface capture DNA strand and its complement by 
incubation with a 20-fold molar excess of 5 mg/mL S-4FB for 2-3 h at room temperature in 33% 
DMF in PBS pH 7.4.  Excess S-4FB is removed by buffer exchange using a 5-kDa molecular 
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weight cutoff filter.  Capture antibody-HyNic conjugates are prepared by incubating the antibody 
with a 10-fold excess of 1 mg/mL S-HyNic at room temperature for 2 h.  Excess S-HyNic is 
removed by buffer exchange using Zeba spin filter columns.  For biotinylation, 0.5 mg/mL 
secondary anti-CRP M701288 in PBS pH 7.4 is incubated with a 10-fold molar excess of 20 mM 
NHS-PEG4-biotin for 3 h at room temperature.  Excess NHS-PEG4-biotin is removed by buffer 
exchange using Zeba spin filter columns.  Capture antibody- DNA conjugates are prepared by 
incubating the capture antibody-HyNic conjugate and the 4FB-modified surface DNA strand at a 
1:20 protein:DNA ratio overnight at 4°C.  The mixture is purified using a Superdex 200 10/300 
GL column on an AKTA FPLC, both from GE Healthcare, and fractions containing the 
antibody-DNA conjugate are concentrated and exchanged into PBS buffer using a 50-kDa 
molecular weight cutoff filter. 
 
6.2.3 Bead Exchange and Surface Modification  
 
Of critical importance, beads are exchanged into PBST buffer immediately before use to 
remove free streptavidin via the following procedure. Without doing so, excess free streptavidin 
rapidly diffuses to the surface and outcompetes the beads for biotin binding sites. To exchange 
the beads, 30 µL of 5 mg/mL streptavidin-coated beads are diluted to 150 µg/mL with PBST 
buffer and centrifuged at 10,000 g for 4 min.  The bead pellet is held at the bottom of the tube 
using a magnet while the supernatant is removed, leaving about 30 µL of solution.  The beads are 
then resuspended in 1 mL of PBST buffer by pipetting the solution up and down ~50 times with 
the tube bottom remaining in contact with the magnet.  This procedure is repeated for a total of 4 
exchanges.  Directly before use in the assay, the final bead solution is adjusted to a concentration 
of 50 µg/mL using the absorbance value at 286 nm as determined by calibration based on direct 
dilution of non-exchanged beads.  For DNA detection, beads are conjugated to a secondary 
complementary DNA strand.  Streptavidin-coated beads are incubated with a large excess of 
biotinylated DNA for at least 2 h.  The excess DNA is removed by buffer exchange according to 






6.2.4 Chip Functionalization  
Chips are batch-functionalized ex-situ by a spotting method.  After a 20-min sonication in 
ethanol, chips are immersed for 20 s in hot Piranha solution (3:1 H2SO4: 30% H2O2) [Caution: 
Pirahna solution must be handled with care as it can react violently with organic compounds.], 
rinsed with water, and dried under a stream of nitrogen.  Each chip is then spotted with a 30-µL 
drop of 1 mg/mL HyNic silane in 95% ethanol and 5% DMF and incubated at room temperature 
in an enclosed chamber for 30 min.  The chip is then rinsed with ethanol and dried.  A 0.5-µL 
drop of 4FB-modified capture DNA strand is then manually pulled across the surface with a 2.5-
µL pipette tip. The 24-sensor chips were functionalized with DNA leaving four sensors on each 
chip unfunctionalized to serve as controls.  The chip is then blocked by submersion in 
StartingBlock at 4ºC for at least 8 h. 
 
6.2.5 CRP Detection Experimental Procedure  
 
The fluidic cell and microfluidic system have been described previously.4  In these 
experiments, a Mylar gasket is used to direct flow to two microfluidic channels, each addressing 
12 of the 24 active rings, allowing two experiments to be carried out on one chip.  A consistent 
amount of capture antibody is loaded by flowing 10 µg/mL DNA-encoded anti-CRP M701289 at 
2 µL/min until the antibody signal reaches ~140 ∆pm. To begin the procedure for the analysis of 
samples, PBST buffer is flowed over the surface to establish a baseline.  A 30 µL/min-flow rate 
is maintained for all assay segments. The sample or standard is introduced and allowed to flow 
over the surface for 20 min, followed by a buffer rinse.  In serum and plasma samples, this rinse 
is longer (~20 min) than the typical 3 min rinse to allow for desorption of non-specifically bound 
proteins.  The biotinylated secondary antibody is then flowed over the surface for 15 min 
followed by another short buffer rinse (3-5 min).  Finally, streptavidin-coated beads (exchanged 
immediately before use as described above) are flowed over the surface for 16 min followed by a 
final buffer rinse.  For DNA detection, there is not a third binding step as the secondary detection 






6.2.6 Instrumental Setup 
 
The microring resonator instrumentation and chips were acquired from Genalyte (San 
Diego, CA), and have been described in detail in previous publications.4, 15 Briefly, each chip is 
fabricated with 32 active microring sensors covered with a perfluoropolymer cladding layer. 
Eight rings on each chip remain occluded by the polymer layer and serve as thermal controls. 
Twenty-four active sensors rings have an annular opening etched over the ring to enable 
exposure to the solution in the microfluidic channel. Each ring resonance is monitored via 
frequency attenuation in an adjacent linear waveguide. Input and output diffractive grating 
couplers are located at each end of the waveguide to enable independent determination of the 
optical cavity spectrum for each microring using a tunable, external cavity diode laser (center 
frequency: 1560 nm).   
 
6.2.7 Data analysis  
 
Calibration curves for primary binding are generated by determining the initial slope as a 
function of analyte concentration, as described in Chapter 3. Secondary and tertiary binding 
calibration curves are generated by plotting the total net relative shift of the secondary and bead 
binding, respectively.  Standard additions were prepared based on an initial estimate of the 
unspiked concentration in a diluted sample based on comparison to calibration plots generated in 
buffer.  Small increments of a concentrated CRP solution are added to aliquots of diluted sample 
and then analyzed in the above described manner.  Standard addition plots were generated based 
on primary, secondary, or tertiary response as a function of the concentration of spiked CRP 
added, and CRP concentrations are determined based on extrapolation of the linear regression fit 
to the x-intercept. Regression lines for calibration in buffer and standard additions were 








6.3 Results and Discussion 
6.3.1 Demonstration of Three-Step Assay 
 
  As shown in the red trace in Figure 6.1, the addition of 10-1 µg/mL CRP (t = 5 min) 
resulted in a visible primary binding response. Subsequent addition of biotinylated anti-CRP (t = 
28 min) gave a ~3-fold larger response. Finally, addition of 100-nm SA-functionalized beads (t = 
46 min) provided an even larger signal enhancement. At this relatively high concentration, 
secondary and tertiary amplification gave large signals, but they were not required for CRP 
detection. However, at lower concentrations such as 10-3 µg/mL CRP (blue trace in Fig. 1), 
amplification was necessary. At or below this concentration, no primary binding was detected, 
and the secondary binding showed ~1 pm resonance wavelength shift. Notably, addition of the 
beads gave nearly a 100-fold signal enhancement at this low concentration. Negative control 
experiments, in which biotinylated antibody and SA-beads were flowed over an anti-CRP-
functionalized chip without initial CRP incubation, yielded no appreciable signal, as shown in 
Figure 6.2. 
 
6.3.2 Chip Reproducibility and CRP Calibration Curve 
 
 After determining the nature of the three-step signal enhancement process, CRP standards 
were measured across a 5-order-of-magnitude concentration range using the sequential primary-
secondary-tertiary assay protocol. In order to use multiple chips to create a calibration curve, we 
first had to verify that chip-to-chip responses for a given sample were reproducible. Figure 6.3 
shows the response plots from identical analyses on 4 chips (8 fluidic channels) with one ring 
shown for each channel. Figure 6.3A demonstrates the reproducibility of the measurements at a 
high concentration of 10-1 µg/mL and Figure 6.3B demonstrates reproducibility for a low 
concentration of 10-3 µg /mL.  
Statistical results of these comparisons are tabulated in Table 6.1. Average shifts/initial 
slopes and standard deviations for 10-1 µg/mL and 10-3 µg /mL CRP are given in Table 6.1A and 
Table 6.1B, respectively.  The ring-to-ring standard deviation is calculated from the standard 
deviation for all rings (n = 80) on all 4 chips tested, while the channel-to-channel standard 





Figure 6.2    Negative control experiment for 10-2 µg/mL CRP sandwich assay with bead amplification. The red plot 
represents the response to 10-2 µg/mL CRP (t = 5 min) followed by the introduction of 1.6 µg/mL biotin-anti-CRP 
M701288 (t = 28 min) and subsequent signal amplification with 50 µg/mL streptavidin-conjugated beads (t = 46 
min). The blue plot represents a ring that is first exposed to buffer without any CRP followed by the same secondary 
antibody and bead solutions. No primary, secondary, or bead signal is observed on rings not exposed to CRP, which 
demonstrates no appreciable non-specific binding of secondary antibodies or beads. * indicates buffer rinse and the 





Figure 6.3    Demonstration of chip-to-chip reproducibility for (A) 10-1 µg/mL and (B) 10-3 µg /mL CRP sandwich 
assays with subsequent bead-based amplification. Both plots display 8 representative rings, with 1 ring selected from 
each of 2 channels on a total of 4 chips for each CRP concentration. * indicates buffer rinse and the arrows indicate 
the introduction of the identified solutions at the times noted. All assays were conducted in freshly degassed 10 mM 
PBS pH 7.4 + 0.05% Tween-20 with 1.6 µg/mL biotin-anti-CRP M701288 and 50 µg/mL streptavidin-conjugated 





Table 6.1 Standard deviations of the variations between sensors and between groups of sensors in a microfluidic 
channel  for CRP analysis at (A) 10-1 µg/mL and (B) 10-3 µg /mL.    
 
 
A Initial Primary Slope Secondary Shift Bead Shift 
 ∆pm/min ∆pm ∆pm 
Average 3.7  117  369 
St. Dev. (ring-to-ring) 0.7  14  47  
St. Dev. (channel-to-channel) 0.3  8  33  
    
B Initial Primary Slope Secondary Shift Bead Shift 
 ∆pm/min ∆pm ∆pm 
Average - 0.9  73  
St. Dev. (ring-to-ring) - 1.5  15  




(2 microfluidic channels/chip). In each case, the ring-to-ring variability exceeds the channel-to-
channel variability, suggesting that the use of multiple chips for calibrations and quantitative 
analyses is satisfactory. It is also worth noting that the 0.9 ± 1.5 pm secondary shift for 10-3 µg 
/mL CRP represents a concentration on the lower boundary of what can be seen with a simple 
CRP sandwich assay. Although difficult to observe with secondary binding, tertiary binding 
creates an easily measurable response (73 ± 15 pm). Thus, in addition to enabling detection at 
previously impossible levels, beads also are important for amplifying small secondary signals. 
After determining chip-to-chip reproducibility, we then detected CRP across a wide range 
of concentrations to create the calibration curve shown in Figure 6.4. In this figure, the response 
curves from the primary, secondary, and tertiary binding assays overlap, allowing continuous 
CRP calibration over a broad dynamic range (10-4 µg/mL to 10 µg/mL). The initial slope of 
primary binding (black squares) is important because, at high concentrations, the surface is 
nearly saturated. Thus, it is impossible to distinguish between high concentrations except by the 
rate at which they approach saturation.4 Using initial slopes, it is possible to quantify 
concentrations from 10-2 to >10 µg/mL in buffer. The dynamic range is extended (10-3 to >10-1 
µg/mL) by measuring the relative shift in resonance wavelength following addition of secondary 
antibody (red circles) and further expanded down to <10-4 µg/mL though the use of SA-bead 
enhancement (blue triangles). Using the bead-based enhancement, the overall assay LOD is ~3 × 
10-5 µg/mL (~200 fM). 
 The dynamic range of each step of the three-part analysis method has a region of overlap 
with one of the other steps (Figure 6.4), providing the opportunity for confirmation of the 
measurement. For example, 10-3 µg/mL CRP is quantifiable by secondary detection, but tertiary 
amplification significantly increases the measurement precision. As suggested by the results in 
Table 6.1. 
 
6.3.3 Detection of CRP in Plasma and Serum 
 
 Following assay calibration, the same three-step detection protocol was applied to the 
quantitation of CRP in human plasma and serum samples. Because the expected range of 
concentrations of CRP in human blood is from 10-1 µg/mL to 103 µg/mL, each sample was 




Figure 6.4 Log-log calibration plot showing the response of the microring resonators to varying concentrations of 
CRP using the three-step assay. Black squares indicate the initial slope of the primary binding (right axis), red 
circles indicate secondary antibody shift, and blue triangles indicate bead shift (left axis). Error bars represent 95% 





could most accurately be quantified. This uniform dilution, as opposed to repeated dilutions, also 
helped reduce non-specific adsorption of blood proteins and lowered the required sample 
volumes to less than ten microliters, making the assay amenable to fingerprick sampling. 
  For the purposes of quantitation we utilized a standard addition method as it is amenable 
to the complex and variable clinical sample matrices.16 In this method, the diluted serum or  
plasma was first analysed via the three-step assay, and the response was compared to the 
calibration curve (Figure 6.4) to roughly estimate the CRP concentration range. Three 
appropriate samples with increasing standard additions were then successively analysed, and the 
precise CRP concentration was determined via extrapolation. The wide variation in native CRP 
levels required user input into the standard addition procedure, as opposed to simply adding 
uniform amounts of standard. However, the overall methodology is amenable to automation; for 
example, an analytical system pre-programmed with the calibration information could utilize 
integrated microfluidics to create the appropriate standard additions on demand. 
 Figure 6.5 shows the standard addition plots generated for each sample.  Figure 6.6 
shows the results of these serum/plasma analyses. The colours in the graph indicate the method 
used to quantify the CRP concentration. The black bar indicates that a commercially obtained 
pooled plasma sample with elevated CRP was quantified using the primary binding response and 
found to have a CRP concentration of 57.5 ± 3.3 µg/mL.  This value obtained on the microring 
resonator platform agreed reasonably well with the supplier’s provided value of 69.1 µg/mL. The 
red bars indicate secondary binding-based detection, which was used to quantitate the CRP 
values in the pooled-donor normal serum, single-donor serum #2, and single-donor plasma. The 
blue bars indicate quantitation using the tertiary bead binding, which was necessary to detect 
CRP within single-donor serum #1 as well as a commercially-available CRP-depleted serum 
sample (in which CRP had been removed by the vendor). Each of the samples analysed, with the 
exception of the CRP-elevated pooled plasma, had CRP levels less than 1 µg/mL, placing those 
donors in the low-risk range for cardiovascular disease.1 Interestingly, for the CRP-depleted 
sample, analysis of a 1:100 dilution revealed CRP levels at 3×10-5 µg/mL. While this 
concentration is far below what would typically be found in human serum, it is noteworthy that 
this is similar to the lowest levels of CRP present in saliva.17 This means that the three-step assay 
format on the silicon photonic-based platform is amenable to quantifying CRP in all clinically-






Figure 6.5 Standard addition plots used to determine CRP concentrations in 6 human serum and plasma samples 
quantified in Figure 6.6. Since CRP levels vary over a wide dynamic range, quantitation was performed based on 
bead shift (A, B), secondary shift (C, D, E), or primary initial slope (F). Each plot displays the shift or slope data for 
an unspiked sample dilution plus three standard additions of CRP determined by the magnitude of the unspiked 
sample response. The sample identity, fitting equation, quality of fit, x-intercept, and observed CRP concentration 





Figure 6.6 Detection of CRP in human serum and plasma samples. All samples are diluted 1:1000 in buffer except 
for the CRP-depleted serum, which was diluted 1:100. Error bars represent the error in the x-intercept determination 




Table 6.2 Comparison of CRP levels measured by ring resonators with those determined based on a commercial 
CRP ELISA. 
 CRP Concentration (µg/mL) 
 Ring Resonator Array CRP ELISA 
CRP-Depleted Serum 0.0031 ± 0.0015 - 
Single-Donor Serum #1 0.12 ± 0.05 0.19 ± 0.08 
Single-Donor Serum #2 0.70 ± 0.57 0.39 ± 0.08 
Single-Donor Plasma 0.67 ± 0.14 2.05 ± 0.22 
Pooled Normal Serum 0.89 ± 0.18 1.45 ± 0.10 




In addition to microring resonator analysis, a commercial enzyme-linked immunosorbent 
assay (ELISA) was performed for comparison with the results for the six human serum and 
plasma samples depicted graphically in Figure 6.6. Results of this comparison are given in Table 
6.2. In this table, errors for the ring resonator array data represent the error in the x-intercept 
determination used in the standard addition assays (as described above). ELISA errors are the  
standard deviation of triplicate assays run according to the manufacturer’s protocol. All ELISA 
values were measured from samples that were diluted to be within the range of the assay, with a 
1:1000 dilution proving optimal for all but the CRP-elevated plasma which required a 1:40000 
dilution. ELISA failed to detect CRP in the CRP-depleted serum at any dilution tested (1:100, 
1:1000, 1:4000). While ring resonator analysis was in strong agreement with ELISA for most of 
the samples tested, some varied by as much as a factor of 2-3. This variation is typical of what is 
observed when comparing a variety of immunoassays, especially considering different dilution 
factors. Prior analyses of CRP samples by Khuseyinova et al. and Clarke et al. that each 
compared separate immunoassay methodologies showed a similar degree of agreement between 
methods, with most values in strong agreement and some varying by as much as a factor of 3-4.18, 
19
 These variations also tend to be more pronounced at higher concentrations, such as the pooled 
CRP-elevated plasma sample, where additional dilution or use of calibration curve extremes are 
necessary but introduce greater error due to pipetting, regression, or signal saturation. 
 In the course of our studies, we observed that several of the serum and plasma samples 
gave abnormally large signals for primary binding to microrings functionalized with the capture 
anti-CRP antibody, but a much smaller secondary binding response. These interactions, which 
we attribute to cross-reactivity between the primary antibody and some unknown component, 
highlight the fact that sample-to-sample heterogeneity can greatly complicate analysis in clinical 
samples.  In the case of the pooled plasma with elevated CRP, the primary binding signal was 
much larger than any of the off-target responses, and thus it did not interfere with primary 
response-based quantitation. However, for the single-donor plasma and serum samples, as well 
as the pooled normal serum, the primary off-target signal indicated abnormally high CRP content. 
Fortunately, the proportionally smaller secondary binding response increased the specificity of 
the assay, giving more reliable levels of CRP. Although some of the complications associated 
with clinical samples might be reduced by employing alternative antibodies or improved surface 
treatments, cross-reactivity and non-specific interactions are particularly difficult to completely 
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avoid for multiplexed assays from within complex sample matrices, underscoring the utility of 
this three-step measurement format that allows analytes to be measured at multiple levels, 
increasing both the specificity of the assay and reducing false positive responses. 
 
 
6.3.4 Detection of DNA and IL-6 with Bead Amplification 
 
 As a final demonstration of our signal amplification strategy, we not only measure CRP 
concentrations, but we also demonstrate that we can detect DNA strands as well as the cytokine 
interleukin-6 (IL-6) using the bead amplification protocol. Figure 6.7A shows the detection of a 
46-mer DNA strand relevant to the detection of the human papillomavirus (HPV). This ssDNA 
target was measured at four concentrations: 10 nM, 2 nM, 0.4 nM, and 0.16 nM. Each 
concentration is undetectable via primary binding, but addition of beads conjugated to a 30-mer 
DNA probe that is complementary to a portion of the HPV target, a measurable signal is given.  
 IL-6 was detected in a similar manner as CRP using the sandwich assay detection format 
with a biotinylated secondary antibody. Samples at concentrations of 10 ng/mL and 0.1 ng/mL 
are measured using the bead-binding amplification. At the 0.1 ng/mL level, signal is only 
detected by the beads binding to the biotinylated secondary antibody. Overall, these two 





This chapter demonstrates a three-step immunoassay on a scalable silicon photonic 
biosensing platform that enables a protein antigen to be detected over six orders of magnitude of 
concentration in complex, clinically-relevant sample matrices. While primary binding allows 
detection at higher concentrations, subsequent secondary and tertiary binding events significantly 
lower the LOD. The secondary and tertiary binding also increases the specificity of the assay by 
requiring additional target-specific recognition, allowing discrimination against non-specific 
interferants. Using this approach in a standard addition format, we determined the concentration 
of CRP in both human serum and plasma across a broad dynamic range while avoiding the need 
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for multiple serial dilutions. This methodology, which is facilitated by a real-time and modularly 
multiplexable sensor technology, is applicable beyond the detection of CRP and can be applied 
to other analytes. The generality of this technique should make it useful in multiplexed analyses 





Figure 6.7  Bead-based signal amplification universally augments ring resonator signals in assays designed for the 
detection of (A) a 46-mer human papillomavirus (HPV) ssDNA target and (B) the cytokine interleukin-6 (IL-6). In 
(A), 4 concentrations of HPV DNA prepared by serial dilution [10 nM (blue), 2 nM (orange), 0.4 nM (red), 0.16 nM 
(black)] are each undetectable based on primary binding (t = 6-36 min) to rings functionalized with a 30-mer probe 
complementary to the HPV target. Upon the addition of beads conjugated with a separate 30-mer DNA probe 
complementary to the remaining portion of the HPV 46-mer at t = 37 min, all 4 concentrations can be detected in a 
concentration-dependent manner. HPV DNA assays were conducted in freshly degassed 10 mM PBS pH 7.4 + 
0.05% Tween-20 with 20 µg/mL HPV probe-conjugated beads. In (B), 10 ng/mL (blue) and 0.1 ng/mL (black) IL-6 
are detected using bead-based amplification of a sandwich immunoassay. The secondary shift for 10 ng/mL IL-6 is 
amplified ~12x through the use of beads. However, the lower concentration of 0.1 ng/mL IL-6 (5 pM) is only 
detectable through the use of bead-based amplification to amplify the secondary signal. IL-6 assays were conducted 
in 10 mM PBS pH 7.4 + 0.1 mg/mL BSA with 1 µg/mL biotin anti-IL-6 BAF206 and 50 µg/mL streptavidin-
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 In recent years, the development of biomarker panels and proteomic profiles for 
diagnostic purposes has been viewed as a promising means to diagnose and treat cancer patients 
earlier and more accurately.1, 2 Unfortunately, developing validated biomarkers that can be 
incorporated into panels that meet the rigorous requirements for a clinical diagnostic have faced 
several challenges.3, 4 Some of the challenges to developing validated biomarker diagnostics for 
clinical use include avoiding bias in sample collection and storage methods, avoiding 
bioinformatics artifacts, and, perhaps most importantly, developing methods in a laboratory that 
can be reproduced in a clinical setting—a key to success in clinical trials. 
To develop robust, reproducible tools for clinical diagnostics, it is important to 
understand the strengths and shortcomings of current methods. At this time, multiplex 
diagnostics have generally fallen into two classes of analysis: mass spectrometry-related analysis 
and immunoassay-derived analysis.5 Mass spectrometry has the advantage that proteomic 
analysis has the potential to reveal the presence of thousands of proteins in a single sample, 
especially when combined with preparatory steps such as chromatography or sample digestion. 
Unfortunately, the variability in preparation steps and instrumentation between laboratories 
adversely affects the reproducibility of mass spectrometric methods. Conversely, immunoassays 
utilize specific antibody capture agents and are typically designed to analyze one analyte per 
capture agent. Although this practically limits the number of analytes that can be measured in a 
given multiplexed assay, the well-behaved specificity of the capture agents helps immunoassays 
perform in a more robust manner as compared to mass spectrometric analyses. As a result, 
immunoassays typically require simpler procedures—dilution often being the only preparative 
step—and are typically more reproducible and quantitative, even between different laboratories. 
Thus, although mass spectrometry will continue to play a significant role in the discovery and 
analysis of protein biomarkers, immunoassays are a more likely candidate for the development of 
robust, widespread diagnostics that can accurately quantitate biomarkers in human samples in a 
multiplexed fashion. As a result, our research is focusing on the development of an antibody-




For multiplexed immunoassays, the current state of the art typically relies upon planar 
microarrays or multiplexed bead-based assays for measuring concentrations of biomarkers in 
human serum samples.6 Although these techniques are well established and can deliver 
promising results, they typically rely on a signal that is generated at the end of multiple binding 
steps. For example, a standard bead-based detection format would involve immobilized 
antibodies binding to antigens of interest followed by binding of secondary antibodies that are 
attached to some sort of signal generating molecule (enzyme, fluorophore, etc.).6, 7 In contrast, 
with refractive index-based sensors, such as microring resonators, it is possible to gain 
information from each step of the process—primary antigen binding, secondary antibody binding, 
and tertiary signal amplification.8 This additional information can not only improve the dynamic 
range of an assay and provide additional information in a multiplexed analysis, but it also makes 
it possible to more rapidly develop and interpret reliable immunoassays. One of the challenges 
with a multiplexed immunoassay is obtaining appropriate capture agents for a given analyte and 
then avoiding interferences between different capture agents. By being able to observe primary 
binding of antigen in real time as well as secondary antibody binding, it is possible to gain the 
information necessary to rapidly develop an assay that will be limited in cross reactivity, or at 
least in which any cross reactivity will be well understood and characterized. 
Our previous work developing microring resonators has shown that multiplexed 
microring resonator chips can be used to rapidly screen antibodies for binding affinities and for 
sandwich pairs.9 Additionally, we have shown that microrings can be utilized for multiplex 
detection of cancer biomarkers10 and that we can sensitively detect a single biomarker using a 
signal amplification scheme.8 In this paper, we combine these capabilities to create a multiplexed 
cancer biomarker chip that can detect eight different cancer biomarkers in human serum using a 
signal amplification method to improve the limit of detection. 
For our cancer biomarker panel we selected: α-fetoprotein (AFP), for liver and germ cell 
cancer;11  carcinoembryonic antigen (CEA), for colorectal and pancreatic cancer;12-15 cancer 
antigen-125 (CA-125), for ovarian cancer;11, 16 osteopontin, for ovarian cancer;16 cancer antigen 
19-9 (CA19-9), for pancreatic, colorectal, or ovarian cancer; 11, 17 cancer antigen 15-3 (CA15-3), 
for breast cancer;11 prostate specific antigen (PSA), for prostate cancer;18 and activated leukocyte 
cell adhesion molecule (ALCAM), for breast cancer.19  In selecting which biomarkers to use for 
our test panel, we included six very common biomarkers (CEA, CA-125, CA15-3, AFP, PSA, 
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and CA19-9), five of which are FDA-approved biomarkers15 (CEA, CA-125, CA15-3, AFP, and 
PSA), and two less common biomarkers (osteopontin and ALCAM). Our choices were made to 
facilitate a panel that covers a wide variety of cancers as well as those that would be enabled by a 
good selection of commercially available antibodies. This selection is ideal for demonstrating the 
potential to create a robust diagnostic panel that can be utilized for analyzing clinical samples. 
Although future developments would probably narrow down the selection of biomarkers to 
several pertinent biomarkers for a particular cancer type, this work nonetheless demonstrates the 
utility of microring resonators in the creation and implementation of multiplexed biomarker 
panels. 
At time of publishing, this chapter’s work is only partially completed. In this chapter, we 
demonstrate the creation of an 8-plex biomarker panel, the characterization of the signal 
amplification method, and an initial trial with several human serum samples. In the near future, 
this work will continue to advance by developing a method to quantify serum patient samples, as 
well as looking at statistical methods for analyzing and categorizing patient samples.  
 
7.2 Materials and Methods 
7.2.1 Materials 
 
Succinimidyl 4-formylbenzoate (S-4FB), succinimidyl 6-hydrazinonicotinamide acetone 
hydrazone (S-HyNic), and 3-N-((6-(N'-Isopropylidene-hydrazino))nicotinamide)propyltriethy-
oxysilane (HyNic Silane) were purchased from SoluLink (San Diego, CA). Custom DNA 
oligonucleotides were synthesized by Integrated DNA Technologies (Coralville, IA). A list of 
capture and detection antibodies used in these experiments is given in Table 7.1. NHS-PEG4-
Biotin, Zeba spin filters, and Starting Block were purchased from Pierce (Rockford, IL).  NHS-
PEG4-Biotin was dissolved in DMF to make a 20 mM stock solution. Human serum samples 
from cancer patients were purchased from Innovative Research, Inc. (Novi, MI) and Asterand, 
Inc. (Detroit, MI). Fresh single-donor human plasma was obtained from a healthy donor under a 
plan approved by the University of Illinois Institutional Review Board. Vivaspin molecular 
weight cutoff filters (50,000 and 5,000 Da MWCO), were obtained from GE Healthcare 
(Waukesha, WI). Alternately, molecular weight cut-off filters (30,000 and 3,000 Da MWCO) 
were obtained from VWR (Radnor, PA). Anti-biotin (phycoerythrin) and anti-phycoerythrin  
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Table 7.1 List of antigens and antibodies used for eight-plex experiments, company source, product number and 
antibody clone (for monoclonal antibodies) 
Antibody / Antigen Type Source* Product Number Antibody Clone 
AFP 
Antigen Meridian   A81510H 
Capture Meridian   MAM01-301 057-11301 
Detection Meridian   M01254M B491M 
ALCAM 
Antigen R&D Systems 656-AL 
Capture R&D Systems MAB656  105901 
Detection R&D Systems BAF656 Polyclonal 
CA 125 
Antigen Fitzgerald 30-AC21 
Capture Life Span LS-C84288 / 28658 M002201 
Detection Meridian   10-C02F M002203 
CA 15-3 
Antigen Meridian   A32000H 
Capture Fitzgerald 10-C03E M002204 
Detection Fitzgerald 10-C03F M002208 
CA 19-9 
Antigen Fitzgerald 30AC14 
Capture Fitzgerald 10C04C M8073021 
Detection Meridian   M37301M 241 
CEA 
Antigen Fitzgerald 30-AC32 
Capture Meridian   MAM02-009 057-10009 
Detection Meridian   MAM02-008 057-10008 
Osteopontin 
Antigen Fitzgerald 30RA0008 
Capture Meridian   M66102M 2C5 
Detection Meridian   H01278M B697M 
PSA 
Antigen Fitzgerald 30R-AP019 
Capture Meridian   M66279M B731M 
Detection Meridian   M86506M 5A6 
*Sources full names and locations: 
Meridian Life Science, Saco, ME 
R&D Systems, Minneapolis, MN 
Fitzgerald Industries International, Concord, MA 




(biotin) were obtained from eBioscience (San Diego, CA). All antigens and antibodies (capture 
and detection) purchased and used for eight-plex experiments are listed in Table 7.1. 
Streptavidin-coated polystyrene/iron oxide beads with a mean diameter of 114 nm were 
purchased from Ademtech (Pessac, France). Phosphate buffered saline (PBS), with a standard 10 
mM phosphate ion concentration, was reconstituted from Dulbecco’s phosphate buffered saline 
packets purchased from Sigma-Aldrich (St. Louis, MO). All other chemicals were obtained from 
Sigma-Aldrich and used as received.  
All buffers were made with purified water (ELGA PURELAB filtration system; Lane 
End, UK), and the pH was adjusted as necessary with 1 M HCl or 1 M NaOH. For NHS-ester 
chemistry, PBS buffer with 100 mM phosphate (100 mM PBS) was used. This was made with 
150 mM NaCl, 22.5 mM monobasic sodium phosphate, and 77.7 mM dibasic sodium phosphate 
and then pH-adjusted to either pH 7.4 or pH 6.0. PBS with 0.05% Tween-20 (PBST) was made 
by adding Tween-20 to standard PBS buffer (Dulbecco’s formulation). PBST with Starting 
Block (PBST-SB) was made by adding 1% Starting Block to PBST buffer and then adding 
0.01% sodium azide as a preservative. All solutions were degassed under vacuum sonication 
before being flowed across the sensor surface. 
 
7.2.2 Instrumental Setup and Microchip Design 
 
The sensor chips and microring resonator measurement system was acquired from 
Genalyte, Inc. (San Diego, CA). For initial results and testing, we utilized Generation 1 
instrumentation and microring resonator chips as previously described.20 These chips were 6 × 6 
mm microchips with 32 microring sensors, 8 of which are thermal controls. All measurements 
for these experiments were made with the sensor chips loaded into a custom cell with 
microfluidic flow channels defined by a 0.007-inch thick Mylar gasket with a U-shaped channel 
750 µm wide as previously described.21 Solution was flowed through the chips via a Harvard 







7.2.3 Silane Functionalization 
 
Microring array substrates were first cleaned with piranha solution22 (3:1 H2SO4:30% 
H2O2) for 30 seconds followed by rinsing with water and N2 drying. To introduce reactive 
functional groups, all substrates had 20 µL of a 1 mg/mL solution of HyNic Silane (20 mg/mL 
HyNic Silane in DMF stock solution diluted to 1 mg/mL with ethanol) added to the chip surface 
for ~30 minutes, followed by rinsing with ethanol and then sonicating in ethanol for ~30 
minutes. Chips were then dried with N2.  
 
7.2.4 Oligonucleotide Functionalization 
 
Oligonucleotide sequences, which were designed to minimize cross-reactivity between 
DNA probes, were previously used in creating DNA-antibody conjugates.9, 23 The exact 
sequences, named B, B′, C, C′, D, D′, F, F′, J, J′, K, K′, L, L′, and M, M′, (where a prime symbol 
indicates a complementary sequence), are listed in Table 7.2. All oligonucleotides were 
synthesized with a 5′ amino terminal group to facilitate additional chemical reactivity. All 
oligonucleotides were functionalized with S-4FB according to manufacturer (SoluLink) 
instructions. Briefly, oligonucleotides were buffer exchanged to 100 mM PBS pH 7.4 using 5 
kDa MWCO filters and then a 20-fold molar excess of S-4FB in DMF was added. Solutions 
were allowed to react overnight at room temperature and then were buffer exchanged into 100 
mM PBS pH 6.0 using 5 kDa MWCO filters. Anomalously, Strand C had a tendancy to permeate 
the 5 kDa MWCO filters whereas the other strands showed no such permeation. Using a 3 kDa 
MWCO filter helped reduce loss of Strand C in the buffer exchanges. 
 
7.2.5 DNA-Antibody Conjugate Synthesis 
 
 To create DNA-antibody conjugates, antibodies were functionalized with S-HyNic as 
previously demonstrated.9 Briefly, S-HyNic in DMF was added in 20- to 30-fold molar excess to 
~1 mg/mL antibody that had previously been buffer exchanged into 100 mM PBS pH 7.4 with a 
Zeba spin filter and reacted for at least two hours at room temperature. The antibody was then 
exchanged into 100 mM PBS pH 6.0 with a Zeba spin filter. The 4FB-modified DNA was then  
154 
 
Table 7.2 List of DNA oligonucleotide sequences used. All sequences have a 5′ terminal amino group attached via a 
6-carbon chain (5AmMC6 from IDT) 
 
Name Sequence (5′ to 3′) 
B AAA AAA AAA AGC CTC ATT GAA TCA TGC CTA 
B′ AAA AAA AAA ATA GGC ATG ATT CAA TGA GGC 
C AAA AAA AAA AGC ACT CGT CTA CTA TCG CTA 
C′ AAA AAA AAA ATA GCG ATA GTA GAC GAG TGC 
D AAA AAA AAA AAT GGT CGA GAT GTC AGA GTA 
D′ AAA AAA AAA ATA CTC TGA CAT CTC GAC CAT 
F AAA AAA AAA AAT CAG GTA AGG TTC ACG GTA 
F′ AAA AAA AAA ATA CCG TGA ACC TTA CCT GAT 
J AAA AAA AAA ATC TTC TAG TTG TCG AGC AGG 
J′ AAA AAA AAA ACC TGC TCG ACA ACT AGA AGA 
K AAA AAA AAA ATA ATC TAA TTC TGG TCG CGG 
K′ AAA AAA AAA ACC GCG ACC AGA ATT AGA TTA 
L AAA AAA AAA AGT GAT TAA GTC TGC TTC GGC 
L′ AAA AAA AAA AGC CGA AGC AGA CTT AAT CAC 
M AAA AAA AAA AGT CGA GGA TTC TGA ACC TGT 





added in >10-fold molar excess to the HyNic-modified antibody solution and allowed to react 
overnight at 4 °C. DNA-antibody conjugates were then purified away from the excess DNA 
using a Superdex 200 10/300 GL column on an AKTA FPLC, both from GE Healthcare 
(Waukesha, WI). The separation was performed at 4 °C with a PBS isocratic elution. The 
collected fractions were concentrated with either 30 or 50 kDa MWCO filters (with equivalent 
results) to yield purified solutions of DNA-antibody conjugates. The final conjugate 
concentration was determined by measuring the differential absorption at 260 versus 280 nm, 
corresponding to the DNA and IgG, respectively, using a NanoDrop UV-Vis absorbance system 
(ThermoFisher Scientific, Wilmington, DE). The following conjugates were synthesized using 
the capture antibodies listed in Table 7.1: B′-anti-AFP, C′-anti-ALCAM, D′-anti-CA19-9, F′-
anti-osteopontin, J′-anti-CA15-3, K′-anti-CEA, L′-anti-CA-125, M′-anti-PSA.  
 
7.2.6 DNA Spotting and Multiplex Functionalization 
 
 Eight-plex chips were created by microspotting 4FB-functionalized DNA strands onto 
HyNic-functionalized microring resonator chips. Each chip had rings spotted with the eight DNA 
sequences in the sequential order B, C, D, F, J, K, L, and M which was then repeated three times. 
Spotting was accomplished with a Nano eNabler spotting system from BioForce Nanosciences 
(Ames, IA) using a concentration of ~100 µM 4FB-modified DNA in 100 mM PBS buffer pH 
6.0 mixed in a 1:1 ratio with DMSO, to slow solvent evaporation. After spotting, the drops of 
solution were dried on a hot plate (~80 °C) for five minutes. The chips were then incubated in a 
saturated humidity chamber overnight to enable rehydration of DNA and subsequent surface 
reaction without the presence of DMSO. Overnight incubation proved to be important in 
obtaining reproducible results from chip to chip. Following the overnight incubation, chips were 
then immersed into Starting Block. The blocking solution was immediately removed by rinsing 
with water, and then the chips were again reimmersed into fresh Starting Block. Chips were left 
in Starting Block for >3 hours and then immersed in PBST for 1 hour. After PBST immersion, 
chips were removed and briefly rinsed with water and air dried. 
 To add multiple antibodies to the chip surface, all of the DNA-antibody conjugates were 
diluted in a single mixture to 5 µg/mL (except for L′-anti-CA-125, which was used at 1 µg/mL) 
with PBST as the diluting buffer. To each eight-plex, DNA-functionalized microchip, ~10-15 uL 
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of DNA-antibody conjugate mixture was added to the surface of each chip. The chips were 
enabled to incubate overnight to enable maximum binding of the DNA-antibody conjugates to 
the DNA capture probes on the surface. This overnight binding step also proved to be important 
to ensuring that each microring sensor had a uniform surface density of antibody, thus enabling 
more consistent ring-to-ring and chip-to-chip responses. Following overnight binding, the chips 
were immersed in Starting Block. They were loaded into a fluidic cartridge, with care taken to 
make sure the chips stay wet during the loading process to avoid denaturing the antibodies on the 
surface. Typically, we used a method whereby the chips could be loaded while immersed in 
water to prevent any drying of the surface. 
 
7.2.7 Antibody Biotinylation 
 
To biotinylate all eight secondary antibodies, each antibody was initially buffer 
exchanged to 100 mM PBS pH 7.4 via a Zeba spin column. Antibodies solutions had a 20-fold 
molar excess of 20 mM NHS-PEG4-biotin added and were then allowed to incubate for 2 h at 
room temperature. For the anti-AFP secondary, it was determined that a 5-fold molar excess 
gave optimal antibody activity, and for the anti-osteopontin secondary, it was found that a 50-
fold molar excess resulted in the best signal amplification for osteopontin. Excess NHS-PEG4-
biotin was removed by buffer exchange using Zeba spin filter columns. The ALCAM secondary 
antibody came as a pre-biotinylated polyclonal antibody sample, so it was not treated any further. 
 
7.2.8 Bead Exchange  
 
As discovered previously,8 when using the streptavidin-coated 100 nm beads, it is of critical 
importance to buffer exchange the beads immediately before use. This exchange removes free 
streptavidin which would otherwise rapidly diffuse to the surface and outcompete the beads for 
biotin binding sites. To exchange the beads, 100 µL of 5 mg/mL streptavidin-coated beads were 
diluted to 1 mL PBST-SB buffer and centrifuged at 10,000 g for ~8 min.  The bead pellet was 
held at the bottom of the tube off to the side using a rare-earth magnet while the supernatant was 
completely removed. The beads were then resuspended in 1 mL of PBST-SB buffer by pipetting 
the solution up and down ~50 times with the tube bottom remaining in contact with the magnet. 
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Pipetting has proven to be the most effective method of resuspension as compared to using a 
vortex mixer or sonication. After resuspending, the beads were aliquoted into 100 µL aliquots 
and then spun down at 10,000 g for ~4 min and stored for later use. Just prior to use in an 
experiment (~5 minutes prior), these stored beads were placed adjacent to the rare-earth magnet 
for several minutes to enable the concentration of any resuspended beads. Then the supernatant 
was completely removed as just described, and the beads were resuspended in 500 µL PBST-SB 
to make a nominally 100 µg/mL solution of magnetic beads. Where highly reproducible 
concentrations were needed between experiments, the absorbance at 275 nm (via NanoDrop) was 
used. Typically a 100 µg/mL solution will have a A275 absorbance of ~0.2 with the 1 mm 
pathlength on the NanoDrop.  
 
7.2.9 Layer-by-layer Antibody Buffer Exchange 
 
Prior to utilizing the anti-PE (biotin) and anti-biotin (PE) antibodies for the layer-by-layer 
antibody amplification step, it was necessary to buffer exchange these antibodies into PBST-SB. 
This was done using Zeba spin columns, and this step eliminated the bulk refractive index shift 
measured by the microring resonator sensors due to components in the original storage buffer. 
 
7.2.10 Eight-plex Antigen Analysis 
 
Human serum samples were analyzed after diluting to 50% in PBST-SB. This dilution 
was used to enable the cold non-degassed serum samples to be mixed with room temperature, 
degassed buffer preventing any bubble formation; it also diluted the serum solution to make its 
viscosity more amenable to flowing through a microfluidic channel. For antibody evaluation and 
amplification strategy testing, 10% FBS solutions spiked with antigens were used. Initial testing 
was done with antigens diluted in pure buffer.  
To perform an analysis of a sample using an eight-plex chip, the microring resonator chip 
was loaded in the fluidic cartridge and registered. PBST-SB was used as the running buffer and 
was flowed over the surface for ~5 minutes. Then the sample was introduced and flowed over 
the chip for 30 minutes. Then buffer was flowed over the chip to rinse off any non-specifically 
bound proteins for 20 minutes. Then a mixture of each biotinylated secondary antibody at a 
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concentration of 1 µg/mL was flowed over the chip for 15 minutes. A 5 minute rinse with buffer 
occurred next and was followed by the signal amplification step. For bead amplification, a 
buffer-exchanged solution with 100 µg/mL beads was flowed over for 15 minutes. For the layer-
by-layer antibody amplification, 1 µg/mL anti-biotin (PE) was first flowed over the surface 
followed by a brief buffer rinse, and then 2 µg/mL anti-PE (biotin) was next flowed over 
followed by a brief buffer rinse. This process was repeated up to 6 times to amplify the 
secondary antibody signal. Solution flow rate was 30 µL/min for all steps. 
 
7.3 Results and Discussion 
7.3.1 Antibody Screening 
 
 The initial step in creating an eight-plex assay was to first acquire antibodies that would 
bind selectively and specifically to the antigens of interest with sufficient sensitivity. As we 
demonstrated in previous results,9 the microring resonator system is an effective way to screen 
for antibody binding kinetics as well as for antibody sandwich pairs. Thus, after screening for 
antibodies against the antigens AFP, ALCAM, CA125, CA15-3, CA19-9, CEA, osteopontin, and 
PSA, we could then create an eight-plex chip that contained all eight antibodies as DNA-
antibody conjugates. Since each chip has 24 active sensors, each of the eight antibodies was 
deposited onto three microring sensors. The eight-plex chip was then tested to determine if any 
antibody cross-reactivity existed. We did this testing by sequentially flowing a high 
concentration of each antigen in buffer (1 µg/mL for AFP, ALCAM, CEA, osteopontin, PSA and 
1 kU/mL for CA125, CA15-3, CA19-9) over the chip followed by sequential addition of each 
secondary antibody.  
Figure 7.1 shows the sensor responses to each of the antigens as they are individually 
added. Each graph shows the responses for each of the 24 sensors with each sensor colored 
according to the antibody with which it was functionalized. The title above each graph indicates 
which antigen was added, and the line next to the title indicates the color associated with each 
antibody (anti-AFP = black, anti-ALCAM = red, anti-CA19-9 = cyan, anti-osteopontin = blue, 
anti-CA15-3 = purple, anti-CEA = orange, anti-CA125 = yellow, anti-PSA = green). As 
indicated in Figure 7.1, each sensor responds specifically according to the antibody it was 




Figure 7.1 Responses for 8-plex chips following addition of 1 µg/mL antigen (or 1 kU/mL for CA19-9 CA125, 
CA15-3). Each graph shows the responses of all the microring sensors upon addition of the specified antigen as 
indicated by the title above each graph. The colored line next to the antigen name indicates the color used to 





Figure 7.2 Responses for 8-plex chips following addition of 1 µg/mL secondary antibody. Each graph shows the 
responses of all the microring sensors upon addition of the specified antigen as indicated by the title above each 
graph. The colored line next to the antigen name indicates the color used to represent the sensor trace corresponding 




sensors and the anti-CA15-3 sensors. Following addition of 1 kU/mL CA19-9, the appropriate 
anti-CA19-9-functionalized rings (cyan) respond, but so do the anti-CEA-functionalized rings 
(orange). Similarly, addition of 1 kU/mL of CA15-3 results in responses from not only the 
antiCA15-3-functionalized sensors (purple), but also from the anti-CEA- and anti-CA19-9-
functionalized sensors. This inter-antigen interference has two potential sources. First, it could be 
due to contaminant antigens in the “pure” standards. Because the standards for CA19-9, and 
CA15-3 are derived from purified extracts from human cell lines, it is not unlikely that multiple 
cancer biomarkers could be present in a given standard. The CA15-3 antigen product information 
sheet even indicates that CA19-9 and CA125 are present, albeit at less than 1-2% of the CA15-3 
concentration; however, the presence or absence of CEA is not indicated. The second potential 
source of cross-reactivity is from the off-target binding of the capture antibody (e.g. anti-CA19-9 
binding to CA15-3). This is also not totally surprising given that CA19-9, CA125, and CA15-3 
are all mucin-family glycoproteins derived from cancer cells.24-27 Thus, the probability of 
binding epitope overlap between these antigens is non-negligible.  
To further determine the specificity of the interactions, we examined the results from 
secondary antibody binding. As shown in Figure 7.2, addition of 1 ug/mL of each secondary 
antibody (in sequence, following addition of antigens) results in a specific response from the 
appropriate sensors. In the case of CA19-9, there is no further response from the anti-CEA 
functionalized rings following addition of anti-CA19-9. This suggests that the response of the 
anti-CEA rings following addition of CA19-9 was not the result of off-target CA19-9 binding. 
As an additional control (data not shown), we tested the addition of CA19-9 to sensors 
functionalized with anti-CEA followed directly by addition of the anti-CEA secondary. In this 
case, after addition of the anti-CEA secondary, a specific response occurred on the anti-CEA 
rings confirming that the response of the anti-CEA sensors to CA19-9 is very likely the result of 
CEA present in the CA19-9 “standard.”  The response of the anti-CEA rings to the addition of 
CA15-3 proved to have the same cause as the addition of CA19-9. In this case as well, the 
addition of the anti-CA15-3 secondary antibody generated no secondary response (as seen in 
Figure 7.2), but addition of anti-CEA (data not shown) did generate a specific response. 
Apparently, both the CA15-3 and CA19-9 antigen standards are contaminated with CEA at a 
fairly high level. Although CEA contamination in CA15-3 and CA19-9 could be problematic, it 
should be correctable once the levels of CEA present are well characterized. This indicates the 
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importance of having a label-free detection system to accurately determine the source of cross-
reactivity and how it can be corrected. 
On the other hand, the response of the anti-CA19-9-functionalized rings to the addition of 
CA15-3 displayed a different source of cross-reactivity. Unlike the anti-CEA rings, the anti-
CA19-9 rings still respond upon addition of 1 µg/mL anti-CA15-3 secondary antibody. This 
suggests that CA15-3 is binding to the anti-CA19-9 antibodies. Even after changing the 
antibodies used as capture and detection antibodies for CA19-9, CA15-3 would still bind to the 
anti-CA19-9-functionalized rings, and the subsequent addition of anti-CA15-3 would generate a 
response. Furthermore, addition of anti-CA19-9 secondary following addition of anti CA15-3 did 
not generate a measureable response (data not shown) indicating that it was not CA19-9 
contaminants that generated the response. Thus, it became apparent that all of our measurements 
with the anti-CA19-9-functionalized rings would measure both the CA15-3 and CA19-9 content 
in the sample. However, because the anti-CA15-3-functionalized sensors are still specific 
towards CA15-3, our sensor chip can be designed to measure CA15-3 levels and the combined 
levels of CA15-3 plus CA19-9. This is not too different than the tests for PSA which measure 
both free PSA and total PSA (free PSA  + complexed PSA).28 Again, this level of 
characterization and understanding of a multiplexed assay would not be easily achieved with an 
end-point only measurement. Instead, having the real-time, label-free data makes it possible to 
thoroughly evaluate and characterize the source of interference between antigens. 
 
7.3.2 Background Signal Reduction with Beads 
 
 Following the determination of which antibodies to use for the eight-plex analysis as well 
as their characterization, we proceeded to determine the sensitivity of our measurement using 
signal amplification techniques. Our initial tests utilized the streptavidin-coated microspheres to 
bind to the biotinylated secondary antibodies. Unfortunately, initial results showed that there was 
a significant amount of non-specific signal. Figure 7.3A shows the addition of beads to a sensor 
chip where all eight antigens were added to the chip followed by all eight secondary antibodies. 
In this case, the anti-ALCAM secondary was the only biotinylated secondary flowed across the 
chip, and thus the anti-ALCAM sensors should be the only ones that respond upon addition of 




Figure 7.3 Graphs from an eight-plex sensor chip showing the streptavidin-coated bead response following addition 
of all eight antigens followed by the appropriate secondary antibodies. In this example, only the anti-ALCAM 
antibody is biotinylated. (A) Response before optimizing the parameters for non-specific binding. (B) Response 
when the antigens are added within a serum matrix and the running buffer contains 1% Starting Block.  
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anti-ALCAM-functionalized rings giving a ~550 pm shift. However, almost all of the other rings 
also respond even though no biotinylated secondaries specific to those rings were added to the 
chip. Obviously the 30-100 pm background shift significantly reduces the signal to noise ratio of 
the system and raises the limit of detection for each antigen.  
To overcome this limitation, we explored the source of the non-specific bead sticking and 
determined that main culprits were the biotinylated secondary antibodies. In general, the non-
specific bead sticking only occurred when a biotinylated secondary antibody was added, 
regardless of whether there was target antigen added or not. Thus, our challenge was to reduce 
the non-specific binding of the biotinylated secondary antibodies. We found the best method for 
preventing non-specific binding was to perform antigen analyses out of a serum sample and to 
use blocking protein in the running buffer. By flowing a serum sample across the chip, the high 
concentration protein components of the serum sample functioned remarkably well in blocking 
the surface from the non-specific adsorption of biotinylated secondary antibodies—even though 
each chip surface was previously blocked with a commercial blocking solution (Starting Block). 
Fortunately, since the project goal is to measure biomarker levels in serum samples, this 
requirement is met without any additional changes to our assay design. We also found than the 
addition of 1% Starting Block to the running buffer significantly reduced non-specific binding of 
biotinylated secondaries. Figure 7.3B shows what happens when the same experiment as in 
Figure 7.3A is run, but where the ALCAM is initially dissolved in a serum sample (fetal bovine 
serum) and Starting Block is used in the running buffer. As can be seen in the graph, the amount 
of non-specific binding of beads was drastically reduced.  
  
7.3.3 Layer-by-layer Amplification Method 
 
 Although the streptavidin-bead binding method has proven successful as a signal 
amplification technique,8 it still suffers from two major drawbacks. First, the binding of beads to 
the microring surface increases the noise present in the signal. Second, to obtain consistent 
responses between different runs, the beads must be buffer exchanged just prior to being flowed 
over the chip surface to minimize the amount of free streptavidin in solution. This streptavidin is 
presumably desorbed from the beads as they incubate in solution. Due to the ability of free 
streptavidin to diffuse faster than the 100-nm streptavidin-coated beads, the free streptavidin can 
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outcompete the beads for binding sites at the surface, thus reducing the overall signal 
amplification of the assay. Because of the requirement to exchange beads just prior to use (within 
5 minutes), it makes it more challenging to automate the analysis of dozens of human serum 
samples which is the goal of this project. 
 As an alternate signal amplification strategy, we utilized a multilayer antibody 
amplification method. This method is similar to what our group29 and Gauglitz et al.30 have used 
for creating protein multilayers on a surface. Except for a limited use (one bilayer of 
fluoresecence amplification) by Anderson et al. in a Luminex assay,31 this technique has not been 
applied to amplifying the signal of an immunoassay in the literature. Figure 7.4 illustrates this 
methodology on the microring resonator silicon surface. Initially, the microring silicon surface is 
functionalized with a capture antibody. Then primary antigen binding and biotinylated secondary 
antibody binding occur according to standard sandwich assay protocols. For the amplification 
step, instead of adding streptavidin-coated beads, an anti-biotin antibody conjugated to 
phycoerythrin (anti-biotin PE) is added to bind to the biotinylated secondaries. Because 
biotinylated secondaries usually have two or more biotins per antibody, it is possible to add two 
or more anti-biotin antibodies. Next, biotinylated anti-PE (anti-PE biotin) antibodies  are added 
that bind to the anti-biotin PE antibodies. As a further amplification, anti-biotin PE can be added 
again, with amplification due to the multiple biotins per anti-PE biotin antibody. This process 
can be repeated over and over to grow a large, branching antibody agglomeration on the surface. 
 Figure 7.5 shows some data illustrating the layer-by-layer amplification process. The 
figure shows amplification based on the initial binding response to 1 µg/mL AFP (red trace) and 
10 ng/mL CEA (black trace). Upon addition of the antigen at t = 7 min, a noticeable response is 
generated from AFP binding. However, the CEA concentration is low enough that no noticeable 
response is visible from the CEA binding. Similarly, at t = 18 min when the biotinylated 
secondary antibodies are added, there is a visible shift from the anti-AFP functionalized ring, but 
not from the anti-CEA functionalized ring. Subsequently, anti-biotin (PE) and anti-PE (biotin) 
are added alternately. Each additional step increases the signal for the anti-AFP trace. For the 
anti-CEA trace, only a small response is measured at first, but then this response grows into a 
significant (~50 pm) shift by the end of the amplification steps. Importantly, it is noted in both 
processes that the additional signal for each step of the amplification process increases with each 




Figure 7.4 Layer-by-layer amplification strategy. The first steps involve primary binding of antigen followed by 
addition of the biotinylated secondary antibody. The amplification step involves using a pycoerythrin (PE) 
conjugated anti-biotin antibody binding to the biotinylated secondary antibody. This then is followed by addition of 






Figure 7.5 Real-time data showing layer-by-layer amplification with AFP (red) and CEA (black). Antigen is added 
at t = 7 min and a noticeable response is generated from AFP but not CEA. Biotinylated secondaries are added at t = 
18 min, and again the anti-AFP sensor shows signal, but not the anti-CEA sensor. Subsequently, anti-biotin (PE) and 
anti-PE (biotin) are added alternately. This amplification steps increase the signal for the AFP trace significantly and 
give a visible signal for the CEA trace.  
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the t = 24 min addition. This indicates that not only are additional antibodies being added, but 
that there is an exponential growth factor leading to more signal with each layer. This effect is 
more pronounced in the CEA trace than in the AFP trace, presumably because the AFP trace has 
a greater surface coverage of antibodies and thus there are larger steric hindrances to antibody 
layer-by-layer growth at a particular antigen binding site than would be present at the lower 
density CEA sensor. 
 In comparing this method to the streptavidin-bead method, we found that amplification 
responses tend to be similar, but that additional signal can be gained in the layer-by-layer 
approach by adding additional amplification steps. In contrast, adding time to the bead-binding 
amplification step usually results in diminishing marginal returns. In addition, there is no 
requirement for consistent reagent preparations (exchanging the beads) just prior to the 
amplification step. Finally, the baseline noise of the sensors is lower when using the antibodies 
as opposed to the beads. Thus, with all these reasons combined, it has proven advantageous to 
use the layer-by-layer approach rather than the bead approach. 
 
7.3.4 Human Serum Analysis from Cancer Patients 
  
 After developing the amplification method that we would use for the cancer biomarker 
analysis, we proceeded to do some preliminary analyses on six different human blood samples. 
Five of these samples were commercially available blood serum samples from cancer patients 
with ovarian, breast, colorectal, lung, and prostate tumors. The sixth sample was a fresh plasma 
sample collected from a healthy donor. Figure 7.6 shows the sensor plots showing the addition of 
the serum sample at t = 5 minutes followed by rinsing with buffer at t = 35 min and then adding 
the secondary antibody at t = 55 min. The amplification step proceeds after the secondary 
antibody step, and each analysis used a total of 6 amplification bilayers (12 steps altogether) over 
the course of 30 minutes. Since most of the information is contained within the amplification 
step, Figure 7.7 was plotted to show only the amplification step with each ring re-zeroed at the 
time the amplification step started. 
 Although at the information presented at the current time is not quantitative, it does 
provide some interesting insights into cancer biomarker levels among various patients. One 




Figure 7.6 Real-time data showing the addition of human serum at t = 5 minutes followed by a buffer rinse at t = 35 
minutes. Biotinylated secondaries are added at t = 55 minutes and then the layer-by-layer amplification begins at t = 
60 minutes. The title above the graph indicates the tumor type found in the particular patient from which the blood 






Figure 7.7 Layer-by-layer amplification data from Figure 7.6 with each microring sensor data re-zeroed at the point 




detected for all patients—including the healthy donor. Another observation is that the biomarkers 
associated with a particular disease are not always the ones to be elevated significantly in a 
particular patient’s sample. For example the patient with prostate cancer would be expected to 
have elevated levels of PSA, and he could be clinically diagnosed or treated based on that PSA 
level. However, Figure 7.7 indicates that PSA levels are almost unobservable. This low level of 
PSA is confirmed by patient history information provided from the serum vendor indicating that 
that PSA levels were ~0.1 ng/mL—a level far below standard basal PSA levels, and near the 
detection limit for our assay. However, CEA, ALCAM, AFP, and CA-125 are significantly 
higher in the prostate cancer patient sample than in all the other patient samples (note that the 
scale is different in the prostate cancer patient data than in all the other 5 data plots). Similarly, 
the breast cancer patient has near negligible levels of CA15-3, a breast cancer biomarker, 
whereas the ovarian cancer patient serum sample has the highest levels of CA15-3 as compared 
to the other five. Meanwhile, the ovarian cancer patient sample has osteopontin levels that aren’t 
quite as high as the osteopontin levels in the breast cancer patient sample even though 
osteopontin is a purported ovarian cancer biomarker. 
 In addition to the observations for the tertiary amplification portion of the biomarker 
detection, it was also interesting to observe the primary binding upon addition of the serum 
samples. For example, in the ovarian, breast, and colorectal patient samples, the anti-CA125 
functionalized rings (yellow) all gave the highest response in the serum binding region of the 
curve, but subsequent addition of secondary antibody and amplification steps revealed no 
significant CA125 response. Clearly, something in the human serum samples was binding to the 
anti-CA125-coated rings that was not CA125. Similarly, in the prostate cancer patient sample, 
the anti-CA19-9 rings display an initial shift upwards following addition of the serum sample 
and then proceed to gradually slope downward, in contrast with the behavior of the other sensors. 
Although these responses aren’t necessarily indicative of cancer biomarkers, it is possible that 
they are the result of other protein-protein interactions from unknown components in the blood 
serum samples. Future work may reveal whether these observations are significant or not, but at 
present, it is important to note that this behavior is only observable on a label-free, real-time 





7.4 Conclusions and Future Work 
 
 Moving forward on the multiplex analysis of human serum samples, several tasks will 
need to be accomplished. First of all, a standard calibration curve will have to be established for 
each antigen using the multilayer amplification strategy. This can be accomplished in a multiplex 
fashion for several of the anlaytes for which there is not interference. However, for CA19-9, 
CEA, and CA15-3, the antigen calibration curves will likely have to be calculated independently 
to avoid interference effects from cross-reactivity and antigen contamination between standards. 
To verify the reproducibility of the calibration on multiple chips, it will be important to run the 
calibration curve with several replications to ensure that similar results can be derived from 
multiple microsensor chips. 
 Following generation of calibration curves, human serum analysis can proceed. To verify 
the calibration curve, standard addition will be performed on several samples to see how the 
values from a calibration analysis compare to that of standard addition. For a quantitative 
analysis this will be important to ensure that matrix effects from serum samples do not overly 
skew the results of the biomarker analysis. Additionally, several standard single-plex enzyme-
linked immunosorbent assays (ELISAs) will probably have to be utilized for some of the samples 
to verify the results with another commercially available method. However, since running 8 
ELISAs on a single sample will be rather tedious (hence the need for multiplex chip analysis), 
probably only a few samples will be analyzed. 
 After analyzing ~50 human serum samples, it will then be important to understand how 
to process the data for clinical utility. Although it may be true that our specific panel of 
antibodies will not be the right selection to fully develop a diagnostic test for making clinical 
decisions, it will be important to understand how to treat multiplexed data derived from such a 
panel. As a result, we will use statistical methods such as principal component analysis32, 33 or 
hierarchical clustering23, 34 to analyze the data as has been used previously. 
 Overall, this initial work has demonstrated the feasibility of designing an eight-plex 
biomarker panel and then performing eight-plex biomarker analysis on human serum samples. In 
the near future multiple human serum samples will be analyzed via the biomarker chips 
illustrating the potential of microring resonators for multiplexed diagnostics design and 
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